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 Abstract 
Type I diabetes (T1D) is an autoimmune disease in which the insulin 
producing β cells of the pancreas are selectively targeted for destruction by 
autoimmune effector T cells. The aberrant effects of these effector T cells may in 
part be due to a dysfunction in the regulatory T cell (TREG) compartment and 
currently there is great interest in developing methods to strengthen the 
immunoregulation of patients with T1D. A potential way to boost immunoregulation 
in these patients would be the use of adoptive TREG therapy whereby expanded 
polyclonal TREG are transferred into patients. Although this treatment in mouse 
models of disease has shown promise it has been found that antigen specific TREG 
cells are much more efficacious of preventing disease, and can even reverse 
disease.  
The translation of these murine experiments into the human setting is 
however complex, since the generation of large numbers of antigen specific TREG 
from human patients is currently a major hurdle.  One way to remove this barrier is 
to utilise lentiviral gene transfer technology, which can allow for the transfer of 
antigen specific T cell receptor (TCR) genes into a desired cell population. 
Specifically for T1D, it is hypothesised that TREG engineered to express a MHC 
Class I restricted (MHCI) TCR, although unconventional, would selectively function 
at the site of inflammation i.e. within the islets. This project, therefore, aims to 
generate MHCI islet antigen specific TREG with the hypothesis that these would 
confer islet antigen specific suppression. 
To test this hypothesis we engineered human CD4+ TREG to express two 
MHCI islet antigen specific TCRs whilst using a third high affinity pathogenic MHCI 
TCR as a control. As others have shown, we demonstrate that the control TCR 
was effectively able to re-direct the antigen specificity of TREG cells through 
signalling and function. However, we discovered that transfer of autoimmune MHCI 
TCRs were unable to yield the same results as the control TCR due in part to their 
natural low affinity for antigen.   
To circumvent this, we engineered CD4+ TREG to express an MHCI 
autoimmune TCR along with the CD8αβ co-receptor or a CD8αβ high affinity 
 variant. Using this system, human TREG could be successfully re-directed towards 
an islet specific peptide and exhibit antigen specific suppression. Thus, this study 
is the first of its kind to use an autoimmune disease relevant, MHCI TCR to 
successfully re-direct the Ag specificity of TREG cells.   
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1. Introduction 
1.1. Adaptive Immunity – A Double Edged Sword  
The immune system is a complex collection of cells and molecules that mediate 
the protection of the body from harmful and infectious pathogens. For efficient 
protection, the immune system has two arms of defence – the innate immune 
system providing an immediate response to pathogens and the adaptive immune 
system that although taking longer to respond, provides exquisite specificity and 
memory to efficiently eliminate infections. In the absence of a fully functioning 
adaptive immune system, such as in cases of severe combined immunodeficiency 
(SCID) or acquired immunodeficiency syndrome (AIDS), the body is overwhelmed 
by opportunistic pathogens, which would normally have been cleared. The 
specificity required by the adaptive immune system is provided by T and B-
lymphocytes, which through the expression of highly specialised antigen (Ag) 
specific receptors enable the body to detect virtually every potential invading 
pathogen.  
 
There are not enough genes within the whole human genome (estimated 20,000-
25,000 protein coding genes) to fully encode all individual Ag receptor specificities 
that are required to protect the body. Therefore, to achieve this diversity, the Ag 
specific receptor genes of lymphocytes undergo random recombination events 
(Tonegawa, 1983). The recombination events occur within variable (V) regions of 
each of the two chains that comprise an Ag specific receptor. Each variable region 
is composed of two or three gene segments and each of these gene segments is 
present in multiple copies within germline DNA (Early et al., 1980). Thus, gene 
recombination refers to the random joining of single copies from each set of gene 
segments to form a rearranged V region. In a second random process, two 
receptor chains are brought together to form a functional Ag specific receptor 
adding to the diversity within the repertoire of Ag specificities. Although this random 
nature is key to the development of a vast repertoire of Ag specific receptors 
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capable of recognising and destroying all pathogens, it also provides a platform for 
the development of receptors that recognise self-Ags and have the potential to 
target healthy tissue. This in short describes the doubled edged sword of adaptive 
immunity and these self-reactive lymphocytes are widely reported as the 
perpetrators of many autoimmune diseases including type 1 diabetes (T1D), 
multiple sclerosis (MS) and rheumatoid arthritis (RA) (Firestein, 2003; Roep and 
Peakman, 2011; Steinman, 1996). 
 
T lymphocytes, or T cells, derive from the common lymphoid progenitor and 
migrate to the thymus from the foetal liver and adult bone marrow for development. 
During development, they gain expression of an Ag specific receptor known as a T 
cell receptor (TCR). Each TCR is composed of two chains, TCRα and TCRβ, the 
structural composition of which defines the specificity of a TCR. During T cell 
development, the TCRα and TCRβ chains undergo V(D)J recombination, which are 
the somatic recombination events that combine variable (V), diversity (D) and 
joining (J) gene segments to form functional TCR chains. This process generates 
diversity in two ways 1) by combining one each of a multitude of V D and J 
segments and 2) introducing random nucleic acid insertions or deletions at the 
joints between gene segments (Davis and Bjorkman, 1988). In fact, it is estimated 
that at any one time T cells with 25x106 unique specificities can be identified in 
human peripheral blood (Arstila et al., 1999). Importantly, TCRs only recognise Ag 
processed into smaller sized peptides and presented in the context of major 
histocompatability (MHC) cell surface molecules (Babbitt et al., 1985). There are 
two types of MHC molecules known as MHC class I (MHCI) and MHC class II 
(MHCII) molecules. T cells that express TCRs that recognise Ag in the context of 
MHCI express the CD8 co-receptor and those that recognise Ag in complex with 
MHCII express CD4. 
 
As mentioned, the generation of a diverse TCR repertoire is vital to the combatant 
of complex pathogens but has the additional downfall of enabling the development 
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of self-reactive T cells. Therefore, a number of mechanisms exist to prevent the 
development or action of T cells with reactivity to self. During T cell development, 
two checkpoints are in place to maintain central tolerance. Firstly, only T cells that 
possess TCRs that have a low level interaction with self-peptide MHC (pMHC) 
complexes in the thymus are positively selected for T cell development. Secondly, 
during a process known as negative selection, cells that react too strongly with 
self-pMHC are deleted to prevent the release of autoreactive T cells. Alternatively, 
cells that react to self-pMHC can be converted into regulatory T (TREG) cells that 
function in the periphery to inhibit self-reactive T cells.  As negative selection is not 
absolute, potentially due to an absence or low level expression of self Ag in the 
thymus, autoreactive T cells can exit into the periphery. To prevent the activations 
of these autoreactive T cells a number of mechanisms, collectively known as 
peripheral tolerance, exist. These mechanisms include anergy, a functional 
unresponsiveness in cells that encounter Ag in the absence of co-stimulation, 
clonal deletion when apoptosis is induced in chronically stimulated T cells and the 
action of TREG cells (Xing and Hogquist, 2012). 
Despite these complex mechanisms of central and peripheral tolerance, adaptive 
immune responses are elicited against self-Ag and tissues and autoimmunity 
occurs in ~5% of individuals in developed countries (Jacobson et al., 1997). Both 
genetic and environmental factors can play a role in the breakdown of tolerance 
and T1D is a prototypical autoimmune disease in which the adaptive immune 
response elicits a sustained and detrimental attack on self-tissues (Bluestone et 
al., 2010).  
 
1.2. Type 1 Diabetes – An Autoimmune Disease 
1.2.1. Aetiology of Type 1 Diabetes 
T1D is the result of an immune cell mediated destruction of the insulin producing β 
cells within the pancreas (Eisenbarth, 1986). A decline in insulin production can 
render patients with an inability to control their blood glucose levels, which can 
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have severe acute complications as well as secondary complications such as heart 
disease and kidney failure (Vauzelle-Kervroedan et al., 1999). At the turn of the 
20th century, the diagnosis of T1D was relatively rare and with no treatments 
available, the disease was fatal, with an average life expectancy after diagnosis of 
only 6.1 years (Joslin, 1950). With the remarkable discovery of insulin by Drs 
Banting and Best in 1922 came the ability for physicians to treat T1D with insulin 
replacement therapy leading to an increase in patient survival (Banting and Best, 
1922). The last 90 years have seen many advances in T1D management, including 
recombinant insulin, home glucose testing and more recently the use of insulin 
pumps, which allow the provision of insulin through a catheter inserted under the 
skin as opposed to delivery by patient administered injections. Currently, trials are 
underway using “artificial pancreata” that combine glucose monitoring systems, 
insulin pumps and control algorithms to automate glycemic management and initial 
results have shown improved glycemic control compared to a canonical insulin 
pump (Russell et al., 2014). Overall, insulin replacement therapy is still the only 
means to treat the symptoms of T1D and the improved management and diagnosis 
of disease has led to a further increase in the life expectancy of patients.  However, 
a study in 2001 of a T1D cohort found that this group of patients still had a two and 
a half times greater mortality rate than a healthy control cohort (Brown et al., 2001). 
It is well documented that the incidence of T1D is increasing worldwide (Gale, 
2002) and it has been predicted that T1D development in children under the age of 
five will double by 2020 (Patterson et al., 2009). With the incidence of T1D 
increasing at an alarming rate, the reality of a social and economic burden of this 
disease is becoming clear. It is therefore becoming imperative to engineer ways to 
treat or cure the underlying causes of T1D as opposed to the current methods of 
treating the symptoms.  
 
The late George Eisenbarth first proposed a model of T1D pathogenesis in 1986, 
which described a chronic autoimmune disease that could be divided into distinct 
stages (Eisenbarth, 1986). These stages included a genetic susceptibility which, 
when followed by a triggering event, could lead to the autoimmune destruction of β 
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cells perpetrated by autoreactive T cells. Eisenbarth’s model has been adapted 
over the years to incorporate new data garnered from both human studies and 
studies in the non-obese diabetic (NOD) mouse model of T1D (Figure 1-1).  
 
Despite nearly 30 years of study since the proposal of this model, the defining 
trigger that causes the development of T1D has yet to be discovered.  It has 
however been postulated that there is a strong link between genetic predisposition 
and environmental factors in T1D development (Bluestone et al., 2010).   
 
 
Figure 1-1. Model for T1D Disease Progression. T1D can affect people who have a genetic 
predisposition to disease in addition to circulating autoreactive T cells. At disease onset, an 
unknown event triggers disease, which culminates in autoreactive T cell mediate destruction of the 
insulin producing β cells. Symptomatic patients will be treated with insulin replacement therapy that 
leads to a metabolic stabilisation known as the “honeymoon period”. However, increased β cell 
death can lead to further reduction in insulin production that is increasingly difficult to control with 
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1.2.2. The NOD Mouse Model of T1D 
The NOD mouse is an inbred strain that spontaneously develops type 1 
autoimmune diabetes (Makino et al., 1980). Whilst not a perfect model of disease, 
the NOD mouse shares many of the features of human T1D, including 
pathogenesis, genetics and target auto-Ags. This model is therefore used to study 
many aspects of autoimmune diabetes, in particular it is used as a model to test 
potential therapies that may be used to treat human disease. 
 
1.2.3. Factors leading to the development of T1D 
As previously mentioned, T1D development involves a complex interplay between 
genetic and environmental factors. A strong rationale for the involvement of both 
these factors is evidenced by only a 50% concordance rate of T1D between 
monozygotic twins (Redondo et al., 2008). Additional evidence of a role for 
genetics comes from genome wide association studies (GWAS), which have 
identified over 40 “at risk” genetic loci for T1D (Barrett et al., 2009).  
 
In human disease, the strongest genetic associations with T1D development are 
within the Human Leukocyte Antigen (HLA) genes that encode MHC molecules. 
Certain HLA Class I and Class II alleles have been found to have a strong genetic 
predisposition for T1D, whereas others have been found to have a protective 
association (Howson et al., 2009; Nejentsev et al., 2007). In particular, specific 
alleles within the MHCII molecules DRB1, DQA1 and DQB1 loci are strongly 
associated with T1D development (Cucca et al., 1993). MHC molecules possess a 
peptide binding groove that is selective for the length and shape of the peptide with 
which it can complex and subsequently present to T cells. As mentioned, self-
pMHC complexes are vital to the processes of positive and negative selection of T 
cells in the thymus; therefore, the MHC molecules that an individual possesses can 
dictate and shape the TCR repertoire. Another gene polymorphism with a high 
genetic association with T1D is allelic variation within the promoter of the insulin 
(INS) gene. Variation at the Insulin gene’s ‘variable number of tandem repeats’ 
(VNTR) locus can predispose individuals to T1D by altering the level of insulin that 
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is present in the thymus. It has been shown that individuals that are homozygous 
for the susceptible class I INS allele have lower insulin mRNA expression in the 
thymus compared to individuals homozygous for the protective class III INS allele 
(Pugliese et al., 1997; Vafiadis et al., 1997). The reduced expression of insulin in 
the thymus could lead to a reduction in negative selection of insulin reactive T 
cells. Furthermore, it could also lead to a reduction in the thymic generation of TREG 
cells specific for insulin peptides.  
 
Interestingly, several genes associated with T1D susceptibility are thought to play a 
key role in TREG cell development or function, (Todd, 2010) (Figure 1-2) for 
example, there are three T1D associated polymorphisms within the Interleukin-2 
receptor α (IL2RA) and one within the IL2 gene. IL-2Rα, also known as CD25, is a 
component of the high affinity IL-2R complex and is constitutively expressed on the 
surface of TREG cells (Sakaguchi et al., 1995). A vital role for IL-2Rα and IL-2 
protein has been shown in the generation and function of TREG cells, which includes 
the maintenance of peripheral tolerance to self Ags (Bayer et al., 2005; Burchill et 
al., 2007; Malek and Bayer, 2004). Furthermore, defects in the TREG cell 
compartment have been found in patients with T1D, which may be linked to gene 
polymorphisms within the IL2RA and IL2 genes (Brusko et al., 2005; Lawson et al., 
2008; Lindley et al., 2005). 
 
Another polymorphism associated with T1D susceptibility is found within the 
Cytotoxic T-lymphocyte associated protein-4 (CTLA-4) gene, which encodes 
CTLA-4 an important regulator of T cell activation that is constitutively expressed 
by TREG cells (Manzotti et al., 2002; Ueda et al., 2003). This polymorphism has 
been suggested to affect TREG cell function. The protein tyrosine phosphatase, non-
receptor type 22 (PTPN22) is also involved in regulating T cell activation and a 
single nucleotide polymorphism (SNP) within the PTPN22 gene is associated with 
T1D and many other autoimmune diseases. It has been suggested that this SNP 
increases the TCR signalling threshold, which has a negative effect of TREG cell 
thymic development (Maine et al., 2012). Each of these genes described play a 
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fundamental role in immune regulation suggesting that disease susceptibility is 
underpinned by a defective regulation of immune responses.  
 
Figure 1-2 T1D associated gene polymorphisms involved in immune regulation. The relative 
risk of several T1D associated gene polymorphisms with a role in immune regulation is shown. Data 
adapted from John Todd, Etiology of T1D, Immunity, 2010 (Todd, 2010). 
 
These observations in humans are closely mirrored in the NOD mouse. The most 
dominant genetic loci associated with disease in the NOD mouse model is also 
within the genes that encode MHC molecules. In fact, the NOD mouse possess a 
unique MHC haplotype, known as I-Ag7, which is essential for diabetes 
susceptibility (Wicker et al., 1995). Interestingly, T1D susceptibility in humans is 
linked a missing aspartic acid residue within the β chain of HLA-DQ alleles and this 
residue is similarly lacking in I-Ag7 (Acha-Orbea and McDevitt, 1987; Todd et al., 
1987). Additionally, a number of other disease susceptibility loci have been 
identified in the NOD mouse and are termed insulin dependent diabetes (idd) loci. 
A number of genes with a role in immune regulation have been mapped to these 
regions including polymorphisms in the CTLA4, and IL2 genes. 
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It is widely recognised that genetic susceptibility alone does not correlate with T1D 
progression. Even in the disease susceptible NOD mouse strain, diabetes 
spontaneously develops in only 60-80% female and 20-30% of male mice. 
Interestingly, NOD mice that are stored in germ-free conditions have a higher 
incidence of T1D and exposure to certain microbes is found to protect these mice 
from T1D development (Singh and Rabinovitch, 1993). A similar phenomenon has 
been identified in humans and is evidenced by a reduced T1D incidence in 
societies where there is a high risk of infectious disease (Bach, 2002). This theory 
is known as the hygiene hypothesis. Additionally, there is strong evidence that T1D 
is triggered in humans by enteroviral infection. Studies have shown that Coxsackie 
virus B4 can be isolated from the pancreata of newly diagnosed patients (Yin et al., 
2002; Yoon et al., 1979). Furthermore, studies have suggested that enterovirus 
possess tropism for human β cells and that infection with enterovirus can 
exacerbate the development of diabetes in the NOD mouse model (Dotta et al., 
2007; Serreze et al., 2000). Further environmental factors that have been identified 
in T1D include Ags commonly found in dietary products and level of vitamin D 
exposure (Norris et al., 2007; Virtanen et al., 2006; Weintrob et al., 2001).  
 
1.2.4. Immune Mediated Pathogenesis of T1D 
Studies in the NOD mouse model and in patients with T1D have provided strong 
evidence that autoreactive T cells mediate the destruction of insulin producing β 
cells. However, there is evidence that cells of the innate immune system, such as 
natural killer (NK) cells, macrophages and dendritic cells (DCs), mediate the initial 
islet inflammation. Macrophages and dendritic cells have been identified in the pre-
diabetic lesion of NOD mice prior to the recruitment of autoreactive T cells (Dahlen 
et al., 1998). It is thought that low-grade inflammation of the islets can recruit 
APCs, which can pick up and process β cell Ags. These APCs can then migrate to 
the pancreatic draining lymph node where β cell Ags are presented to islet 
autoreactive T cells, which are subsequently activated and endowed with the 
capacity to migrate to the islets. The presentation of β cell Ags to islet autoreactive 
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T cells in the pancreatic draining lymph node has been demonstrated in the NOD 
mouse (Turley et al., 2003). B cells are also thought to play a major role in the 
initial presentation of islet Ags to autoreactive T cells and depletion of B cells in 
pre-diabetic NOD mice has been shown to prevent disease progression (Xiu et al., 
2008).  
 
A major role of autoreactive T cells in T1D is evident by the identification of insulin 
reactive CD4+ and CD8+ T cells in the circulation of patients with T1D (Kent et al., 
2005; Skowera et al., 2008) and in the NOD mouse (DiLorenzo and Serreze, 
2005). In particular, CD8+ T cells have been shown to be the key mediators of β 
cell death; this was first evident following observations that MHCI was hyper 
expressed in the islets of patients with T1D (Foulis et al., 1987; Itoh et al., 1993). 
An increase in MHCI molecules in complex with β cell Ags have the potential to 
enhance the activation of low affinity autoreactive CD8 T cells. Further evidence 
has been identified using in-depth immunohistochemistry staining of pancreatic 
samples from patients with T1D. In these sections, CD8+ T cells were found to be 
the most abundant cell infiltrate, followed by CD68+ Macrophages and to a lesser 
extent, CD4+ T cells (Willcox et al., 2009). Furthermore, an elegant study utilised in 
situ MHCI tetramer staining of pancreatic sections from T1D patients and detected 
autoreactive CD8+ T cells within the islets (Coppieters et al., 2012).  
 
Autoreactive CD4+ T cells, although not as abundant in insulitis as CD8+ T cells 
have also been shown to contribute to T1D development and pathogenesis in 
humans. CD4+ T cells from T1D patients show increased proliferation to β cell Ags 
in comparison to HLA matched non-diabetic controls (Peakman et al., 1999; Roep 
et al., 1995). Additionally, there is strong evidence that human β cells are highly 
susceptible to apoptosis by cytokines secreted by CD4+ T helper 1 (TH1) cells such 
as IFN-γ and TNF-α in combination with macrophage secreted IL1-β (Cnop et al., 
2005). In particular, IFN-γ secreting cells in response to MHCII restricted islet Ags 
have been identified in patients with T1D (Arif et al., 2004). Moreover, a role for T 
helper 17 (TH17) cells has been described with the identification of IL-17 secreting 
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CD4+ T cells in the peripheral blood of newly diagnosed patients (Arif et al., 2011; 
Honkanen et al., 2010; Marwaha et al., 2010). Furthermore, IL-17 has been found 
to contribute to cytokine mediated β cell apoptosis (Arif et al., 2011), which 
suggests that a primed pro-inflammatory response mediated by autoreactive CD4+ 
T cells contributes to β cell death and T1D progression.    
 
In combination with genetic evidence, it is clear that autoreactive T cells that 
escape negative selection in the thymus mediate T1D (Roep and Peakman, 2011). 
However, multiple studies have identified the presence of autoreactive T cells in 
individuals with no evidence of T1D suggesting that other factors mediate the 
pathogenesis seen in T1D patients and in the NOD mouse (Arif et al., 2004; Danke 
et al., 2005). As mentioned, a number of genetic loci that predispose to T1D 
development are involved in the complex process of immune regulation and 
defects in this process have been widely studied in the context of T1D.   
 
1.2.5. Impaired Immune Regulation in T1D 
Peripheral tolerance consists of a number of mechanisms that the immune system 
has developed to prevent the activation of T cells to self- or non-harmful Ags such 
as commensal bacterial or dietary Ags (Xing and Hogquist, 2012) and there is 
overwhelming evidence that T1D occurs in part due to a failure in immune 
regulation (Roep and Tree, 2014). A major mediator of immune regulation is the 
specialised T cell subset known as TREG cells. A number of TREG cell subsets have 
been characterised; however, the most abundant and well-characterised subset 
are defined by co-expression of CD4 and CD25. These cells stably express the 
transcription factor FoxP3, which is the master regulator of CD4+CD25+ TREG cells 
and can develop either in the thymus, or in the periphery where naïve CD4+ T cells 
can take on a regulatory phenotype. Over the past decade there has been an often 
confusing nomenclature used to describe different populations of cells with 
regulatory function (Abbas et al., 2013). In this thesis, I will use the term TREG cell 
to refer to CD4+CD25+FoxP3+ regulatory T cells isolated from or present in the 
periphery of mouse and man.  
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CD4+ T cells that possess a TCR with a relatively high affinity for self-peptide can 
be deleted in the thymus by negative selection or undergo a program of 
differentiation into a TREG cell (Sgouroudis et al., 2008). These cells then migrate 
into the periphery where they can mediate peripheral tolerance using a variety of 
suppressive mechanisms. These mechanisms include: secretion of suppressive 
cytokines such as IL-10, IL-35 and TGF (transforming growth factor)-β, granzyme 
and perforin mediated killing of APCs and CTLA-4 expression (Collison et al., 
2007; Gondek et al., 2005; Gregg et al., 2004; Puccetti and Grohmann, 2007; 
Rubtsov et al., 2008; Takahashi et al., 2000). CTLA-4 expression can inhibit co-
stimulatory molecule expression of APCs and induce these cells to secrete 
metabolites with immune cell toxicity. Importantly, all the suppressive functions 
exhibited by TREG cells reported to date require prior TCR stimulation, thus their 
highly self-reactive TCR repertoire is vital to preventing autoimmune diseases.  
 
The strongest evidence that demonstrates the importance of an intact TREG cell 
compartment comes from patients with the immune disorder immune 
dysregulation, polyendocrinopathy, enteropathy x-linked syndrome (IPEX). These 
patients have a loss of function mutation in their FOXP3 gene and therefore have 
no TREG cells and an overwhelming 80% of these patients develop T1D at a young 
age, irrespective of other genetic risk factors (Wildin et al., 2001). Furthermore, 
scurfy mice, which also have a defect in the foxp3 gene, develop severe and fatal 
autoimmune diseases including diabetes (Brunkow et al., 2001); this points to a 
clear role for TREG cells in the prevention of T1D and although not as profound as 
observed in IPEX, a number of studies in mouse and man suggest that defects in 
the fitness and function of TREG cells play a role in “normal” T1D pathogenesis.  
 
In man, the majority of studies have identified that the function, but not the 
frequency of TREG cells, differs between patients with T1D and healthy controls 
(Brusko et al., 2007; Glisic-Milosavljevic et al., 2007a; Glisic-Milosavljevic et al., 
2007b; Lawson et al., 2008; Long et al., 2010). In classical in vitro co-culture 
suppression assays, TREG cells from patients with T1D are less able to suppress 
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the proliferation of autologous effector T (TEFF) cells in comparison to healthy 
controls. (Brusko et al., 2005; Lawson et al., 2008; Lindley et al., 2005). At least 
some of the observed reduction in TREG cell function has been linked to an 
increased resistance to suppression of the TEFF cells from patients with T1D 
(Lawson et al., 2008; Schneider et al., 2008). However, many studies have also 
identified additional defects within the TREG cells of patients. Firstly, it has been 
observed that TREG cells from patients are more prone to apoptosis (Glisic-
Milosavljevic et al., 2007a; Glisic-Milosavljevic et al., 2007b). Moreover, in 
expanded populations of TREG cells, patients with T1D have an increased 
proportion of IFN-γ secreting cells compared to healthy controls (McClymont et al., 
2011).  Furthermore, TREG cells from patients with T1D have a reduced sensitivity 
to IL-2, which leads to a reduced maintenance in FoxP3 expression (Garg et al., 
2012; Long et al., 2010).  This reduced sensitivity to IL-2 may have an effect on 
TREG cell fitness and persistence at the site of inflammation. Interestingly, staining 
of pancreatic sections from individuals with T1D revealed that the presence of 
FoxP3+ TREG cells in the islet cell infiltrate is uncommon (Willcox et al., 2009).   
 
Several studies in the NOD mouse have suggested that although the frequency of 
TREG cells is unaltered, the function and stability of TREG cells is progressively lost 
as disease develops. It has been identified that within the inflamed islets of the 
NOD mouse there is an increase in the TEFF:TREG cell ratio (Tang et al., 2008). 
Additionally, genetic lineage tracing of FoxP3+ TREG cells in the NOD mouse 
revealed a proportion of inflammatory cytokine secreting “Ex-FoxP3+” cells within 
the inflamed islets (Zhou et al., 2009). There is also evidence suggesting that 
reduced levels of IL-2 at the site of inflammation has a damaging effect on TREG 
cell fitness and function. For example a mutation in the idd3 allele found in the 
NOD mouse is associated with reduced levels of IL-2 production by activated TEFF 
cells. Interestingly, the expression of a protective idd3 allele in NOD mice reduced 
the incidence of diabetes and was concurrent with an increase in TREG cell 
proliferation and suppressive function (Sgouroudis et al., 2008). Furthermore, 
although the frequency of TREG cells is unaltered there is evidence that thymic 
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derived TREG cells from the NOD mouse have a highly restricted TCR repertoire 
compared to other mouse strains (Ferreira et al., 2009). A reduced TCR diversity 
could compromise TREG cells ability to prevent autoimmunity by restricting the 
range of self-peptide they can recognise. This defect was linked to a reduction in 
TCR signalling during negative selection in the thymus leading to a decrease in 
TREG cell differentiation (Ferreira et al., 2014). Interestingly, another study in mice 
identified that a loss of the PTPN22 gene, which encodes an inhibitor of TCR 
signalling, resulted in reduced TREG thymic development (Maine et al., 2012). 
Coupled with the autoimmune disease associated SNP within the PTPN22 gene, 
these data infer that TCR signalling can lead to a restricted TREG cell repertoire that 
may be less well equipped to prevent autoimmunity. 
 
It is still debatable whether reduced TREG cell function in T1D patients is causative 
or a consequence of T1D (Roep and Tree, 2014). The T1D associated IL2 
polymorphism, rs12722495 has been shown to affect the phenotype of both TEFF 
and TREG cells and is proposed to contribute to the reduced TREG cell function seen 
in T1D (Dendrou et al., 2009; Garg et al., 2012). Similarly to the idd3 allele in the 
NOD mouse, this polymorphism reduced the amount of IL-2 produced by 
conventional T cells and can reduce the sensitivity of TREG cells to this cytokine 
(Dendrou et al., 2009; Garg et al., 2012). Importantly, the study performed by Garg 
et al assessed the importance of this polymorphism on TREG cell function in 
subjects with no evidence of disease. A second study by Gilisic-Milosavljevic et al 
identified that TREG cell apoptosis was greater in patients with newly onset T1D and 
in subjects who are at a high risk of disease, as evidenced by the presence of two 
or three autoantibody specificities, compared to healthy control subjects (Glisic-
Milosavljevic et al., 2007b). These studies suggest that the defects in TREG cells are 
causative of T1D rather than a consequence of disease. However, there is a strong 
rationale that these defects, decreased sensitivity to IL-2 and increased apoptosis 
would be overcome by increasing TREG cell number to boost overall suppression 
and prevent the occurrence or prohibit the progress of T1D.   
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Other TREG subsets have been found to be impaired in patients with T1D. Studies 
have identified CD4+FoxP3- cells that secrete high levels of the 
immunosuppressive cytokine IL-10 upon recognition of β cells Ags (Gregori et al., 
2012; Petrich de Marquesini et al., 2010; Sanda et al., 2008). These cells have 
been shown to kill APCs pulsed with β cell Ags in vitro thereby preventing the 
function of effector T cells subsets (Tree et al., 2010). Interestingly, these IL-10 
secreting cells are present in healthy controls and enriched in individuals who 
develop T1D at an older age versus those who are younger at disease onset 
suggesting they may play a role in disease prevention (Arif et al., 2004; Petrich de 
Marquesini et al., 2010).  
 
CD8+ TREG cells have also more recently been identified as having a role in the 
suppression of T1D. Although these cells are less well characterised than CD4+ 
TREG cells, a study in 2010 showed that CD8+ T cells specific for HLA-E bound to 
heat shock peptide hsp60sp could mediate self/non-self discrimination in the 
periphery (Jiang et al., 2010). This study also showed that CD8+ T cells from 
patients with T1D had a defect in this self/non-self discrimination pathway; 
however, it could be rescued by vaccinations with autologous DCs loaded with 
hsp60sp. This study provided further evidence of an impaired immune regulation in 
patients with T1D.  
 
1.2.6. Current Therapies to Strengthen Immune regulation 
The overwhelming evidence that defective immune regulation contributes to T1D 
development has provided a strong rationale for the use of therapies designed to 
strengthen regulatory mechanisms (Figure 1-3). In the 1980’s, it was recognised 
that non-specific immunosuppressive agents such as cyclosporine A could prevent 
T1D progression in newly diagnosed patients (Silverstein et al., 1988). 
Cyclosporine A functions by preventing IL-2 transcription and reduces the function 
of all T cells. However, the overall reduction in T cell activity causes large numbers 
of side effects that therefore limits its use in T1D, especially in the young. More 
recently, therapies aimed at preventing or reversing T1D have increased in their 
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immune specificity. These now include monoclonal antibodies (mAbs) that target 
specific immune cell subsets, islet Ag specific immunotherapy to promote Ag 




Figure 1-3 Re-addressing the balance of immune regulation and autoimmunity. In health, 
autoreactive T cells are kept in check by TREG cells and autoimmunity does not occur. Patients with 
T1D have a genetic predisposition to reduced immune regulation with reduced fitness and 
suppressive function of TREG cells. Prolonged inflammation ensures that TEFF cells from T1D patients 
are more resistant to suppression, which also contributes to T1D progression. Therefore, therapies 
that are aimed to readdress the balance of immune regulation are being investigated to treat 
patients with T1D. The majority of these therapies are aimed at increasing TREG cell number and 
fitness with a view of overcoming the dominant autoimmune response.  
 
The use of αCD3 mAbs (teplizumab and otelixizumab) has been investigated as an 
immunotherapy in the treatment of T1D. In the NOD mouse, αCD3 treatment has 
been shown to prevent diabetes development in pre-diabetic mice and reverse 
disease in mice with overt diabetes (Chatenoud et al., 1994). It has been 
suggested that αCD3 mAbs can induce tolerance via a TGF-β mediated induction 
of TREG cells (Belghith et al., 2003).  
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Six phase II or III clinical studies have been completed using teplizumab to treat 
patients with recent onset T1D (Daifotis et al., 2013). These trials showed efficacy 
with a reduced loss of c-peptide levels and insulin usage in the treated cohort 
compared to placebo treated groups. Phase II studies of patients with new onset 
T1D treated with a second αCD3 monoclonal antibody, otelixizumab also showed 
preservation of c-peptide levels and reduced insulin usage in comparison to 
placebo treated groups. However, side effects of this treatment included 
reactivation of Epstein-Barr virus (EBV) in 75% of treated patients. Two phase III 
studies; DEFFEND-1 and DEFFEND-2, were subsequently conducted using lower 
doses of otelixizumab. In the DEFFEND-1 study, there was no significant 
difference in c-peptide levels observed between drug treated and placebo treated 
groups and enrolment in the DEFFEND-2 study was suspended (Ambery et al., 
2014; Aronson et al., 2014). In both phase III studies, the reduced dosage had a 
significant decrease in serious adverse events compared to the phase II studies 
but correlated with a reduced efficacy. Therefore, further studies are required to 
improve the balance between efficacy and adverse events with this treatment. In 
addition to the αCD3 mAbs trials, Rituximab, an αCD20 mAb and Abatacept, a 
CTLA-4-Ig fusion protein, have been trialled as treatments for T1D. Rituximab 
functions by depletion of CD20+ B cells and in a phase II study could partly improve 
insulin secretion over 1 year in comparison to the placebo treated cohort 
(Pescovitz et al., 2009). Abatacept modulates T cell co-stimulation by binding to 
CD80 and CD86 co-stimulation molecules and preventing “signal two” – a 
requirement for T cell activation. Continuous treatment with Abatacept for two 
years of subjects newly diagnosed with T1D slowed the decline of β cell function by 
an average of 9.6 months compared to the placebo treated group (Orban et al., 
2011). The significant decrease in c-peptide decline was associated with the 
expansion of naïve CD4+ T cells and the subsequent contraction of the CD4+ 
central memory population (Orban et al., 2014). However, these changes in CD4+ 
T cell populations were reversed upon Abatacept administration. Therefore, it is 
suggested that the continuous use of Abatacept can modify the CD4+ T cell 
compartment of T1D patients with the effect of slowing down disease progression. 
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The aim of Ag specific immunotherapy is to promote an immunomodulatory 
response to certain Ags that are targets in autoimmunity. The administration of 
whole islet Ag or peptides have shown efficacy in the treatment of murine models 
of diabetes. The proposed mechanism of peptide immunotherapy is the promotion 
of IL-10 secreting CD4+ T cells that are activated by immature DCs that present the 
administered peptide (Tarzi et al., 2006). The induced IL-10 secreting CD4+ T cells 
can then suppress islet Ag specific responses. In 2009, a first in man phase I 
clinical trial assessed the safety of proinsulin peptide immunotherapy in the 
treatment of patients with T1D (Thrower et al., 2009). Most interestingly, this study 
identified an induction of proinsulin specific IL-10 secreting CD4+ T cells in 
individuals treated with peptide, although these cells were short-lived. Peptide 
immunotherapy trials have also been performed using DiaPep277, an Ag derived 
from hsp60sp. Pathogenic T cell responses to this peptide have been found in both 
the NOD mouse and in patients newly diagnosed with T1D (Abulafia-Lapid et al., 
1999). Administration of this peptide has found to induce Ag specific IL-10 
secreting CD4+ T cells and enhance the function of TREG cells via signalling through 
toll like receptor-2 (Huurman et al., 2008; Zanin-Zhorov et al., 2006). Furthermore, 
a recently completed phase III clinical trial reported that administration of this 
peptide could preserve β cell function and improve glycemic control (Raz et al., 
2014).  
 
IL-2 is crucial for TREG cell function and development. The high levels of CD25 on 
the surface of TREG cells, endow an increased sensitivity to IL-2 compared to other 
immune cell subsets such as TEFF cells or NK cells. It is therefore hypothesised 
that low dose therapy of IL-2 will selectively target TREG cells for activation and 
improved function. In fact, low dose IL-2 therapy has been successful in the 
treatment of GVHD and autoimmune vasculitis (Koreth et al., 2011; Saadoun et al., 
2011). In both settings, low dose IL-2 therapy selectively increased TREG cell 
number without any alteration in the TEFF cell compartment. Importantly clinical 
improvements were seen in treated patients in both trials and no adverse events of 
treatments were reported. Pre-clinical efficacy of this treatment has previously 
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been shown in the NOD mouse model and subsequently low dose IL-2 therapy is 
currently being investigated as a potential treatment for T1D. Specifically, a 
reversal of diabetes was seen in 60% of NOD mice treated with low dose IL-2 
therapy at the time of disease establishment (Grinberg-Bleyer et al., 2010). This 
reversal in disease was concurrent with an increase in TREG cell frequency within 
the islets. However, no disease reversal was identified in NOD mice that were 
deficient in TREG cells thus identifying the specific effect of this therapy on TREG cells 
(Grinberg-Bleyer et al., 2010). Rapamycin (RAPA), an immunosuppressive drug, 
blocks the activation of the mammalian target of Rapamycin complex 1 (MTOR-1), 
which preferentially inhibits proliferation of TEFF cells. The use of this drug to treat 
patients with T1D was found to improve the suppressive capacity of TREG cells 
(Monti et al., 2008b). The combination therapy of low dose IL-2 and RAPA was 
found to prevent the spontaneous occurrence of T1D in the NOD mice and the 
reoccurrence of diabetes in mice that were subject to islet transplantation 
(Rabinovitch et al., 2002).  Based on these successes, a phase I safety clinical trial 
assessing the use of low dose   IL-2 therapy with RAPA has now been completed 
(Long et al., 2012). However, despite the promising pre-clinical data, this trial 
observed a transient decrease in β cell function and no overall improvement of 
function over time. Additionally, a large rise in the frequency of NK cells and 
eosinophils was observed. Subsequently, the additional use of RAPA in this trial 
was stopped in the last few patients in the treatment group. The study however, did 
observe a transient increase in TREG cell frequency and an overall improvement of 
IL-2R signalling was discovered in CD25+ cells a year after treatment. Two further 
“ultra” low dose IL-2 therapy trials are currently underway to determine the optimal 
dosage of IL-2 for the treatment of T1D. The adaptive study of IL-2 dose of TREG 
cells in T1D (DILT1D) study has recently completed and aims to identify the doses 
of IL-2 that achieve a minimum or maximum TREG cell increase in adults aged 18-
50 (ClinicalTrials.gov identifier NCT01827735) (Waldron-Lynch et al., 2014). The 
dose finding study of IL-2 at ultra-low dose in children with recently diagnosed T1D 
(DFIL2-child) study is also aiming to find the optimal dose of IL-2 to treat T1D 
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patients but is selectively enrolling children aged 7-12 years of age 
(ClinicalTrials.gov identifier NCT01862120). 
 
The immunotherapies described have all aimed to strengthen the immune 
regulation of patients with T1D via a targeted induction of immunosuppressive TREG 
cells. Although efficacy has been seen, these therapies can elicit off target effects 
and serious adverse events. An alternative route to strengthening the immune 
regulation of patients with T1D and improving TREG cell frequency and function is in 
the form of adoptive TREG cell therapy, which will be the focus of this thesis.  
 
1.3. Adoptive Regulatory T Cell Therapy 
1.3.1. Principles of Adoptive Regulatory T cell Therapy 
The potential of so-called “suppressor T cells” as a therapeutic tool was first 
suggested nearly 40 years ago (Gershon, 1975). Following on from this, seminal 
work in 1995 by Sakaguchi et al reported that nude mice reconstituted with CD25+ 
depleted T cells developed widespread autoimmunity, which was reversed upon 
re-introduction of the CD25+ T cell compartment (Sakaguchi et al., 1995). Despite 
nearly four decades of study, therapies aimed at harnessing the suppressive 
function of TREG cells have only been implemented in the past 10-15 years. In 
addition to the IL-2 trials discussed above, a number of trials have aimed to 
modulate the frequency or suppressive effects of TREG cells in vivo. The Phase I 
safety clinical trial that tested the super agonist αCD28 antibody, TGN412, had 
particularly dramatic consequences. In pre-clinical testing, this antibody was shown 
to preferentially activate TREG cells and could suppress autoimmunity in a number 
of mouse disease models (Beyersdorf et al., 2006). However, all participants 
treated with this drug developed multi-organ failure due to non-targeted activation 
of all T cells subsets and not just the intended TREG cells (Suntharalingam et al., 
2006). Other therapies, such as low dose IL-2 therapy, which is aimed at 
strengthening and increasing the TREG cell compartment of patients with T1D, have 
also had off target effects (Long et al., 2012). These data highlight the risks in the 
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augmentation of a specific immune cell subset in vivo, particularly the TREG cell 
subset, which so far has no unique identifying marker. 
 
An alternative approach to harnessing the suppressive function of TREG cells and 
increasing their frequency in vivo is the use of adoptive TREG cell therapy. This 
therapy, put simply is the isolation, activation, expansion and/or modification of 
TREG cells in vitro and the re-infusion of the cells back into patients (Figure 1-4). 
The use of adoptive TREG cell therapy has stemmed from adoptive T cell therapy, 
which has been used successfully to increase the immune response to cancers 
and infectious diseases. Although these therapies have only recently been 
introduced into clinical trials, the principle of adoptive cell therapy is relatively old in 
terms of immunological based therapies. Studies in the 1950’s identified that the 
adoptive transfer of cells from the tumour draining lymph node of one mouse could 
mediate immunity to the tumours of a second mouse (Billingham et al., 1954). 
From these studies, the phrase “adoptive immunity” was coined and the benefits of 
adoptive T cell therapy was realised. These therapies were further enhanced by 
the discovery of IL-2 which permitted the ex vivo expansion of human T cells 
(Lotze et al., 1980). This discovery has allowed the field of adoptive T cell therapy 
to progress and to date, the treatment of melanomas with ex vivo expanded tumour 
infiltrating lymphocytes have yielded promising results (Rosenberg et al., 2008). 
Adoptive T cell therapy is also being investigated in the treatment of patients with 
human immunodeficiency virus (HIV) (Riddell and Greenberg, 1995).  
 
With the successes of adoptive T cell therapy at enhancing anti-tumour and anti-
pathogen responses, investigators are now researching the possibility of using 
adoptive TREG cell therapy to promote tolerance in autoimmunity and 
transplantation.  
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Figure 1-4 Principle of Adoptive TREG cell Therapy. TREG cells can be isolated from the peripheral 
blood of patients by magnetic bead sorting using the markers CD4+ and CD25+ or by Fluorescent 
activated cell sorting (FACS) of CD4+CD25+CD127- cells. TREG cells can be expanded using 
αCD3/CD28 antibodies and a high dose of IL-2. After the in vitro expansion period, cells can be 
tested for purity (including sterility of final product) and their ability to suppress in vitro. The final 
TREG cell product can then be infused into the patient or cryopreserved for infusion later.  
 
1.3.2. Efficacy of Adoptive TREG cell therapy from Pre-Clinical Models 
A number of animal models have so far demonstrated efficacy using adoptive TREG 
cell therapy in the promotion of immune tolerance in the context of GVHD, solid 
organ transplantation and autoimmunity. However, this therapy is limited by the low 
frequency of TREG cells, ~5-10% total CD4+ T cells that are found in the periphery 
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of both mice and humans. Therefore, protocols have been designed for the ex vivo 
expansion of these cells to ensure sufficient cell numbers. These protocols typically 
involve a polyclonal TCR stimulus such as αCD3/CD28 mAb and high doses of   
IL-2 to promote expansion and survival of the TREG cells (Tang et al., 2004).  
 
A model of GVHD was the first in mouse disease to be successfully treated with 
the adoptive transfer of TREG cells (Taylor et al., 2002). GVHD is a lethal disease 
that occurs when alloreactive T cells from a donor bone marrow graft reacts 
against the host’s MHCI and MHCII molecules. Models of GVHD use the transfer 
of CD4+ T cells from an MHC mismatched mouse to a second immunodeficient 
mouse to induce disease. The study by Taylor et al identified that the co-transfer of 
an equal number of ex vivo expanded and activated CD4+ TREG cells prevented 
GVHD mediated by the adoptive transfer of CD4+ TEFF cells. This study identified 
that ex vivo activated TREG were potent suppressors of immune cell mediated 
disease. The efficacy of the adoptive transfer of TREG cells has also been shown in 
solid organ transplantation models; this was first demonstrated in a cardiac 
allograft rat model whereby the adoptive transfer of CD4+ T cells from rats with 
long term survival of an allografts, promoted tolerance to rats receiving mis 
matched heart transplants (Hall et al., 1990). More recently, adoptive TREG cell 
therapy was shown to promote the tolerance of a porcine islet transplant in a 
humanised mouse model (Yi et al., 2012). 
 
It is widely recognised that TREG cells require activation through their TCR before 
eliciting suppressive function, however the subsequent suppressive mechanisms 
can act in a non-Ag specific manner (Thornton and Shevach, 2000).  Although the 
TREG cells are activated in vitro prior to infusion into mouse models/patients, it is 
hypothesised that these cells will require further TCR activation in vivo to elicit full 
suppressive function. Thus, it is widely suggested that adoptive TREG cell therapy 
using Ag specific TREG cells would be more efficacious than polyclonal TREG cells, 
and indeed this has been investigated in a number of mouse models.  A study by 
Tang et al in 2004 demonstrated the superior potency of Ag specific TREG cells by 
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using the BDC2.5 TCR Transgenic mouse (Tang et al., 2004). This mouse is 
transgenic for the TCR genes of the BDC2.5 CD4+ T cell clone, which was isolated 
from the NOD mouse and has been shown to be specific for a peptide of islet Ag 
chromogranin A (Stadinski et al., 2010). Isolated and expanded BDC2.5 TREG cells 
were found to suppress the transfer of diabetes by diabetogenic T cells in the 
immunodeficient NOD.RAG-/-mice (Tang et al., 2004). Moreover, in comparison to 
polyclonal TREG cells derived from a NOD mouse, a much lower number of Ag 
specific TREG cells were required to mediate this suppression. Furthermore, the 
transfer of Ag specific TREG cells could prevent the rejection of transplanted 
syngeneic islet cells in a NOD mouse. In the same model, the transfer of expanded 
polyclonal TREG cells could not promote tolerance to the transplant. The study by 
Tang et al expanded BDC2.5 TREG cells using αCD3/CD28 stimulation and high 
dose IL-2 but it has been identified that Ag specific TREG cell can also be expanded 
using peptide pulsed DCs in combination with high dose IL-2 (Yamazaki et al., 
2003). Two subsequent studies identified that BDC2.5 TREG cells expanded with 
cognate peptide pulsed DCs were capable of suppressing diabetes onset in a 
diabetes transfer model (Tarbell et al., 2007; Tarbell et al., 2004). The first study 
also identified that the Ag specific TREG cell were >100 fold more potent at 
preventing diabetes development than polyclonal TREG cells (Tarbell et al., 2004). 
Furthermore, the Ag specific TREG cells were able to prevent diabetes development 
in pre-diabetic mice and delay development in recent onset diabetic NOD mice 
(Tarbell et al., 2007). Interestingly, the second study identified that the successfully 
treated NOD mice retained diabetogenic T cells in the pancreatic draining lymph 
node and pancreas but had an increased frequency of TREG cells that were host 
derived (Tarbell et al., 2007), suggesting that the adoptively transferred TREG cells 
were able to promote a regulatory environment at the site of inflammation leading 
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1.4. Moving Adoptive TREG cell therapy into Man 
1.4.1. TREG cell selection and Expansion 
One of the main drawbacks to adoptive TREG cell therapy in humans is the lack of a 
definitive marker for this cell subset. As previously mentioned, these cells are 
typically characterised as CD4+CD25+FoxP3+. However, FoxP3 is an intra-nuclear 
protein and staining for this marker requires the fixation and permeabilisation of 
cells. To remove the requirement of staining for FoxP3, the expression of IL-7 
receptor α chain, CD127, has been found to inversely correlate with FoxP3 
expression (Liu et al., 2006). Therefore, the isolation of CD4+CD25+CD127low cells 
typically yields a greater than >95% pure TREG cell population. However, recently 
activated TEFF cells can up-regulate CD25 and FoxP3 expression and there is a 
possibility of contaminating TEFF cells within the isolated TREG cell population. Due 
to the polyclonal expansion protocols of human TREG cells, contaminating TEFF cells 
would expand to a greater extent that TREG cells, therefore increasing their 
frequency in the whole population. Thus, it is vital that the isolation of TREG cells 
minimised TEFF cell contamination. CD45RA is another marker that can be used to 
further delineate human TREG cells. Ag stimulated T cells lose expression of 
CD45RA in favour of CD45RO expression and therefore CD45RA expression can 
denote naïve T cells. It was further identified by Miyara et al that three 
subpopulations of TREG cells could be delineated by CD45RA and FoxP3 
expression (Miyara et al., 2009). TREG cells that are CD45RA+FoxP3low are found to 
be “resting TREG cells” and CD45RA-FOXP3high “effector TREG cells,” both these 
subsets have shown suppressive function in vitro. However, cells that are 
CD45RA-FoxP3low have been shown to secrete pro inflammatory cytokines such as 
IL-17, although this has recently been found to not compromise TREG cell 
suppressive function (Afzali et al., 2013). Additionally, “resting TREG” cells have 
been shown to have greater suppressive capacity that total CD4+CD25hi TREG cells. 
These cells have also been found to remain demethylated at the TREG specific 
demethylation region (TSDR) within the FOXP3 gene after ex vivo expansion 
(Hoffmann et al., 2009). Demethylation within this region has been shown to 
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correlate with FOXP3 stability and specific demethylation within this region denotes 
a stable TREG cell in comparison with recently activated TEFF cells (Baron et al., 
2007). However, a caveat with isolation of TREG cells based on CD45RA 
expression is that the expression of this marker decreases with age (Seddiki et al., 
2006).  
 
Another potential problem with adoptive TREG cell therapy in humans is the isolation 
and expansion of sufficient quantities of cells for effective therapy. A study by 
Putnam et al isolated CD4+CD25+CD127low TREG cells from the peripheral blood of 
patients with T1D using fluorescent activated cell sorting (FACS) and expanded the 
cells in vitro with αCD3/CD28 coated microbeads and high dose IL-2 for two weeks 
(Putnam et al., 2009). This protocol, on average, yielded a 1500 fold expansion of 
TREG cells and the cells retained high levels of FoxP3 expression and suppressive 
capabilities in in vitro suppression assays. Moreover, comparison of the expansion 
potential of CD45RA+ and CD45RA- TREG cells revealed that the CD45RA+ TREG 
cells expanded at a greater rate. The benefit of FACS sorting over other methods 
of cell isolation, such as magnetic beads, is a higher purity and yield of TREG cells 
(typically 95% for FACS and 60% for magnetic beads) (Peters et al., 2008; Putnam 
et al., 2009). Additionally, the protocol outlined in the study by Putnam et al can be 
modified to meet good manufacturing practice (GMP), which is vital to therapies 
using cell products. The addition of RAPA to expanding TREG cell cultures has also 
been shown to improve the purity of expanded TREG cells by inhibiting the 
expansion of TEFF cells (Battaglia et al., 2006). However, the addition of RAPA to 
cultures has been shown to reduce the expansion of TREG cells by >10-fold 
(Golovina et al., 2008). An alternative source of TREG cells is from umbilical cord 
blood (UCB) as opposed to peripheral blood.  UCB cells are immunologically naïve 
as the blood cells derive in a protected environment, thus UCB cells lack memory 
or recently activated CD25+ TEFF cells that may contaminate the CD25+ TREG cell 
population. CD4+CD25+ TREG cells isolated from UCB were found to expand ~200-
300 fold, be potent suppressor cells and have limited capacity for producing 
cytokines including IL-2, IFN-γ and IL-10. Although these cells provide an attractive 
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therapeutic tool, this therapy would largely rely on the use of allogeneic TREG cell 
transfer, which could open up the possibility of the rejection of transferred cells.  
  
1.4.2. Moving TREG Cell Therapy Into The Clinic 
GVHD became the first human disease to be treated by the adoptive transfer of 
TREG cells. The first study treated two patients, one with chronic GVHD that had 
persisted two-years post bone marrow transplant and the second had acute GVHD 
at one-month post transplant (Trzonkowski et al., 2009). The patient with chronic 
GVHD was treated successfully with a single infusion of ex vivo autologous 
expanded CD4+CD25+CD127- TREG cells that led to complete withdrawal of 
immunosuppressive drugs. The patient with acute GVHD however, was treated 
with multiple infusions of expanded donor TREG cells that were unable to prevent 
the progression of disease. A second phase I/II trial administered expanded 
CD4+CD25hi TREG cells from a third party UCB graft to patients receiving UCB stem 
cell transplants (Brunstein et al., 2011). This study demonstrated the safety and 
tolerability of the UCB derived TREG cells and although the severity of acute GVHD 
decreased the overall incidence was not. Currently there is an on-going multicentre 
phase I/II study investigating the safety of administering ex vivo expanded TREG 
cells to patients receiving kidney transplants (ClinicalTrials.gov identifier 
NCT02129881).  
 
A phase I safety clinical trial assessing the use of polyclonal TREG cells to treat 
newly diagnosed (within >3 and <24 month) patients with T1D is ongoing 
(ClinicalTrials.gov identifier NCT01210664). This study is implementing the 
polyclonal expansion of FACS isolated CD4+CD25+CD127low/- TREG cells with 
αCD3/CD28 coated beads and IL-2 and will administer TREG cells at a single time 
point and include a dose escalation study. The primary end-point of this study is 
the safety and tolerability of TREG cell infusion in T1D although C-peptide response, 
the use of insulin and immunological markers will be assessed as secondary 
outcomes. Although this study is not due for completion until December 2016, it 
should provide valuable data on the feasibility of TREG cell transfer in the treatment 
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of T1D. A second study that administered FACS sorted CD4+CD25+CD127- TREG 
cells to children within two months of T1D diagnosis completed in 2012 (Marek-
Trzonkowska et al., 2012). This study treated ten children with a single infusion of 
TREG cells at either 10x106 or 20x106 TREG cells/kg weight. Firstly, the study 
identified the safety of the transfer of TREG cells and that no significant difference 
between the two doses of TREG cells was observed. Of the ten children treated with 
TREG cells, two children remained insulin independent at 6 months, compared to no 
children in the non-treated cohort. In a follow up study the investigators 
administered previously treated children with a second dose of TREG cells (Marek-
Trzonkowska et al., 2014). The two children who were initially insulin independent 
after the first dose of TREG cells remained insulin independent after the second 
dose. In total, 66% of the treated children were in disease remission post TREG 
treatment, including five treated with two TREG cell infusions, two with a single 
infusion of 20x106/kg body weight and one with an infusion of 10x106/kg body 
weight. This was in comparison to 20% of children in the non-TREG cell treated 
cohort.  
 
1.4.3. Therapy With Ag Specific TREG Cells in Man 
The results from the small number of trials assessing adoptive TREG cell therapy 
using ex vivo expanded polyclonal TREG cells have been promising. However, the 
data is limited and the results from the two on-going trials assessing these cells in 
T1D and solid organ transplantation should expand the knowledge base on this 
therapy. It has been shown in animal models that Ag specific TREG cells are more 
efficacious at suppressing disease than polyclonal TREG cells. The studies by 
Marek-Trzonkowska et al also identified that the therapeutic benefit of TREG cells 
waned over time and that multiple doses may be required (Marek-Trzonkowska et 
al., 2014). Evidence from animal studies indicates that treatment with Ag specific 
TREG cells would require much lower numbers of cells, compared to polyclonal TREG 
cells, as these cells can be >100 fold more potent. A number of methods that can 
be used to expand Ag specific populations of TREG cells have been identified 
(Figure 1-5).  As discussed, DCs pulsed with islet Ags have been used to expand 
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Ag specific TREG cells isolated from mice (Tarbell et al., 2007). However, the 
frequency of Ag specific TREG cells in peripheral blood is reported to be only 
1:20,000-1:200,000 cells making it harder to achieve a suitable number of TREG 
cells for therapy (Di Lorenzo et al., 2007).  
 
Several methods to generate Ag specific TREG cells by stimulation of naïve 
CD4+CD25- T cells in the presence of cytokines or growth factors have been 
described. For example, these so called “adaptive TREG cells” can be generated in 
vitro from naïve CD4+CD25- T cells by incubation with peptide pulsed DCs and lL-2 
(Long et al., 2009; Walker et al., 2005). Adaptive TREG cells can also be generated 
by exposure to Ag in the presence of TGF-β and RAPA (Chen et al., 2003). 
However, there are major questions over the stability of adaptive TREG cells with 
the possibility that these cells can revert to an TEFF cell phenotype under 
inflammatory conditions (Roncarolo and Battaglia, 2007). Therefore, the use of Ag 
specific adaptive TREG cells as a treatment to autoimmune disease would pose a 
high risk as the reversion of these cells at inflammatory sites could worsen disease 
state. To circumvent issues over low frequency and stability of Ag specific TREG 
cells, it has been suggested that designer TREG cells can be generated using viral 
vectors (Brusko et al., 2010; Plesa et al., 2012). This process involves the transfer 
of TCR genes of any chosen Ag specificity to polyclonal TREG cells with the aim of 
generating a large population of Ag specific TREG cells. The transfer of TCR genes 
could also be supplemented with the transfer of genes that can stabilise TREG cell 
function.  
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Figure 1-5 Methods to Expand Ag Specific TREG cells. (A) Polyclonal TREG cells can be expanded 
from isolated CD4+CD25+ cells using αCD3/CD28 stimulation with high dose IL-2. (B) Peptide 
pulsed APCs can be used to expand Ag specific TREG cells from CD4+CD25+ TREG cells and (C) 
generate de novo Ag specific adaptive TREG cells (aTREG) from CD4+CD25- naïve T cells. (D) The Ag 
specificity of activated polyclonal TREG cells can be re-directed using viral vectors to deliver TCR 
genes. Adapted from Brusko et al, Immunol Rev. 2008 (Brusko et al., 2008) 
1.5. Gene Therapy Using Viral Vectors 
1.5.1. History and Principles of Viral Based Gene Transfer 
T-cell engineering is a form of gene therapy in which genetic material is transferred 
to a target T cell to enhance its therapeutic application. A number of vehicles, 
referred to as vectors, can be exploited for the transfer of genetic information. A 
common method involves the use of viruses. Some viruses possess an exquisite 
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biological mechanism for cell entry and integration into the host DNA, which can be 
harnessed for the delivery of therapeutic genes. In particular, RNA viruses such as 
retroviruses, are unique in their ability to reverse transcribe their RNA genome into 
double stranded DNA (dsDNA) and stably integrate into the genome of the host 
cell. For T cell engineering, this includes the delivery of specific TCR genes into a 
T cell in order to re-direct the Ag specificity of a bulk population of cells.  This 
method of T cell engineering has been used to generate large numbers of Ag 
specific T cells for the treatment of cancers and infectious diseases (Cooper et al., 
2000; Morgan et al., 2006; Robbins et al., 2011). Recently, this concept has been 
applied to the generation of Ag specific TREG cells, which can circumvent the 
problems associated with the isolation and expansion of rare populations of TREG 
cells (Brusko et al., 2010).  
 
The earliest viral vectors for gene therapy generated were γ-retroviral vectors 
based on the Moloney Murine Leukaemia Virus (MoMLV) and research on these 
vectors peaked in the 1980’s (Friedmann, 1992). The main principle of retrovirus 
engineering for gene therapy is to separate viral components required for DNA 
replication from those that cause disease. Therefore, genes that are required for 
viral entry, replication, assembly and packaging and genes that encode 
immunogenic Ags were deleted from the MoMLV viral genome. The remaining viral 
genome was then used as a backbone to clone in any gene of interest, referred to 
as a transgene (Mann et al., 1983) (Figure 1-6). The resulting construct, known as 
the transfer plasmid, retains cis acting genomic sequences known as long terminal 
repeats (LTRs), which encode all the genes crucial for the transcription, integration 
and expression of the transgene. Importantly, the transfer vector does not encode 
any genetic information for viral replication or the packaging of virions. Rather, the 
helper genes required for the production of virions are provided in trans by two 
separate DNA plasmids (Markowitz et al., 1988). The envelope plasmid encodes 
the genes for the viral envelope and subsequently provides the tropism of the virus. 
The second helper plasmid, referred to as the packaging plasmid, encodes the 
genes required for the virus structure and viral replication (Figure 1-6). Importantly, 
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the transfer plasmid is the only plasmid to retain the Ψ sequence, which directs 
viral RNA encapsidation (Cooray et al., 2012). Therefore, only the transgene is 
packaged into the virus capsid and released into the host cell cytoplasm upon virus 
infection. These replication incompetent retroviruses can be generated by transient 
transfection of the transfer plasmid and two helper plasmids into a packaging cell 
line. The recombinant virus is then released into the packaging cell supernatant 
and can be used for the transduction of a plethora of host cells. Transduction refers 
to the infection of host cells with replication incompetent virus as opposed to a 
productive virus infection.  
 
Figure 1-6 First Generation γ-Retroviral Vectors Derived from MoMLV. (A) The transgene 
vector is cloned into the transfer plasmid that contains the viral derived long terminal repeats (LTR) 
consisting of a U3, R and U5 domain. The 5’ U3 region contains promoter and enhancer sequences 
that are crucial to reverse transcription and the 3’ U5 region allows for transcriptional termination. 
The R region is vital to the strand transfer that occurs during reverse transcription. The transfer 
plasmid also contains the Ψ sequence, which is essential for viral RNA encapsidation (Cooray et 
al., 2012). (B) The packaging plasmid encodes the gag gene, which provides the structure of the 
virus and the pol gene, which allows for viral DNA replication. Both genes are transcribed by an 
internal promoter (P) (C) The Envelope Plasmid encode the virus envelope, env gene and 
determines the tropism of the virus The Ψ sequence is removed (ΔΨ) in both the envelope and 
packaging plasmid to ensure only the transfer plasmid DNA is encapsulated in the resulting 
retrovirus.  
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For productive transgene expression, the proteins in the envelope of the virus must 
first interact with its cognate receptor on the host cells to gain entry into the cell 
(Figure 1-7).  
 
 
Figure 1-7 Schematic Representation of Recombinant Retroviral Mediated Gene Transfer. (1) 
The replication incompetent virus is constructed from the genes of three separate plasmids, 
envelope, packaging and transfer. The viral capsid contains the viral RNA encoding the transgene 
and the reverse transcriptase and integrase enzymes encoded by pol. (2) The proteins in the viral 
envelope interact with their cognate receptors on the host cell surface. (3) The virus and host cell 
membranes fuse and the viral capsid containing the vector RNA and viral enzymes are released 
into the host cell cytoplasm. (4) The vector RNA transgene is reverse transcribed to generate 
dsDNA, and is now known as the provirus (5) The provirus associated with the viral enzymes 
forming a pre-integration complex (PIC) and translocates to the nucleus during cell division when 
the nuclear membrane is permeable. (6) The provirus is integrated into the host DNA. (7) The LTRs 
act as a promoter and the vector DNA is transcribed by the host machinery and expressed in the 
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As the genes for the envelope are provided in trans, the envelope plasmid can 
encode the ENV gene of any retrovirus, which allows the virus to be pseudotyped. 
For example, viruses are commonly pseudotyped with the envelope glycoprotein 
from the pan tropic Vesicular Stomatitis Virus (VSV), which interacts with the low 
density lipoprotein receptor - a receptor ubiquitously present in the cell membrane 
(Agnello et al., 1999). Thus the pseudotyping of recombinant retrovirus with an 
envelope such as VSV-G, provides the virus with a selective advantage as it 
increases the pool of host cells that it can infect.  
 
The first clinical trial to use cells modified by viral vectors was carried out in 1990. 
In the first trial, Rosenberg et al treated five advanced melanoma patients with the 
adoptive transfer of tumour infiltrating lymphocytes that had been modified using 
retroviral vectors (Rosenberg et al., 1990). The cells were modified to express a 
neomycin resistance gene, which permitted the tracking of these cells in vivo. The 
main success of this study was the absence of serious adverse advents due to the 
gene modified T cells. All patients were tested for the presence of replicating virus 
post T cell transfer to ensure the virus remained replication incompetent, all tests 
were negative. Interestingly the gene-modified cells could be detected in the 
circulation and tumour biopsies over 50 days after T cell therapy. 
 
In more recent years, CD34+ stem cells from patients with adenosine deaminase 
(ADA)-SCID have been transduced ex vivo to express the ADA gene. So far, two 
thirds of the ADA-SICD patients who have been treated with ADA expressing 
CD34+ cells have shown clinical benefit with no adverse events (Aiuti et al., 2009). 
Another variant of SCID, known as SCID-XI, is caused by a loss of function 
mutation in the gene encoding the IL-2R common γ chain, IL2RG. Clinical trials 
completed in London and Paris used retroviral vectors to express a functioning 
IL2RG gene in CD34+ stem cells and transfuse these cells back into patients. The 
treatment was successful in 18 out of 20 patients; however, five of the patients 
developed T cell leukaemia after treatment (Howe et al., 2008). Subsequent 
research found that the retroviral vectors favoured integration within active genes 
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such as proto-oncogenes. It was also identified that the enhancer regions within 
the LTRs of the virus could permanently activate the transcription of the active 
gene leading to the ensuing T cell leukaemia.  
 
1.5.2. Benefits of Lentivirus Derived Viral Vectors for Gene Therapy 
The insertional mutagenesis observed in the SCID-XI trials, which used MoMLV 
retroviral based vectors, highlighted the safety concerns of such vectors.  
Investigators have demonstrated that the safety of these vectors can be improved 
by deletion of the enhancer regions, U3, in the 3’ LTR (Yu et al., 1986). During 
reverse transcription, this deletion is transferred to the 5’ LTR, which results in 
transcriptional inactivation. These vectors, known as self-inactivating (SIN) vectors, 
require the use of an internal promoter for transgene expression. Lentiviral (LV) 
vectors such as those derived from HIV-1 have also been employed for use in 
gene therapy. These vectors are similar to γ-retroviral derived vectors in that they 
can stably integrate within the host genome to provide continuous transgene 
expression. However, LV derived vectors have the additional benefit of being able 
to infect quiescent cells (Naldini et al., 1996). Furthermore, unlike γ retroviral 
vectors, LV derived vectors have a tendency to integrate within active genes and 
not at transcriptional start sites, therefore reducing the chances of insertional 
mutagenesis (Schroder et al., 2002; Wu et al., 2003). An additional advantage that 
LV vectors have to γ-retroviral vectors is their larger packaging capacity of up to 
10kb, although increasing transgene size can have a negative effect on viral titre 
thereby reducing transduction efficiency (Sinn et al., 2005).  
 
LVs represent more complex viruses than γ-retroviruses and encode additional 
regulatory genes, tat and rev and accessory genes vpr, vif, vpu and nef (Amado 
and Chen, 1999). Rev interacts with the rev responsive element (RRE) to enable 
the nuclear export of viral mRNA into the cytoplasm, whilst tat activates the 
promoter of the LTR to enabling an increased efficiency in provirus production. The 
first generation SIN LV vectors consisted of a transfer plasmid, a packaging 
plasmid expressing gag and pol as well as the six LV associated genes and an 
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envelope plasmid. The transfer plasmid incorporated additional elements that were 
not found in γ-retroviral derived transfer vectors. These included the central 
polypurine tract (cPPT), which facilitated the nuclear translocation of HIV PICs and 
a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) that 
can increase viral RNA stability and subsequently transgene expression (Sinn et 
al., 2005). In a bid to improve the safety of LV vectors, investigators identified that 
the removal of the four accessory genes (vpr, vif, vpu and nef) from the packaging 
plasmid did not affect the production of LV or transduction by LV of a majority of 
cell types (Zufferey et al., 1997). These modified vectors, known as second 
generation packaging plasmids, significantly improved the safety of LV vectors as 
any potential replication competent LVs generated by recombination events would 
be devoid of the necessary HIV virulence factors (Figure 1-8).  
 
Further improvements in the safety of these vectors have seen the construction of 
third generation LV vectors that use two packaging plasmids for LV production. In 
these packaging plasmids rev is separated from gag and pol and provided in trans 
on a separate plasmid. Furthermore, tat is removed from the packaging plasmids 
as third generation LV transfer vectors possess a chimeric 5’LTR, that encodes a 
constitutive viral promoter in the place of the 5’ U3 enhancer region (Dull et al., 
1998) (Figure 1-8). The constitutive promoter provides sufficient transcription 
rendering the tat gene redundant. The third generation LV system therefore has 
added safety benefits as the use of two packaging plasmids instead of a single one 
reduces the likelihood of recombination events resulting in replication competent 
LVs. It is important to note that third generation LV transfer vectors can use either 
the second or third generation packaging plasmids. 
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Figure 1-8 Schematic of second & third Generation SIN LV Transfer vectors. (A) The third 
generation SIN transfer vector consists of a chimeric 5’ LTR that replaces the U3 enhancer region 
with the Rous Sarcoma Virus (RSV) promoter, whereas the U3 region of the 3’ LTR is deleted 
(ΔU3). An internal promoter is used to drive the expression of the transgene upon incorporation into 
the hosts’ chromosome. (B) A second generation packaging plasmid consists of a single plasmid 
and (C) a third generation packaging plasmid consists of a packaging plasmid and a rev expressing 
plasmid. (D) LV vectors for gene therapy are commonly pseudotyped using the envelope gene of 
VSV to broaden the virus tropism. P – promoter, RRE – rev responsive element, cPPT – central 
polypurine tract, WPRE - woodchuck hepatitis virus post-transcriptional regulatory element, CMV – 
cytomegalovirus promoter. 
 
1.6. T Cell Engineering 
The transfer of Ag specific T cell receptor genes to a different T cell of unknown 
specificity provides an elegant solution to the generation of large numbers of Ag 
specific T cells. As previously mentioned the Ag specificity of a T cell is conferred 
by its expression of a TCR, which recognises its specific peptide in complex with 
MHC molecules. A landmark study by Dembic et al was the first to identify that the 
expression of TCR genes from one T cell could confer the TCRs Ag specificity to a 
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successfully re-directed the Ag specificity of CD4+ and CD8+ T cell populations by 
the transfer of viral and tumour Ag specific TCRs (Clay et al., 1999; Cooper et al., 
2000).  In addition to TCR gene transfer, T cells have also been engineered to 
express artificial Ag receptors. These receptors, known as chimeric Ag receptors 
(CARs), combine both Ag recognition and immune receptor signalling. 
 
There are three main challenges with TCR gene therapy. Firstly, the introduced 
TCR must have an optimal avidity for its cognate pMHC to allow productive TCR 
signalling. This avidity is determined by the overall affinity that the TCR has for 
cognate pMHC as well as its expression levels on the surface of the introduced 
cell. Furthermore, the engineered T cell must be long-lived to ensure their 
therapeutic effect is met and the safety of the cells must be absolute with no off or 
on target toxicity. 
 
1.6.1. T Cell Receptor Composition 
Over 95% of circulating T cells possess a TCR comprised of a TCRα and TCRβ 
chain. The TCRα and TCRβ chains consist of a TCRα or TCRβ constant (C) 
domain linked to a vα or vβ domain (Figure 1-9). The V domains undergo V(D)J 
recombination in the thymus during T cell development and provide the Ag 
recognition site of a TCR. Within the vα and vβ domains are hypervariable 
complementary determining regions (CDR) known as CDRs 1-3 and the highest 
variability is found in CDR3. Although the TCR is a heterodimer, the genes that 
encode the TCRα and TCRβ chains are continuous, which allows for cloning of 
each chain into a viral vector. Therefore, the genes that encode a TCR can be 
transferred to T cells using viral vectors in the same manner described previously 
for other therapeutic genes.  
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Figure 1-9 Schematic Diagram of TCR structure. A TCR is comprised of a TCRα and TCRβ 
chain. Both the TCRα and TCRβ chain have conserved constant (C) domains, Cα and Cβ 
respectively as well as variable domains, the structural arrangement of which provides the Ag 
recognition site. The Vα chain is comprised of a linked Vα and Jα domain, whereas the Vβ chain 
has an added D domain. The complimentary determining region 3 (CDR3) provides the most 
variability within the Ag recognition site.  
The composition of viral vectors encoding TCR genes is essential to the success of 
TCR gene therapy. To ensure that the avidity of the interaction between the 
introduced TCR and cognate pMHC is not compromised, the expression of the 
introduced TCR must be maximised. Additionally, equimolar translation of both the 
TCRα and TCRβ genes is required for optimal expression and pairing of the 
introduced TCR chains. The original viral vectors for TCR gene therapy either 
expressed the two TCR chains in separate viral vectors or utilised a single vector 
with two internal promoters. Additionally, the inclusion of an internal ribosome entry 
site (IRES) between the two TCR chains generated multicistronic vectors allowing 
for expression of both the genes under control of the same promoter. However, all 
of these methods have been linked to problems of poor TCR expression due to 
inequalities in the translation of the TCR chains (Mizuguchi et al., 2000). To 
circumvent these problems, multicistronic vectors have been generated that 
incorporate a self-cleaving 2A peptide derived from the Picornaviridae family of 
viruses (Szymczak et al., 2004). The 2A peptides contain a consensus motif that 
acts as a ribosomal skip site thereby preventing the formation of a peptide bond 
between adjoining protein-coding sequences. Therefore, the 2A peptide sequences 
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can link several genes within a single open reading frame resulting in equimolar 
translation of the genes. Furthermore, the use of these sequences has been shown 
to improve pairing and expression of introduced TCR chains by up to four fold in 
comparison to the use of an IRES (Wargo et al., 2009).  
 
1.6.2. TCR signalling 
The cytoplasmic tails of the TCRα and TCRβ chain are very short and do not 
possess any signalling domains. Therefore, the TCR forms a complex with a group 
of molecules collectively known as CD3. The CD3 signalling complex is made up of 
four proteins, γ, δ, ε and ζ, all of which possess long cytoplasmic tails that between 
them contain ten immunoreceptor tyrosine-associated based activation motifs 
(ITAMs). Upon TCR recognition of its specific pMHC complex, the tyrosine kinase, 
Lck is recruited to the TCR-CD3 complex where it can phosphorylate the ITAMs on 
the CD3 proteins, enabling the recruitment of the ζ-chain associated protein kinase 
of 70kDa (Zap70), which is activated by Lck mediated phosphorylation. Activated 
Zap70 can in turn phosphorylate the tyrosine residues on the linker for activation of 
T cells (LAT), which subsequently recruits a number of downstream signalling 
molecules resulting in T cell activation (Figure 1-10) (Brownlie and Zamoyska, 
2013). 
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Figure 1-10 Schematic of T Cell Receptor Signalling. The TCR is associated with the δ, ε, γ, and 
ζ chains of the CD3 signalling complex. Upon TCR engagement by pMHC the T cell co-receptor 
(CD4 or CD8) recruits Lck to the CD3 signalling complex and phosphorylates the ten ITAMS. Zap70 
is recruited to the complex and becomes phoshorylated and activated by Lck. Activated Zap70 
phosphorylates key residues on the linker for activation of T cells (LAT) and a number of signalling 
molecules are recruited leading to downstream gene expression and T cell regulation. 
 
CD8+ T cells and CD4+ T cells are restricted by MHCI and MHCII pMHC 
complexes respectively and are aided in the recognition of pMHC by the 
expression of the CD8 and CD4 co-receptors. CD8+ T cells recognise pMHCI 
complexes that are present on every nucleated cell on the body, whereas MHCII 
expression is normally limited to professional APCs, such as DCs and other 
immune cells. The CD8 co-receptor is most commonly expressed as a CD8αβ 
heterodimer but can also be expressed as a CD8αα homodimer. The CD8αβ co-
receptor specifically is important in stabilising the interaction between TCR and 
pMHC (Wooldridge et al., 2005). 
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CD4 is a single chain co-receptor and, unlike CD8αβ, is not thought to play a role 
in stabilising TCR and pMHCII complexes. However, both co-receptors are 
involved in the recruitment of Lck to the TCR signalling complex (Artyomov et al., 
2010). An elegant study by Holler et al performed a quantitative analysis on the 
contribution of CD8 to the overall affinity of a TCR and pMHC interaction (Holler 
and Kranz, 2003). The authors expressed a panel of TCRs of varying affinities for 
the same Ag in a TCRαβ- hybridoma and tested the sensitivity of the TCRs for 
peptide in the presence and absence of the CD8 co-receptor. The data from these 
experiments identified that the highest affinity TCR could be activated by pMHCI in 
the absence of CD8, whereas the lowest affinity TCR pMHC interaction was 
dependent on CD8. Furthermore, the highest affinity TCR could be activated with 
1000 fold lower concentration of peptide that the TCRs with lower affinity for 
pMHCI. It was therefore identified that CD8 can augment sensitivity of a low affinity 
TCR pMHC interaction. Moreover, it was identified that high affinity TCR-pMHCI 
interactions could lead to productive T cell activation without the requirement of 
CD8, i.e. were CD8 independent, suggesting that both the affinity between a TCR 
and pMHC and co-receptor presence on a T cell are important factors to consider 
in T cell receptor gene therapy. 
 
1.6.3. Chimeric Antigen Receptors 
Pioneering studies by Gross et al sought to engineer T cells to recognise Ags in a 
non MHC restricted manner. During these investigations an antibody derived single 
chain variable fragment (scFv) was fused to the signalling domain of a TCR to 
generate a chimeric receptor, which was found to signal in response to Ag when 
expressed in a T cell (Gross et al., 1989). This receptor endowed the T cells with 
an “antibody like specificity.” Since this initial report, a number of modifications 
have been made to CARs to improve their signalling ability. The original first 
generation CARs consisted of an scFv linked to a CD3ζ chain which, upon 
phosphorylation of the ITAMs within the chain, could mediate downstream 
signalling. However, although this provided “signal one” (stimulation of receptor by 
specific Ag), the “signal two” (co-stimulation) was absent, which resulted in T cell 
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anergy. To overcome this problem, second generation CARs were developed that 
incorporated the CD28 co-stimulatory molecule. CD28 is the best studied of T cell 
co-stimulatory molecules and provides a second T cell stimulation signal by 
interacting with the B7 molecules CD80 and CD86 on the surface of APCs. The 
second generation CARs have proved more successful than the first generation 
receptors and can enhance Ag specific T cell activation as evidenced by increased 
cytokine secretion and T cell proliferation. Furthermore, third generation CARs 
have been established, which incorporate an additional co-stimulatory domain 
within the second generation complex.  
 
One of the main advantages of CARs is that they are not restricted by MHC and 
therefore can be used universally irrespective of a patients MHC haplotype. 
Furthermore, CARs can be derived to target any protein in the body that a mAb 
can be raised to ensuring a broader range of specificities than a native TCR. 
Additionally, CARs should be able to function in any T cell subset as co-receptor 
interaction with MHC would be redundant. However, CARs are restricted to 
extracellular expressed Ags whereas gene therapy using TCRs has the added 
benefit of targeting internal Ags that are expressed in the context of MHC on the 
cell surface.  
 
1.6.4. The Use of T Cells With Re-directed Ag specificity in The Clinic 
In 1999 the first study was published that used retroviral mediated gene transfer of 
an MHCI restricted TCR to redirect the Ag specificity of human T cells (Clay et al., 
1999). Since this study, the use of engineered T cells in cancer immunotherapy 
has grown rapidly. In particular, the group of Dr Steven Rosenberg have performed 
a number of clinical trials using TCR gene engineered T cells in the treatment of 
melanoma. The first of these studies used a γ-retroviral vector to transfer a HLA-A2 
restricted TCR specific for the melanoma Ag MART-1 to isolated peripheral blood 
lymphocytes. This clinical study identified that the TCR gene engineered T cells 
were well tolerated in all patients and in 2/15 (13%) patients treated, the 
engineered T cells mediated regression of large established tumours. In a second 
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study, the same group engineered T cells to express a TCR with a higher reactivity 
towards MART-1, with the hypothesis that cells bearing this TCR would mediate 
greater cancer regression (Johnson et al., 2009). However, these T cells had on 
target reactivity towards basal level MART-1 expression in normal melanocytes in 
the skin, eyes and ears. Despite these on target toxicities, clinical responses were 
seen in 6/20 (30%) patients treated with high avidity MART-1 specific T cells. 
Interestingly, this high avidity MHCI restricted TCR was co-receptor independent 
and could redirect the Ag specificity of CD4+ T cells as well as CD8+ T cells. In the 
same study, T cells were engineered to express a high avidity gp100 specific TCR 
that was cloned from a HLA-A*02-01 transgenic mouse immunised with the human 
gp100 Ag. The particular gp100 epitope is not conserved between mice and 
humans and therefore central tolerance mechanisms do not prevent the release of 
high avidity murine α-human gp100 specific T cells from the thymus. In total 
sixteen patients were treated with murine TCR expressing T cells and 19% showed 
cancer regression with tumours responding in the lung, brain, lymph nodes liver 
and spleen. These studies therefore identified the ability of TCR engineered T cells 
to traffic to sites of Ag expression. Clinical trials have also been performed using T 
cells re-directed towards the NY-ESO-1 Ag, which is expressed in many tumours 
but expression in healthy tissue is restricted to cells in the testis (Robbins et al., 
2011). The HLA*02-01 restricted TCR used contained two amino acid substitutions 
in the CDR3 region of the TCRα chain, which increased the affinity of the TCR for 
cognate pMHC enabling re-direction of both CD4+ and CD8+ T cells.  An objective 
clinical response was seen in 4/6 synovial cell carcinoma patients and 5/11 
melanoma patients treated with NY-ESO-1 specific gene engineered T cells 
(Robbins et al., 2011). Furthermore, despite the use of an affinity modified TCR no 
on or off target toxicities by the engineered cells was observed.  Although in this 
study TCRs with increased affinity showed no toxicity, this is not always the case. 
A phase I clinical trial administered T cells engineered to express an affinity 
enhanced TCR specific for an HLA*01-01 restricted epitope of MAGE 3, which 
resulted in the death of the two treated patients a few days after infusion due to 
cardiogenic shock (Cameron et al., 2013; Linette et al., 2013). It was later identified 
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that the affinity enhanced T cells could kill in vitro generated cardiomyocytes due to 
reactivity towards the protein titin found in striated muscle. Despite extensive pre-
clinical testing of this TCR the cross reactivity was not predicted, highlighting a 
need for further examination of the affinity enhancement of TCRs for gene therapy. 
 
Clinical trials have also been reported using T cells engineered to express first 
generation CARs. In one study, T cells expressing a first generation CAR targeting 
the α-folate receptor failed to show efficacy in the treatment of ovarian cancer, 
which was potentially due to poor persistence (< 1 month) of the engineered T cells 
(Kershaw et al., 2006). Another study assessed the use of T cells expressing 
CARs specific for the tumour associated Ag CAIX in renal cancers, showed no 
clinical response observed on target liver toxicity. A severe case of on target 
toxicity resulted in the fatality of a metastatic adenocarcinoma patient who was 
treated with T cells expressing a third generation CAR specific for ERBB2 (Morgan 
et al., 2010). It was reported that low-level expression of ERBB2 in the lung 
resulted in a cytokine storm leading to patient death. The most successful clinical 
outcomes have been observed in the treatment of B cell leukaemia using T cells 
expressing CARs directed to the B cell specific Ag CD19. In a trial published in 
2012, eight patients with advanced B cell malignancies were treated with CD19 T 
cells and IL-2 with six patients obtaining clinical remission (Kochenderfer et al., 
2012). A similar clinical trial assessed the in vivo persistence and expansion of 
CD19 CARs with and without a CD28 signalling domain and identified an 
enhanced persistence and expansion of the CD19 CAR with both CD3ζ and CD28 
signalling domains (Savoldo et al., 2011). Additionally, a third study identified that 
CD19 CARs incorporating CD3ζ and a CD137 signalling domain could mediate 
cancer regression and persist in vivo for up to 6 months (Porter et al., 2011). These 
studies identified the requirement of TCR activation and co-stimulation in the in 
vivo persistence and efficacy of adoptively transferred T cells. 
 
The success of T cell engineering in cancer immunotherapy has provided the basis 
for investigating the use of TCR gene engineered TREG cells in mediating tolerance 
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to transplants and in the treatment of autoimmune disease. In particular, the 
studies on viral vector design, T cell persistence in vivo and the TCR affinity and 
avidity requirements to ensure efficacy but prevent toxicity. In a study by Tsang et 
al, murine TREG cells with indirect allospecificity (recognition of donor MHC 
presented by host APCs) were generated by retroviral TCR gene transfer and 
found to mediate tolerance to partially mis-matched heart transplants (Tsang et al., 
2008).  This study showed that co-transfer of a short-term immunosuppressant with 
TCR transduced TREG cells promoted a significant increase in allograft survival 
compared to the use of immunosuppression alone. Another study by Wright et al 
revealed the therapeutic potential of TCR engineered TREG cells in the treatment of 
a mouse model of rheumatoid arthritis (Wright et al., 2009). Using retroviral vectors 
the TCR genes for an Ab MHCII restricted ovalbumin TCR was transferred into 
αCD3/CD28 stimulated murine TREG cells. The Ag inducible model of rheumatoid 
arthritis used, involved the immunisation of mice with methylated BSA followed by 
an intra-articular knee re-challenge with the same Ag. To assess the therapeutic 
potential of ovalbumin specific T cells, the mice were re-challenged with a 
methylated BSA and ovalbumin mix in one knee and methylated BSA alone in the 
other. The TCR transduced TREG cells were then adoptively transferred into the 
mice and found to selectively home to and decrease inflammation in the ovalbumin 
challenged knee. This data suggested that Ag specific TREG cells could home to the 
site of Ag expression and mediate local immune suppression of pathogenic T cells. 
A later study by Brusko et al identified that the Ag specificity of human TREG cells 
could be successfully re-directed using LV mediated TCR gene transfer (Brusko et 
al., 2010). Unconventionally, this study used a MHCI restricted TCR, which was 
specific for the melanoma Ag tyrosinase, to re-direct the specificity of human TREG 
cells. First, this study identified that neither the phenotype, expansion potential or 
suppressive capabilities of human TREG cells were affected by gene transfer using 
LV vectors. Secondly, the study identified that TREG cells expressing an MHCI 
restricted TCR could directly recognise tissue bearing cognate pMHCI. A tumour 
model system was set up whereby HLA-A2 transgenic mice were transplanted with 
an HLA-A2 tyrosinase-expressing tumour. In this model, adoptively transferred 
Chapter 1 Introduction 
61 
TCR transduced TREG cell could prevent the tumour pathogenesis mediated by 
transferred TEFF cells expressing the same TCR. These studies have identified a 
means to generate therapeutic numbers of Ag specific TREG cells. It is therefore 
possible that TREG cells re-directed towards a disease relevant Ag specificity may 
be beneficial in the treatment of autoimmune disease.  
 
1.7. Aims of this project 
The aim of this thesis is to test the hypothesis that the LV mediated transfer of 
MHCI restricted TCRs can re-direct the Ag specificity of human TREG cells towards 
MHCI restricted islet Ags. As discussed, the adoptive transfer of polyclonal TREG 
cells is currently being investigated as a treatment for patients with T1D. However, 
there is strong evidence from animal models that Ag specific TREG cells would 
persist for longer in vivo, home to the sites of Ag expression and be more 
efficacious at suppressing autoimmunity than their polyclonal counterparts (Tang et 
al., 2004; Tarbell et al., 2004). Furthermore, an increased potency of these cells 
would allow for a reduced quantity of Ag specific TREG cells required for transfer.  
Conventional CD4+ TREG cells possess TCRs that are restricted towards MHCII 
self-Ags; however, the expression of MHCII in the inflamed islets of patients with 
T1D is minimal, whereas MHCI is hyper-expressed (Itoh et al., 1993; Willcox et al., 
2009). Therefore, it is hypothesised that TREG cells re-directed towards an MHCI 
islet Ag would favour trafficking to the site of Ag presentation within the islets and 
mediate Ag specific suppression at the site of inflammation upon recognition of 
pMHCI complexes on the surface of the islets. 
 
LV gene transfer of TCR genes provides an elegant solution to generating large 
numbers of TREG cells directed towards a defined Ag specificity.  Currently, a strong 
rationale for the use of engineered T cells has been provided in the field of cancer 
immunotherapy, opening the possibility that this technique could be applied in 
other clinical settings including autoimmune disease. Additionally, protocols have 
already been thoroughly investigated in the ideal design of viral vectors for TCR 
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transfer. Furthermore, the report by Brusko et al, and a more recent report have 
provided a pretext for engineering human CD4+ TREG cells to express an MHCI 
restricted TCR (Brusko et al., 2010; Plesa et al., 2012). However, neither of these 
studies used an autoimmune disease relevant MHCI restricted TCR. Therefore, 
this thesis will detail a proof of principle study in the feasibility of transferring a TCR 
restricted to an MHCI restricted autoimmune disease relevant epitope to human 
CD4+ TREG cells.  
 
The main areas that this thesis will investigate are:  
1. The expression and pairing of TCRα and TCRβ chains on the surface of 
model cells lines post LV gene transfer as well as the ability of MHCI 
TCRs to re-direct the Ag specificity in the absence of the CD8 co-
receptor. 
2. The ability of MHCI TCRs to confer Ag specific suppressive capabilities 
to human CD4+ TREG cells. 
3. Methods to optimize the expression and function of MHCI restricted 
TCRs in CD4+ TREG cells.  
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2. Materials and Methods 
2.1. Culture of Cell lines and Primary Cells 
Cell Lines 
Human Embryonic Kidney 293T (HEK 293T) cells were maintained in 10mls of 
DMEM + Glutamax (Gibco, Life Technologies, UK) supplemented with 10% foetal 
calf serum (FCS) (Gibco, Life Technologies, UK) and 1% Pen/Strep (D10F) in    
10cm2 tissue culture dishes (Corning, UK). The cells were maintained by splitting 
at a 1:3 ratio every two days using TrypLE express (Gibco, Life Technologies, UK) 
as a dissociation agent. Jurkat 76 (J76) cells, a TCRαβ deficient Jurkat cell line, 
were used for verification of MHCI restricted TCRs (Heemskerk et al., 2003). 
These cells transfected with the human CD8α chain (J76CD8α) were a kind gift 
from Professor Woolfgang Uckert (Max-Delbrück-Centre, Berlin, Germany). J76 
and J76CD8α cells were cultured in RPMI + Glutamax (Gibco, Life Technologies, 
UK) supplemented with 10% FCS and 1% Pen/Strep/Fungizone (R10F) and 
maintained by splitting at a 1:5 ratio every 2–3 days.  
 
Blood Donors 
For initial studies, blood was obtained with informed consent from individuals who 
are therapeutically bled owing to primary heamochromatosis, but who are 
otherwise healthy. All blood donors were genotyped for HLA-A2*01 expression 
prior to their blood being used for experiments in this study and each individual 
subject denoted with an HAE number. For further experiments, leukapheresis 
cones were purchased from the National Blood Transfusion Service (Tooting, 
London, UK). Cells from these healthy control donors are denoted with a T number 
in this thesis. Staining with an anti-HLA-A2 antibody prior to use assessed the 
HLA-A2 positivity of these blood donors. All experiments in this study were 
conducted with ethical approval under the heading “Development of protocols for 
the generation in vitro of clinical grade T cells for adoptive cell therapy for use in 
autoimmune, inflammatory and malignant diseases” (REC reference 09/H0707/86). 
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Isolation of PBMCs 
PBMCs were isolated by density centrifugation. Briefly, 30mls of undiluted blood 
was layered onto 15mls of lymphoprep (Axis Shield, Scotland) and centrifuged at 
1000g for 20 minutes (Heraeus Multifuge 1, Thermo Scientific, USA). The 
interphase layer was collected into 50ml falcon tubes (Corning, UK) and washed in 
warm PBS (Gibco, Life Technologies, UK) at 300g for 10 minutes. The PBMC 
pellet was re-suspended in 20mls PBS and a second centrifugation step of 200g 
for 10 minutes was performed. The cell pellet was again re-suspended in 20mls 
PBS and viable cells were enumerated on a haemocytometer using trypan blue 
(Sigma-Aldrich, UK) for dead cell exclusion. The cells were then either 
cryopreserved or stained with fluorescently labelled antibodies for cell sorting by 
FACS. 
 
Cryopreservation and Recovery of Cryopreserved Cells 
Cells to be cryopreserved were pelleted by centrifugation at 4°C using a standard 
centrifugation step of 5 minutes at 400g. The supernatant was removed, the pellet 
re-suspended in 500 µl FCS per 107 cells and the cells placed on ice. An equal 
volume of FCS + 20% DMSO (Sigma-Aldrich, UK) was added, drop wise to the cell 
suspension with gentle agitation, to bring the final percentage of DMSO to 10%. 
The cells were added to 2ml cryovials (Corning, UK) in a total volume of 1ml, 
placed in a CoolCell (BioCision, USA) and transferred to the -80°C freezer. For 
long-term storage, the cells were transferred to liquid nitrogen 24 hours after 
cryopreservation. Cells were recovered by incubation in a 37°C water bath until a 
small ice pellet remained, followed by drop wise addition of cell culture media. The 
cells were then centrifuged at 400g for 5 minutes and re-suspended in the 
appropriate growth media. 
 
Flow Cytometry Surface Staining 
For FACS and flow cytometry, cells were harvested into round bottom polystyrene 
FACS tubes (BD, UK) and washed in at least 2mls of FACS buffer; PBS 
supplemented with 2% FCS and 0.5mM EDTA. The supernatant was decanted and 
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a master mix of fluorescently labelled antibodies was added to the residual buffer. 
The cells were stained on ice for 25 minutes with the addition of 0.25µl 7AAD 
(Calbiochem, Merck Millipore, UK) for the final 5 minutes and then washed in at 
least 2 mls of FACS buffer. Flow cytometry samples were acquired on a FACS 
Canto II (BD, UK) using FACS Diva software v6.0 (BD, UK). For cell sorting by 
FACS, cells were stained in sterile polypropylene FACS tubes (BD, UK) and sorted 
on a FACS Aria III (BD, UK). All Flow cytometry data was analysed using FlowJo 
software v9.4.11 (TreeStar, USA). All antibodies were titrated before use to ensure 
the highest discrimination between negative and positive populations. A full list of 
all antibodies used in this study can be found in Table 2-1.  
 
HLA-A2 staining of whole blood 
To determine the HLA-A2 status of blood donors, 10µl of whole blood was 
aliquoted into two FACS tubes and diluted at a ratio of 1:10 in PBS. Either 2µl of an 
anti HLA-A2 antibody or 2µl of an isotype-matched control antibody (IgG2b) was 
added to each tube, vortexed and incubated at room temperature, around 22°C, for 
15 minutes in the dark. Red blood cell lysis buffer (BD, UK) was diluted at a ratio of 
1:10 in ddH20 (MiiliQ, Merck Millipore, UK) and 2mls were added to each FACS 
tube. The FACS tubes were again vortexed and incubated for 15 minutes at room 
temperature, in the dark. Each tube was then washed twice in 2mls of PBS and the 
cells were immediately acquired on the FACS Canto II. 
 
Flow Cytometry Staining for intracellular FoxP3 
For intracellular FoxP3 staining, the FoxP3 transcription buffer staining kit 
(Ebioscience, UK) was used and the one step protocol for intracellular (nuclear) 
proteins followed. To minimise any activation induced up-regulation of FoxP3 on 
expanded and transduced populations, cells were rested in IL-2 free media 
overnight. Following cell surface staining, the cells were washed, vortexed to 
dissociate the pellet and re-suspended in 1 ml fix/perm buffer for 1 hour at room 
temperature in the dark. The cells were then washed twice in perm buffer, the 
supernatant removed and 20µl FoxP3-APC antibody added. The cells were stained 
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in the dark for 1 hour at room temperature in the dark, washed twice and 
immediately acquired on the FACS Canto II.  
Table 2-1 List of Antibodies 
Target Conjugate Clone Origin Dilution Manufacturer 
CD3 PE Cy7 HIt3a Mouse 1/100 Biolegend 
CD4 APC SK3 Mouse 1/100 Biolegend 
CD8α FITC/APC-Cy7 RPAT8 Mouse 1/100 Biolegend 
CD14 FITC HCD14 Mouse 1/20 Biolegend 
CD19 FITC 3G8 Mouse 1/50 Biolegend 
CD25 PE M-A251 Mouse 1/5 BD 
CD45 RA eflour450 HI100 Mouse 1/20 Ebioscience 
CD69 APC FN50 Mouse 1/5 Biolegend 
CD127 PerCP Cy5.5 ebioRDR5 Mouse 1/20 Ebioscience 
FoxP3 APC 259D Mouse 1/20 BD 
HLA-A2 FITC BB7.2 Mouse 1/50 BD 
IgG2b κ FITC 27-35 Mouse 1/50 BD 
RatCD2 PE/FITC OX34 Mouse 1/400 Biolegend 
TCRvβ2 PE MPB2D5 Mouse 1/10 Beckman 
Coulter TCRvβ5a FITC 1C1 Mouse 1/20 Thermo 
Scientific TCRvβ8 PE 56C5.2 Mouse 1/10 Beckman 




The HLA-A2 biotinylated monomers containing the preproinsulin (PPI)15-24 epitope 
ALWGPDPAAAA (HLA-A2 ALW) and  GAD65114-122 epitope VMNILLQYV (HLA-A2 
VMN) were a kind gift from Garry Dolton (Cardiff University, UK). Monomers were 
thawed on ice and tetramers were assembled by x 5 additions of streptavidin-APC 
(Life Technologies, UK) at 20 minute intervals on ice. PBS was added to each tube 
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to give a final working volume of tetramer of 0.2µg/ml. HLA-A2 SL9 dextramer 
(Immunodex, Copenhagen, Denmark) was used as per manufacturer’s 
instructions. All multimers were centrifuged at 10000g for 2 minutes and only the 
supernatant was used for staining. Between 2x105 and 5x105 cells were aliquoted 
into FACS tubes and washed in PBS. The supernatant was decanted, leaving a 
residual volume of 80µl to which 40µl 15nM protein kinase inhibitor (PKI) solution 
(Dasatinib, Axon Medchem, Netherlands) was added. The tubes were incubated 
for 30 minutes at 37°C prior to addition of 0.5µg multimer to each tube and 
incubated for a further 10 minutes at 37°C. The cells were then washed in FACS 
buffer and surface stained with CD3 antibody and 7AAD as previously described. 
The cells were kept on ice until analysis to prevent multimer degradation. 
 
Isolation and Activation of Primary T cell Populations. 
PBMCs were stained with fluorescently labelled antibodies against CD4, CD25, 
CD127 and CD8 and sorted into three cell populations, CD8+ T cells, CD4+CD25-
CD127+ effector T cells (TEFF) and CD4+CD25+CD127- regulatory T cells (TREG). 
The cells were also stained with CD14, CD16 and CD56 FITC conjugated 
antibodies for exclusion on this channel of monocytes and NK cells. Positively 
selected cells were sorted into FACS tubes containing 2mls of X-VIVO 15 (Lonza, 
Switzerland) 10% heat inactivated Human AB serum (GE healthcare, UK) (XV10) 
and centrifuged at 400g for 10 minutes. Established protocols were followed for the 
activation of cells (Brusko et al., 2010; Canavan et al., 2012; Skowera et al., 2008). 
Cells were activated using αCD3αCD28-coated magnetic beads (Dynal, Life 
Technologies, UK) at a bead to cell ratio of 1:1 for both CD8+ T cells and CD4+ 
TREG and 0.5:1 for CD4+ TEFF. The culture media used was X-VIVO 5% Human AB 
(XV5) supplemented with 200IU/ml IL-2 (Proleukin, Novartis, UK) for CD8+ T cell 
growth, 50IU/ml IL-2 for TEFF cell growth and 600IU/ml IL-2 for TREG cell activation. 
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Preparation of Feeders 
Irradiated PBMCs were used to support expansion of transduced CD8+ T cells. 
Cryopreserved PBMCs from three donors, at least one an HLA-A2*01 donor, were 
thawed and re-suspended in XV10 at a cell concentration of 5x106 ml. The cells 
were then irradiated with 3000 RAD. Irradiated cells were then washed three times 
with XV5 and re-suspended in fresh XV5 at the desired cell ratio. 
 
Cell Labelling with Cell Tracker Dye 
For FACS-based proliferation and Jurkat cell activation assays, target cells were 
labelled with Cell Trace Violet Stain (Life Technologies, UK). Briefly, cells to be 
labelled were washed twice in PBS to remove all traces of serum. A 1uM working 
stock of Cell Trace Violet was prepared by dilution of 2µl of 5mM stock 
concentration in 10mls of PBS. A total of 1ml of violet working stock was added per 
107 cells to be labelled. For equal labelling, cells were gently agitated for               
10 minutes in the dark at room temperature before quenching of the reaction with 
an equal volume of FCS for 2 minutes. The cells were then washed in RPMI, 20% 
FCS by centrifugation at 400g for 5 minutes before use in assays. 
 
Statistical Analysis 
An unpaired Student’s t Test was used to calculate the statistical significance of 
peptide specific stimulation of transduced T cells compared to non-Ag specific 
stimulation where data was normally distributed. Where indicated, a paired 
Student’s t Test was used to calculate the statistical significance of endogenous 
TCR expression and introduced TCR expression within the same cell population. 
All means, standard deviations and statistical significance were calculated using 
GraphPad Prism5 software.   
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2.2. Molecular Biology Techniques and Cloning 
2.2.1. General Molecular Biology Methods 
Plasmids pMDG-2 Vesicular Stomatitis Virus-G (VSV-G) expressing plasmid and 
P8.91 expressing gag and pol for viral encapsulation were a kind gift from the 
group of Michael Malim (Kings College London, UK). The 1E6 and 868 TCRα and 
TCRβ gene were inserted into the pELNS third generation SIN LV vector 
(Richardson et al., 2008) and were kindly provided for this study by John 
Bridgeman (Cardiff University, UK). The generation of all other plasmids used for 
this study is described in subsequent sections. 
 
Restriction Digest 
All restriction enzymes used in this project were purchased from NEB and included 
XbaI, SalI, EcoRI and NsiI. For a standard 10µl restriction digest of plasmids, the 
following reaction was set up: 1µl of 10x buffer, 1 unit of enzyme (as defined by 
NEB), 1µg of plasmid DNA and molecular biology grade H2O (Ambion, Life 
Technologies, UK) to 10µl. This mixture was then vortexed, the contents collected 
by brief centrifugation and incubated for 1 hour in a 37°C water bath. The reaction 
mix was then loaded on to a 1% agarose gel for visualisation of the final product. 
For preparations of inserts and plasmids for ligation reactions, restriction digests 
were scaled up to 50µl with all reagent ratios kept as standard. 
 
Gel Electrophoresis and Extraction  
Agarose gel electrophoresis was used for analysis of DNA fragments. 1% agarose 
gels with a 1:10,000 dilution of SyberSafe (Life Technologies, UK) were made by 
dissolving agarose powder (Sigma-Aldrich, UK) in 5% Tris-Borate-EDTA (TBE) 
buffer and used to resolve products of 0.7–7kb in size. For resolution of standard 
10µl restriction digest reactions, 2µl of 6x blue loading dye (NEB, UK) was added 
to each tube. The 12µl reaction was subsequently loaded into the agarose gel and 
5x TBE was used to cover the gel in the gel electrophoresis tank (Biorad, UK), The 
gels were run at 100V for 1 hour or until the products and ladder had fully 
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separated before being visualised using a UV transilluminator (BioRad, UK). For 
cloning, PCR products were excised from agarose gels using sterile razor blades 
and purified using the QIAquick Gel Extraction kit (Qiagen, UK) following the 
manufactures protocol. Briefly, the excised fragments were weighed, dissolved in 
three gel volumes of QG buffer before one gel volume of >99% molecular biology 
grade isopropanol (Sigma Aldrich, UK) was added. This mix was loaded and bound 
onto a QIAquick spin column, washed and eluted in 30µl of buffer EB. The DNA 
was quantified using a NanoDrop1000 spectrophotometer (LabTech, USA).  
 
Ligation 
All ligation reactions performed in this study utilised the LigaFast Rapid DNA 
Ligation System (Promega, UK). For standard cohesive end ligations a molar ratio 
of vector to insert of 3:1 was employed were the amount of vector used was 50ng. 
The amount of insert DNA required was calculated using the following formula: 
50ng of vector x insert size (Kb)/ size of vector (Kb) x 1/3. In a 15µl reaction, 7.5µl 
of 2x rapid ligation buffer and 2µl of T4 DNA ligase were added to the volume of 
DNA calculated with sterile H2O used to complete the 15µl total reaction volume. If 
preparations of vector or insert where too dilute then a Vacuum Concentrator 
(Eppendorf, Germany) was used to reduce the DNA to the required concentrations. 
Negative control reactions were included, whereby sterile H2O was substituted for 
insert DNA. Each reaction was incubated for 1 hour at room temperature before 
being stored overnight at 4°C. 
 
Transformation of Plasmid DNA  
Plasmid DNA was transformed into chemically competent cells for mass production 
of the plasmid. For standard transformation of VSV-G, p8.91 and pELNS viral 
vectors, including ligation reactions using these vectors, XL-10 Gold Cells (Agilent, 
UK) were used. One shot Top10 competent cells (Life Technologies, UK) were 
used when cloning into the pGEM T Easy Vector (Promega, UK). As standard 
protocol, competent cells that were stored at -80°C were thawed on ice for 10 
minutes. Either 50ng of plasmid DNA or 4µl of a ligation reaction were then added 
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to each vial of competent cells, mixed by flicking, and incubated on ice for 30 
minutes. The bacteria were then subjected to heat shock at 42°C for 45 seconds 
and then placed on ice for 5 minutes. SOC media (Sigma-Aldrich, UK) that had 
been preheated to 42°C was added to each vial (900µl for XL-10 and 450µl for 
Top10 cells) and each vial incubated in a 37°C shaking incubator (New Brunswick 
Scientific, Eppendorf, Germany) for 2 hours. The transformed cells were then 
plated onto LB agar plates supplemented with 100µg/ml Ampicillin (Amp) (Sigma-
Aldrich, UK) employing sterile technique; typically 100µl of cells were plated for 
each ligation reaction whereas 100µl of a 1:20 dilution of plasmid DNA was plated 
for standard transformations. The plates were left to air dry for 10 minutes followed 
by incubation at 30°C for 16–20 hours.  
 
Preparation of DNA from Bacterial Colonies 
Successful transformants were picked from the agar plates using a pipette tip that 
was subsequently used to both re-streak a second agar plate and inoculate 3 mls 
of LB broth 100µg/ml Amp. The re-streak plates were incubated at 30°C and the 
LB-Amp broth in a shaking incubator set to 30°C for 16–20 hours. Re-streak plates 
were wrapped in parafilm and transferred to 4°C for future use. The cultures were 
then centrifuged in 1.5ml Eppendorfs at 8000g for 5 minutes and the plasmid DNA 
extracted using the QIAprep Spin MiniPrep Kit (Qiagen, UK) following the 
manufacture’s protocol. The DNA was eluted from the QIAprep Spin Columns in 
30µl of elution buffer. Following this, the plasmid DNA was then used in a 
restriction digest reaction to check for successful ligation or correct plasmid 
preparation using diagnostic cuts and any unused plasmid stored at -20°C.  
 
2.2.2. Clonotyping of the 1D7 TCR RNA Extraction 
RNA was extracted from the 1D7 clone, a CD8+ T cell clone specific for the 
GAD65114-122 epitope, in order to determine the sequence of the TCR (Knight et al., 
2014). Total RNA from this clone was extracted from previously cryopreserved 
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cells that had been stored in RLT buffer at -80°C using the RNeasy Mini Kit 
(Qiagen, UK) according to manufacturer’s protocol. 
 
cDNA Conversion 
In order to fully elucidate the complete sequence of the unknown TRAC and TRBC 
genes of the 1D7 clone, the SMARTer RACE cDNA Amplification kit (Clontech, 
France) was used. The specifics of this technique are described in Figure 2-1 and 
the manufacturer’s protocol was adhered to. For initial first strand synthesis 3.25µl 
of RNA, or as a negative control ddH2O, was incubated with the 5’ CDS Primer A in 
0.2µl PCR tubes (Appleton Woods, UK) and heated to 72°C for 3 minutes and then 
cooled to 42°C for 2 minutes using a 2720 Thermo Cycler (Applied Biosystems, 
Life Technologies, UK). To each tube, 6.25µl of a previously prepared mastermix 
incorporating 2µl 5x buffer, 1µl DTT, 1µl DNTP, 0.25µl RNase inhibitor, 1µl SMART 
reverse transcriptase enzyme and 1µl of the SMARTer oligo, was added. This 
mixture was then incubated at 42°C for 120 minutes and the reaction terminated by 
heating to 72°C for 10 minutes. Each tube was then washed out using Tricine-
EDTA (TE) (Sigma-Aldrich, UK) at a 1:1 ratio prior to the purification of the reaction 
using the Nucleospin Gel and PCR Clean up kit (Machery Nagel, Germany) 
 
 
Chapter 2 Materials and Methods 
73 
 
Figure 2-1 SMARTer 5’ RACE cDNA Synthesis. All polyadenylated RNA within the extracted RNA 
was amplified using the 5’CDS primer, the sequence of which is 5’ T(25)XXX where X are 
nucleotides other that T. This step ensures that complete mRNA strands will be amplified from the 
3’ end. The SMARTScribe Reverse Transcriptase (RT) enzyme exhibits terminal nucleotide 
transferase, which enables the addition of extra nucleotides to the 3’ end of the transcribed mRNA. 
The SMARTer II Oligo is able to bind the extra nucleotides and the RT enzyme is able to switch 
template from the mRNA molecule to the SMARTer II oligo. The RT then transcribes 5’ to 3’ 
generating a complete cDNA molecule from the original mRNA, incorporating the SMARTer 
sequence. 
 
PCR Amplification of 1D7 TRAC and TRBC Gene 
The 1D7 cDNA incorporating the SMARTer RACE sequence was PCR amplified 
using the universal primer A mix (UPM) (Clontech, France) and primers        
specific for either the C region of the TRAC gene (CCAGGCCACAGCACT 
GTTGCTCTTGAAGTCC) or the TRBC gene (GCTGACCCCACTGTGCACCTCC 
TTCCC). The PCR reaction is described in Table 2-2 and an additional negative 
control was included for the PCR reaction with sterile H2O. The PCR cycling 
reaction was initiated with a high temperature for 5 cycles, termed touchdown 
PCR, to allow the long UP to bind to the cDNA. This temperature was then reduced 
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for a second annealing step to enable the short UP to bind the DNA. The cycling 
reactions are detailed in Table 2-3. The 50µl reaction was then purified using gel 
electrophoresis as described with the expected PCR product size for both the 
TCRα and TCRβ chains being between 500–700bp in size (Figure 2-2 (A)). The 
negative controls from the initial cDNA conversion and PCR reaction were run on 
separate gels to confirm absence of DNA. 
 
Table 2-2 PCR Reaction Mix for the Amplification of the 1D7 TRAC and TRBC Genes 
























Table 2-3 PCR Cycling condition for the Amplification of the 1D7 TRAC and TRBC Genes 
PCR Condition Temperature (°C) Time (s) Cycles 
Initial Denature 98 30 1 
Denature (1) 98 10 5 
Annealing (1) 70 30 5 
Elongation (1) 72 40 5 
Denature (2) 98 10 30 
Annealing (2) 65 30 30 
Elongation 72 40 30 
Final Elongation 72 60 1 
 
 
Poly-A-Tailing and Ligation into the pGEM T vector 
For sequencing of PCR products, the PCR products were poly-A-tailed and ligated 
into the pGEM T Easy vector system (Promega, UK). For poly-A-tailing, the 30µl 
gel elution was concentrated to a volume of 8µl using a vacuum concentrator 
(Eppendorf, Germany). The 8µl gel elution was then incubated with 1.14µl Taq, 
1.14µl 10x advantage 2 PCR buffer (Clontech, France), 0.456µl dATP (Life 
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Technologies, UK) and 0.664µl H2O. This mixture was incubated in a 70°C heat 
block (Jencons PLS, UK) for 30 minutes, with centrifugation after 15 minutes to 
collect any contents that may have evaporated. The ligation reaction was then 
completed using 4µl of poly-A-tailed insert and 1µl of the pGEM T easy vector or 
4µl sterile H2O as a negative control. 
 
Figure 2-2 Clonotyping of the 1D7 TCR. TCRα  and β  genes were identified from the 1D7 
clone using SMARTer 5’ RACE technology. Agarose gels show the resolved PCR products of (A) 
1D7 cDNA with the incorporated 5’ SMARTer RACE sequence, amplified with a TCRα constant 
region primer (TRAC) and Universal Primer Mix (UPM) A (B) and the 1D7 cDNA  amplified with a 
TCRβ constant region primer (TRBC) and UPM. (C) The 1D7 TCRα and TCRβ PCR products were 
ligated into the pGEM T easy vector and transformed into TOP10 competent cells, from which DNA 
was prepared. EcoRI restriction sites flank the cloning site of the pGEM T easy vector and an 
agarose gel shows successful ligation of a TCRα and TCRβ chain into the vector, which were sent 
for sequencing. The – control represents an empty vector ligation and the + control was a digest of 
a previously successful PCR product ligation. The furthest left hand lane was loaded with a 2-log 
DNA ladder (NEB, UK). The white arrows in each gel picture indicate the 600bp marker, 
 
Sequencing of the TCR chains 
The ligations of the 1D7 α and β chains into the pGEM T easy vector were 
transformed into TOP10 cells and the DNA prepared as described. A single colony 
was also picked from the negative control plate. A restriction digest reaction of 
each plasmid using EcoRI, which has two cut sites in the pGEM T easy vector 
flanking the T overhang sites, was preformed (Figure 2-2 (C)). The plasmid 
preparations that were positive for a 500–700bp insert after the restriction digest 
A B C 
- + ! " 
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were considered successful ligation products and at least 3 DNA preparations for 
each chain were shipped to MWG Eurofins, Germany, for DNA sequencing. The 
DNA was sequenced using the T7 promoter, which is 52bp 5’ of the first T 
overhang. Upon receipt, the DNA sequences were imputed into the IMGT website 
(www.IMGT.org) to ascertain the variable regions of the TCRα and TCRβ chains. 
Using Geneious Pro 5.6.3 software (Biomatters Ltd, Auckland) the full sequencing 
of the 1D7 TCRα and TCRβ chains were constructed (Figure 2-3).  
 
Figure 2-3 Amino Acid Sequence of the 1D7 TCRα  and TCRβ  Chains. The amino acid 
sequence of the 1D7 TCRα is as shown with the signal peptide highlighted in blue, the variable 
region in red and the TCRα constant region in black. The 1D7 TCRβ sequence highlights the signal 
peptide and variable region in blue and red respectively followed by the sequence of the TCRβ 
constant region 2. 
 
Slight modifications were made in the addition of an extra disulphide bond between 
the TCRα and TCRβ chains (Cohen et al., 2007) and appropriate restriction sites at 
both the 5’ and 3’ end as shown (Figure 2-4). This complete gene was then 
synthesised by MWG Eurofins, which included codon optimisation of the entire 
sequence. Upon receipt of the fully synthesised gene it was subjected to restriction 
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that had been similarly digested to removed the 1E6 α and β TCR genes. This 
process resulted in the generation of the pELNS.1D7.RatCD2 construct.  
 
 
Figure 2-4 1D7α .T2A.1D7β .P2A Gene Synthesis. The black arrows show the position of the 
TRAC and TRBC primer sites. Owing to these positions the 3’ end of the 1D7 α and β chain 
constant regions were absent from the original sequence. To rectify this, the 1D7 TCRα and TCRβ 
chains were aligned with the sequences of the 1E6 counterpart chains to complete the full TCR 
chains. Additionally, a T2A and P2A cleavage sequence were included before and after the 1D7 β 
chain. The restriction sites XbaI and SalI were similarly included at the positions shown. Finally, the 
amino acid substitutions shown in red were preformed to include a second disulphide bond between 
the 1D7 TCRα and TCRβ chains to improve pairing as previously described.  
 
2.3.  Lentivirus Production 
Plasmid Maxi-Preparations 
For production of lentivirus, plasmids were prepared using the Nucleobond 
Endotoxin Free Maxiprep kit (Machery Nagel, Germany). Briefly, a single colony 
was picked from a transformation plate and used to inoculate a 3ml starter culture 
of LB–Amp, which was incubated for 6–8 hours at 30°C in a shaking incubator. An 
overnight culture of 600 ml LB–Amp was inoculated with 600µl of starter culture 
and incubated at 30°C for 16–18 hours with shaking. The bacteria were pelleted at 
6000g for 10 minutes re-suspended in re-suspension buffer, lysed and then the 
lysis reaction neutralised according to manufacturer’s protocol. The lysate was 
then loaded onto an equilibrated NucleoBond Xtra Column, which allows 
simultaneous loading of the column and clearance of lysed bacteria through a 
column filter. After two wash steps to ensure complete recovery of endotoxin-free 
184 D K T V L 188 486 G V S T D 490 
TRAC TRBC 
 G V C T D  D K C V L 
XbaI SalI 
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plasmid, the plasmid was eluted in 15mls of elution buffer. For DNA precipitation, 
10.5mls of molecular grade isopropanol (Sigma-Aldrich, UK) was added drop wise 
to the eluted DNA, vortexed and centrifuged at 15,000G for 30 minutes at 4°C. The 
DNA pellet was then washed in 70% ethanol, left for 20 minutes at room 
temperature to air dry and re-suspended in TE buffer (Machery Nagel, Germany). 
The yield of DNA was assessed by a NanoDrop1000 spectrophotometer and the 
plasmid DNA concentration adjusted to 1µg/ml.  
 
Transfection 
293T cells were seeded at a density of 1x106/ml in a six-well plate 24 hours prior to 
transfection in 2 ml D10F. For each well to be transfected 1µg of p8.91, 1µg of 
genome vector and 0.5µg of VSV-G were incubated with 498.5µl of serum free, 
DMEM. To a separate tube, 10µg of polyethylenimine (PEI) (Polysciences, 
Germany) was mixed with 490µl serum free DMEM. Both were incubated for          
5 minutes before mixing together and incubating for 20 minutes at room 
temperature. 1 ml of D10F was removed from the 293T cells and replaced with 1 
ml of the transfection mixture, which was added drop wise to the 293T cells. The 
media on the transfected cells was changed after 6 hours and the LV containing 
supernatant was collected 48 and 72 hours post transfection. Supernatant 
collected at 48 hours was filtered through a 0.45µm filter (Minisart, Sartorious, 
Surrey) and stored at 4°C overnight before being pooled with the clarified 72 hour 
supernatant. Typically, 8 x 6 well plates were transfected for each LV preparation. 
 
Lentivirus Concentration 
LV was dispensed into 38.5 ml ultracentrifuge tubes (Beckman Coulter, UK) and 
was pelleted by centrifugation at 28K RPM for 1 hour and 15 minutes in an 
ultracentrifuge (Sorval, Thermo Scientific UK). The supernatant was decanted and 
100µl of serum-free DMEM added to each pellet. The ultracentrifuge tubes were 
kept on ice for 1 hour to aid the LV pellet re-suspension before the pellet was re-
suspended by pipetting. The virus was then topped up with DMEM for a final virus 
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293Ts were plated in a 24 well plate overnight at a density of 1x105/ml/well. The 
next day the LV to be titrated was thawed and 5 x 1:2 serial dilutions were 
preformed in a total volume of 500µl D10F. The medium on the 293Ts was 
removed and replaced with the diluted LV. The 293Ts were spin infected at 1200g 
for 1.5 hours at room temperature. The media on the 293Ts was replaced with 
D10F and transduction assessed 72 hours later by flow cytometry. The titre of the 
LV was calculated by (% of cells transduced * total number of cells) / volume of LV 
in mls.  
 
Transduction of Jurkat Cells and Generation of Cell Lines. 
Jurkat cells were harvested, counted and re-suspended to a cell ratio of 1x106/ml 
in R10F. 1ml of cells was aliquoted into 1.5ml sterile eppendorfs (Appleton Woods, 
UK) per transduction and centrifuged at 8000g for 5 minutes. The cell pellet was 
re-suspended in LV supernatant at 5TU/ml and the volume made up to 100µl. The 
tubes were incubated for 2 hours at room temperature with agitation every 15 
minutes. The Jurkat cells were spin infected for 45 minutes at 1000g in a micro 
centrifuge (Eppendorf, Germany). The cell pellet was re-suspended in R10F and 
cultured for 72 hours before assessment of transduction by flow cytometry. 
Transduced cells were then FACS sorted based on TCRαβ expression and 
cultured for use in subsequent assays.  
 
Primary Cell Transduction 
Primary cell populations were sorted and activated for 48 hours as described in 
section 2.2. The cells were harvested, counted and 2x105 cells were added to      
1.5 ml sterile eppendorfs. The cells were then centrifuged in a micro centrifuge at 
8000g for 5 minutes and the cell pellet re-suspended in LV supernatant at 5TU/cell. 
The primary cells were then transduced using the same protocol for Jurkat 
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transduction. After the transduction period, the LV supernatant was removed and 
replaced with the specific cell culture media for each cell population and added to a 
well of a 96 flat bottom plate. 
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3. Evaluating the Transfer of MHCI Restricted TCRs in 
Model T cell Lines 
3.1. Introduction 
The experiments in this chapter were designed to fully test the expression and 
function of the MHCI restricted TCRs that are used throughout this thesis. These 
three HLA-A2*01 restricted TCRs, summarised in Table 3-1, are namely the 868 
TCR, the 1E6 TCR and the 1D7 TCR. Historically there was thought to be a 
strong association with the HLA-A2*01 allele and susceptibility to T1D, with one 
report in children with T1D showing a frequency of 60-70% of this allele 
(Fennessy et al., 1994). Since then, more comprehensive genome wide 
association studies have identified other MHCI alleles that have a stronger 
association with susceptibility to T1D than the HLA-A2*01 allele (Howson et al., 
2009; Nejentsev et al., 2007). However, HLA-A2*01 is known to be the most 
predominant Class I HLA-A allele – genotyping of 5 US populations has revealed 
that 49.8% of the American Caucasian population carry this allele (Ellis et al., 
2000). Therefore, re-direction of human CD4+ TREG cell with HLA-A2*01 restricted 
antigenic relevant autoreactive TCRs could potentially be a tailored treatment for 
a large percentage of the population.  
 




The 868 CD8+ T cell line was first expanded using the immunodominant HIV 
GAG peptide SL9 (SLYNTAVTL) in 1996 from an HIV+ subject known as patient 
TCR TRA TRB TRBV MAb Index Peptide 
868 TRAV12-2*01 TRBV5-6*01 TRBv5 HIV-1 P1777-85 
SLYNTVATL (SL9) 1E6 TRAV12-3*01 TRBV12-4*01 TRBv8 PPI15-24 
ALWGPDAAA (ALW) 1D7 TRAV12-2*01 TRBV20-1*02 TRBv2 GAD65114-122 
VMNILLQYV (VMN) 
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868 (Sewell et al., 1997). This cytotoxic T lymphocyte (CTL) line was found to 
successfully lyse autologous B cell targets that were pulsed with the SL9 peptide. 
After attempts to isolate a single clone from this 868 CD8+ T cell line by limiting 
dilution were unsuccessful, clones were isolated using HLA-A2-SL9 phage 
display. These clones were then used to generate TCR bearing phage, from 
which the TCR genes of each clone could be sequenced. One of the clones 
sequenced was found to have a TCR made up of a TCRβ chain from the TRBV5-
6 family and a TRAV12.2 family TCRα chain (IMGT nomenclature) (Varela-
Rohena et al., 2008). This confirmed previous findings in the 868 patient whereby 
isolated SL9 MHCI tetramer+ T cells were predominately TRBV5-6+ (Wilson et al., 
1998). Additionally, further analysis of the 868 CTL line revealed that all HLA-A2-
SL9 tetramer+ cells expressed a TCR composed of the TCRBV5-6 and 
TRAV12.2 chains. To further characterise this TCR, now known as the 868 TCR, 
a soluble recombinant form was generated. Surface plasmon resonance (SPR) 
could therefore be used to measure the affinity for which the 868 TCR binds the 
SL9 peptide. Interestingly, this TCR-pMHCI interaction was identified as the 
highest affinity interaction of its kind so far on record (dissociation constant Kd of 
85nM as measured by kinetic injection analysis), which was in fact 25-fold higher 
than any other TCR-pMHC interaction documented (Cole et al., 2007a). The 
identification of this high affinity interaction led to this TCR being selected as an 
ideal candidate to investigate the re-direction of the Ag specificity of human 
primary T cells using MHCI TCRs (Plesa et al., 2012). In fact, the 868 TCR was 
found to not only be able to re-direct the Ag specificity of human CD8+ T cells but 
also of human CD4+ TEFF and CD4+ TREG cells. These findings therefore identified 
the interaction between the 868 TCR and cognate SL9 peptide as a CD8 
independent interaction. Therefore, this TCR will serve as a useful positive 
control for the transfer of MHCI TCRs into CD4+ TREG cells. 
 
1E6 TCR 
The parental 1E6 CD8+ T cell clone was cloned in 2008 from a patient with T1D 
and recognises the preproinsulin (PPI)15-24 epitope (Skowera et al., 2008). In this 
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first paper, the authors identified the PPI15-24 epitope, from herein designated 
ALW, as a naturally processed and presented HLA-A2 restricted Ag. To do this, 
the authors engineered a K562 cell line, an HLA negative chronic myelogenous 
leukemic cell line, to express both HLA-A2 and the human PPI genes. By 
engineering this cell line to encode the full PPI gene, they ensured that only PPI 
peptides that were naturally processed by the cells’ peptide processing 
machinery could be loaded into the HLA-A2 binding groove. Therefore, upon acid 
elution of peptides from the HLA-A2 binding groove, the investigators were 
confident that the ALW peptide was a bona fide, naturally processed and present 
epitope (NPPE). Using MHCI tetramers, CD8+ T cells with specificity for the ALW 
peptide were identified in the circulation of patients with T1D, proving the disease 
relevance of this peptide (Skowera et al., 2008; Velthuis et al., 2010). Following 
on from these data, the investigators isolated CD8+ T cell clones specific for this 
peptide, which culminated in the identification of the 1E6 CD8+ T cell clone. This 
clone was generated by the incubation of CD8+ T cells from a T1D patient with 
ALW peptide pulsed autologous mature DCs (mDCs). After a second round of re-
stimulation, cells were stained with an ALW HLA-A2 tetramer and positive cells 
were single cell sorted into 96 well plates containing allogeneic PBMCs, PHA and 
a cocktail of cytokines. Once a clone had been fully established the authors 
verified its specificity by tetramer staining and its ability to produce the pro-
inflammatory cytokines TNF-α and IFN-γ upon peptide specific stimulation. 
Importantly, the 1E6 CD8+ T cell clone was found to specifically kill β cells from 
an HLA-A2+ donor highlighting the relevance of this clone, and subsequently its 
TCR in vivo. Since the initial identification of this clone, further work has been 
performed to characterise the clone and specifically it’s TCR. One such study by 
Bulek et al assessed the structural basis behind the 1E6 CD8+ T cell clones’ 
autoreactivity (Bulek et al., 2012). In this study, it was identified that the 1E6 
TCR’s interaction with ALW-HLA-A2 was very weak, with a dissociation constant 
of only ~278µM Kd. This affinity is considered very low in comparison to 
published binding affinities for pathogen-specific TCR interactions with pMHCI, 
which are typically 1-10µM (Cole et al., 2007a). Despite this proven low affinity, 
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the 1E6 TCR is currently the only autoreactive disease relevant, MHCI restricted 
TCR that has been described and thus had been chosen as a candidate TCR for 
this study.  
 
1D7 TCR 
The 1D7 clone was isolated from a healthy control donor against the GAD65114-
122 epitope and was generated using the same protocol as for the 1E6 CD8 T cell 
clone (Knight et al., 2014). Upon incubation of this clone with human HLA-A2+ 
islets, the clone was found to produce the inflammatory cytokine MIP-1β. 
Furthermore, when HLA-A2+ K562 target cells that had been transfected with 
GAD65, were used to stimulate the clone it produced inflammatory cytokines 
such as IFN-α and IL-12 (Knight et al., 2014). At present no other work has 
continued to characterise the significance of this TCR, however the disease 
relevance of the HLA-A2 restricted GAD65114-122 epitope has been shown in 
patients with T1D (Monti et al., 2008a; Monti et al., 2007). Thus, this TCR, which 
is specific for a peptide with evidence of disease importance, was chosen as a 
second autoreactive TCR for this study. 
 
In order to initially validate these TCR constructs the Jurkat J76 clone was used 
as a model CD4 T cell line. This Jurkat cell line had previously been engineered 
to lack expression of both TCRα and TCRβ chains and thus serves as a useful 
tool in which the TCR expression constructs could be tested (Heemskerk et al., 
2003). Moreover, the aim of this study was to ascertain whether the MHCI 
restricted autoreactive TCRs used in this project could effectively signal in the 
absence of the CD8 co-receptor. To this end the J76CD8α cell line, which was 
generated by transfection of J76 cells with CD8α, were also obtained (Schub et 
al., 2009). These two Jurkat T cell lines enabled the testing of both the signalling 
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3.2. Material and Methods 
Generation of pELNS.RatCD2 Mock Vector 
The Rat CD2 gene was amplified from the pELNS.1E6.RatCD2 vector and using 
the following primers the XbaI restriction site was incorporated into the 5’ end of 
the gene: forward primer (AAAATCTAGAATGCATATGCGGTGCAAG) and 
reverse primer (TTAGTCGACCCGCTTCTTC). The PCR reaction mix used was 
identical to those detailed in Table 2-2 and the PCR cycling reaction used is 
detailed in Table 3-2. The resulting PCR product was then purified using the 
Nucleospin Gel and PCR cleanup kit. To prepare the vector for which the Rat 
CD2 fragment would be inserted, the pELNS.1E6.RatCD2 vector was digested 
with XbaI and SalI, as previously described, in order to excise the 1E6 TCR 
chains and the residing Rat CD2 molecule. The restriction digest mix was run on 
a 1% agarose gel and the fragment excised and cleaned up using the QIAquick 
gel extraction kit. The concentration of DNA of the Rat CD2 and vector fragments 
was quantified using the NanoDrop and a 15µl ligation reaction was set up using 
a vector:insert molar ratio of 3:1, T4 DNA ligase and 2x rapid ligation buffer 
(Promega, UK). XL-10 cells were transformed using 4µl of the ligation mix. Ten 
successful transformants were picked, cultured and the plasmid DNA prepared. 
The DNA preparations were then screened by restriction digest with XbaI and 
SalI to visualise the correct 705bp sized Rat CD2 insert. The original 
pELNS.1E6.RatCD2 vector was used as a control and the digestion of this with 
XbaI and SalI yields a 2.6Kb fragment. This cloning strategy is summarised in 
Figure 3.1. 
 
Table 3-2 PCR Cycling Conditions for Cloning of Rat CD2 
PCR Condition Temperature (°C) Time (s) Cycles 
Initial Denature 98 30 1 
Denature 98 10 25 
Annealing 55 30 25 
Elongation 72 40 25 
Final Elongation 72 600 1 
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Figure 3-1 Cloning Strategy for Generation of Mock Vector. A Mock vector for the sole 
transcription of the Rat CD2 gene was generated as a control for LV transduction of cells. (A) The 
Rat CD2 gene was PCR amplified with 5’XbaI primer and 3’SalI primer using the 
pELNS.1E6.RatCD2 vector as a template. (B) Using restriction enzymes XbaI and SalI the 
pELNs.1E6.RatCD2 vector was digested to remove the full 1E6 TCR and Rat CD2 construct. (C) 
The PCR product from (A) and digested pELNS vector from (B) were ligated together to generate 
the pELNS.RatCD2 Mock vector. 
 
Generation of pELNS.1E6.CD8α Vector 
A CD8α gene fragment with flanking 5’ NsiI and 3’ SalI restriction sites was kindly 
provided by Professor Linda Wooldridge (University of Bristol). The 
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enzymes to excise the Rat CD2 fragment and the remaining vector was purified. 
The vector and CD8α fragment were then ligated as described in Section 2.2.1. 
Ligations were subsequently transformed into competent cells, cultured overnight 
and DNA from the colonies prepared. To determine a successful ligation, 
prepared vectors were transfected into 293T cells and after 48 hours were 
stained with α-Rat CD2 and α-CD8α antibodies. A vector that yielded 
CD8α+RatCD2- 293T cells was then selected. A summary of this cloning strategy 




Figure 3-2 Cloning Strategy for the 1E6.CD8α Vector. For the generation of the 
pELNS.1E6.CD8α vector (A) a CD8α fragment with 5’ NsiI and 5’ SalI restriction sites was 
obtained. (B) The pELNS.1E6 vector was prepared by digestion with NsiI and SalI restriction sites 
to remove the Rat CD2 fragment. (C) The CD8α fragment from (A) was ligated into the prepared 
vector from (B) to generate the pELNS.1E6.CD8α vector. 
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Peptides 
Peptides were obtained by custom peptide synthesis service (Thermo Scientific) 
to a purity of >95%. Peptide sequences were as follows ALW – ALWGPDPAAA, 
RQF – RQFGPDFPTI, YQY – YQYGPDFINA, SL9 – SLYNTVATL, VMN – 
VMNILLQYV. All peptides used in this study, excluding SL9, were dissolved in 
PBS to a concentration of 1mg/ml. The SL9 peptide was dissolved in sterile 
DMSO to a concentration of 10µg/ml and diluted to 1µg/ml in PBS resulting in a 
final DMSO concentration of 10%.  
 
Activation of Jurkat Cell Lines 
Cryopreserved PBMCs from an HLA-A2*01+ donor were thawed and labelled with 
Cell Trace Violet as described in section 2-1. A schematic of the culture 
conditions for this assay are as shown (Figure 3-3(A)). Briefly, PBMCs were re-
suspended to 4x106/ml and 1ml of cells was added to labelled 15ml falcon tubes. 
Peptide was added at a concentration of 10µg/ml, PBS and CytoStim served as 
negative and positive controls respectively. PBMCs were pulsed for 2 hours at 
37°C with rotation and then washed in R10F at 400G for 5 minutes. All 
supernatant was removed from the pulsed PBMCs and the cells were re-
suspended at a concentration of 1x106/ml. Jurkat cells to be activated were 
counted and re-suspended to 1x105 cells/ml. For a final PBMC:Jurkat cell ratio of 
10:1 an equal volume of cells was added to the wells of a 96-u bottom plate. The 
cells were incubated for 16 hours and the following day harvested into FACS 
tubes and stained with APC conjugated CD69 antibody and 7AAD. The gating 
strategy used for this assay is detailed (Figure 3-3(B)). 
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Figure 3-3 Schematic Representation of Jurkat Activation Assay. (A) Violet labelled PBMC 
were incubated in 1ml of R10F with the addition of 10µg of peptide, PBS or CytoStim for 2 hours 
at 37°C. The PBMCs were then washed and incubated with Jurkat cells at a ratio of 10:1 for 16 
hours. (B) The assay was analysed by gating on Jurkat cells based on their FSC-A/SSC-A profile 
and excluding any doublets. Live Jurkat cells were then identified based on a 7AAD-Violet- 
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3.3. Results 
3.3.1. TCR constructs  
For introduction of de novo TCRs into Jurkat cell lines both the pELNS.1E6 
vector and the pELNS.868 vector were obtained from John Bridgeman (Cardiff 
University). Both the TCRα and TCRβ chains of each TCR had been clonotyped 
from the 1E6 and 868 parental clones previously. The pELNS LV vector is a third 
generation replication deficient vector that had initially been adapted from the 
pRRL-SIN-CMV-eGFP-WPRE vector (Richardson et al., 2008). The original 
adaptation made to the vector was to replace the cytomegalovirus promoter 
(CMV) promoter with the human elongation factor 1α promoter (EF1-α). Both 
promoters are considered strong promoters, however, the CMV promoter has 
been shown to be unreliable due to its silencing in certain mammalian cell lines 
(Qin et al., 2010), unlike the EF1-α promoter. The 1E6 and 868 TCRα and TCRβ 
chains were then inserted downstream of the EF1-α promoter and linked by a 
T2A linker site (Figure 3-4). The inclusion of the self-cleaving 2A peptide allows 
the generation of a multi-cistronic vector, which ensures equimolar transcription 
of all genes within the vector (Szymczak and Vignali, 2005). A further adaptation 
to the pELNS vector was to include a second 2A sequence downstream of the 
TCRβ chain followed by the Rat CD2 gene, which was a useful marker to assess 
transduction efficiency. The 1D7 TCRα and TCRβ chains were clonotyped and 
inserted into the pELNS vector as described in Chapter 2.2.3. Prior to insertion 
into the pELNS LV vector, all TCRα and TCRβ chains were codon optimised. 
Codon optimisation is a technique used to improve the translational efficiency of 
a gene by altering rare codons to more commonly used codons and can improve 
the expression of TCRαβ chains post transduction in primary cells (Scholten et 
al., 2006). To control for effects of LV transduction of cell lines a mock vector 
consisting of the EF1-α promoter followed by the Rat CD2 marker gene was 
generated (Figure 3-5 (A)). For construction of this control vector the 1E6 TCRα 
and TCRβ chains and Rat CD2 marker genes were excised from the pELNS 
vector using XbaI and SalI restriction enzymes (Figure 3-5 (B)). The Rat CD2 
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marker gene was then PCR amplified from the original pELNS vector to 
incorporate a 5’ XbaI site allowing the PCR product to be ligated into the empty 
pELNS vector using sticky end ligation (Figure 3-5 (C)). Successful ligation 
products were analysed by restriction enzyme digest and agarose gel screen 
(Figure 3-5 (D)). The DNA from a single ligation product was subsequently 
prepared, verified and used as a control mock vector. 
 
 
Figure 3-4 T-Cell Receptor Expression Plasmids. The TCR constructs, consisting of the α 
chain of the TCR linked by a T2A site of its paired TCRβ chain were inserted into the SIN pELNS 
lentivirus plasmid under the control of the EF1α promoter. A second cleavage site was inserted to 
link the Rat CD2 marker to the TCR chains, to assess for successful LV transduction. 
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Figure 3-5 Generation of pELNS.RatCD2 Vector. (A) The pELNS.RatCD2 control mock vector 
consists of the Rat CD2 marker gene downstream of the EF1-α promoter. The Rat CD2 gene 
was PCR amplified from the pELNS.1E6.RatCD2 vector to incorporate a 5’ XbaI site as indicated. 
(B) The 705bp product was resolved on an agarose gel as indicated by the white arrow and was 
excised and purified. (C) The pELNS.1E6.RatCD2 vector was digested with XbaI and SalI to 
remove the 1E6 TCR and Rat CD2 genes (sized 2.6Kb in total) and resolved on an agarose gel. 
The white arrow indicates the 3000bp marker (D) The DNA was prepared from bacteria 
transformed with the ligation products and digested with XbaI and SalI. Lane 1 shows the 
pELNs.1E6.RatCD2 un-digested. Lane 2 shows the pELNs.1E6.RatCD2 digestion product of a 
2.6kb insert. Lanes 3-7 show multiple ligation preps whereby the insert is the 705bp fragment of 
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3.3.2. Production and Titration of LV 
The generation of LV for this project was performed by co-transfection of 293T 
cells with the pELNS transgene constructs, an envelope plasmid pMDG2-VSV-G 
(VSV-G) and a packaging plasmid p8.91, which is based on the HIV-1 LV with all 
dispensable genes for virus encapsulation removed as described (Zufferey et al., 
1997) (Figure 3-6 (A)). Transfection efficiency of 293Ts was assessed by staining 
with an α-Rat CD2 antibody and was typically >75% for transfection with pELNS 
LV vectors (Figure 3-6 (B)). Post transfection, LV containing supernatant was 
harvested, concentrated 100x and titrated on 293T cells by spin infection of 
2x105 cells using 1:2 serial dilutions of LV. To calculate the titre in transducing 
units/ml, graphs were plotted of LV input against % transduction (Figure 3-6 (C)). 
Using the linear portion of the curve, the titre could be assessed using the 
calculation described in Chapter 2.4. Typically, the mock vector yielded higher 
titres than LV generated from TCR containing vectors (~5x107 TU/ml vs. ~1x107 
TU/ml). However, the LV generated from each TCR containing vector yielded 
similar titres suggesting that the smaller mock vector is more efficiently packaged 
and thus produced greater numbers of virus particles compared to larger TCR 
containing vectors. The titres calculated in this manner were then used to 
calculate multiplicity of infection for transduction of Jurkat cell and primary cell 
populations in subsequent chapters (Figure 3-7).  
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Figure 3-6 Production and Titration of LV. (A) LV was produced by co-transfection of 3 
plasmids: VSV-G, p8.91 and pELNS transgene construct into 293Ts. The 293T cells produced 
packaged LV particles containing the transgene of choice, which was then validated by LV 
transduction of 293Ts. (B) 293Ts were transduced in the presence or absence of mock LV and 
then cultured for 72 hours. The successful transduction with mock LV was then assessed by 
staining with an α-Rat CD2 antibody. (C) The titre of each LV was calculated by transducing 
293Ts with serial dilutions of virus. Titres were calculated by (% transduced cells * total cells 
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3.3.3. Generation of TCR+ Jurkat T cell Lines 
Jurkat T cell lines were generated by transduction of both the J76 and J76CD8α 
Jurkat T cell lines with LV encoding mock vector, the 868 TCR, the 1E6 TCR and 
the 1D7 TCR. Transduced cell were then sorted via FACS based on the 
expression of TCRαβ, for cells transduced with TCR encoding LV, or Rat CD2 for 
cells transduced with the control mock LV. Expression levels of TCRαβ, Rat CD2 
and CD8α on sorted cell lines were assessed by flow cytometry following staining 
with the relevant fluorochrome-conjugated mAb (Figure 3-7 (A) and (B)). The 
mean fluorescent intensity (MFI) of TCRαβ staining for each transduced cell type 
was determined (Figure 3-7 (C)). For transduction of both the J76 and J76CD8α 
cells, the MFI of TCRαβ expression was greatest for the 868 TCR with MFI of 
5126 and 8157 respectively. Expression of the 1E6 TCR in both Jurkat cell lines 
gave MFI readings of 3810 and 5540 for the 1E6+ J76 cells and 1E6+J76CD8α. 
The lowest TCR expressed was the 1D7 TCR with an MFI of 1821 in J76 cells 
and 2106 in J76CD8α cells. For all TCRs tested, the MFI expression in J76CD8α 
cells was higher than in J76 cells, as the J76CD8α cells have a slightly larger 
FSC-A/SSC-A profile. As expected, transduction with the mock vector gave 
negligible readings for TCRαβ MFI of 178 and 396 in the both cell lines. Within 
the transduced J76CD8α T cell population, the MFI of CD8α was consistent, 
showing that the difference in TCRαβ expression was TCR dependent and not 
cell line dependent (Figure 3-7 (C)). To ensure J76 cells were re-constituted with 
the correct TCR, each TCR cell lines was stained with the relevant TCR vβ 
specific antibody (Figure 3-8 (A-C)). Staining results revealed the correct vβ 
antibody staining for each TCR as detailed (Table 3-1). The vβ5 antibody stained 
the 868+ J76 cells, vβ8 stained the 1E6+J76 cells and the 1D7 TCR stained with 
the vβ2 antibody. The mock J76 cells were negative for all antibodies tested. 
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Figure 3-7 Transduction of Jurkat Cell Lines. TCR- Jurkat cell lines were transduced with 
5TU/ml of the indicated LV (A) TCR- J76 cells and (B) TCR- CD8α+ J76CD8α were stained with 
antibodies against TCRαβ, Rat CD2 and CD8α to measure successful expression of all 
constructs. Non transduced J76 cells served as a negative control for all antibodies tested. The 
mean fluorescence intensity of (C) TCRαβ expression on J76 and J76CD8α cells and  (D) CD8α 
on transduced J76CD8α was calculated at the same time point on the transduced cell lines. Data 
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Figure 3-8 TCR transduced Jurkat cells express the specific vβ chain of each TCR. 
Transduced J76 cell lines were incubated with antibodies against (A) TCRvβ8, the 1E6 TCR vβ 
(B) TCRvβ5 of the 868 TCR and (C) TCRvβ2, which identifies the 1D7 TCR. Cells were gated on 
a live FSC-A/SSC-A gate and the positivity for each TCRvβ antibody was set to the 99th 
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3.3.4. Multimer Staining of Pathogen Specific and Autoreactive MHC Class 
I TCRs 
MHCI multimers, such as tetramers and dextramers, are well-established 
reagents that can be used to identify Ag specific MHCI restricted TCRs 
(Wooldridge et al., 2009). Positive staining with a MHCI multimer therefore 
identifies a TCR that has the correct conformation of its TCRα and TCRβ chain, 
which enables it’s binding to pMHC. Thus they are a useful tool to address that 
the TCR transduced Jurkat cell lines express a productive, correctly folded 
TCRαβ as opposed to staining with monoclonal Abs that only infers expression of 
each chain. To this end, the ability of TCR transduced J76 and J76CD8α cells to 
stain with its Ag specific MHCI multimer was tested. Jurkat cell lines were 
similarly stained with a non-Ag specific, irrelevant multimer as a negative control. 
The high affinity 868 TCR transduced J76 and J76CD8α cell lines stained 
specifically with the SL9 MHCI multimer (Figure 3-9 (A) and (C)) but not with the 
irrelevant ALW MHCI multimer (Figure 3-9 (B) and (D)). The 1E6 and 1D7 
transduced Jurkat cell lines were each stained with either the PPI specific ALW 
MHCI multimer or the GAD65 specific VMN MHCI multimer, with the non specific 
peptide for each TCR acting as the irrelevant multimer control. For the 1E6 TCR 
transduced Jurkat cell lines, it was interesting to note that only the 
1E6+J76CD8α, and not the 1E6+J76 cell were capable of binding the ALW MHCI 
multimer (Figure 3-10). Moreover, only around 40% of CD3+ 1E6+J76CD8α cells 
were capable of binding ALW tetramer (Figure 3-10 (C)). The inability of the 
1E6+J76CD8α to stain with the VMN MHCI multimer demonstrated specificity as 
well as the correct TCRαβ conformation of the introduced 1E6 TCR (Figure 3-10 
(D)). The 1D7+ Jurkat cells yielded a similar pattern of MHCI multimer binding to 
the 1E6+ Jurkat cells in that only the 1D7+J76CD8α, and not the 1D7+J76 cells, 
demonstrated an ability to stain with the VMN MHCI multimer (Figure 3-11 (A and 
C)). This staining was above background as calculated by staining with the 
irrelevant ALW MHCI multimer (Figure 3-11 (D)). However, the positive VMN 
MHCI multimer staining was not as distinct as that seen when 1E6+ or 868+ cells 
were stained with their specific pMHC multimer. The proportion of cells that could 
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be identified with the VMN MHCI multimer was also minimal with less that 10% of 
cells showing positive staining.  
 
 
Figure 3-9 A SL9 MHCI Multimer efficiently and Specifically Identifies 868 TCR Transduced 
Jurkat Cell Lines. 868 transduced J76 cells were stained with either (A) peptide specific SL9 
MHCI Multimer or (B) ALW MHCI Multimer as an irrelevant pMHC control. (C)-(D) J76CD8α cells 
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Figure 3-10 Staining of 1E6 TCR Transduced Jurkat Cells with an ALW MHCI Multimer is 
Dependent on CD8α  expression. 1E6 transduced J76 cells and J76CD8α cells were stained 
with either (A) & (C) peptide specific ALW MHCI Multimer or (B) & (D) VMN MHCI Multimer as an 
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Figure 3-11 A VMN MHCI Multimer Identifies a Proportion of 1D7+J76CD8α  cells. 1D7 
transduced J76 cells and J76CD8α cells were stained with either (A) & (C) peptide specific VMN 
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3.3.5. TCR Transduction of TCR- Jurkat Cell Lines Restores TCR Signalling 
Capabilities 
The expression and function of a TCRαβ on the surface of a T cell is dependent 
on its association with the CD3 signalling complex (CD3δε, CD3γε and CD3ζζ) 
(Brenner et al., 1985; Geisler, 1992). The three subunits that make up the CD3 
complex consist of 10 ITAMs, which account for TCRαβ engagement induced 
signal transduction within a T cell.  TCRαβ- Jurkat cell lines used in this study fail 
to express CD3 complex on their cell surface highlighting the dual reliance of 
TCR for the CD3 complex and vice versa. Thus, when these cells are re-
constituted with TCRαβ genes, their CD3 expression is rescued (Figure 3-12 (A) 
and (B)). Similar to the hierarchy of TCR expression between different introduced 
TCRs, the 1D7 TCR had the lowest CD3 expression with an MFI of 4861 and 
5369 in J76 and J76CD8α respectively (Figure 3-12 (C), (D)). The levels of CD3 
expression on the 1D7+ Jurkat cell lines is much reduced in comparison to both 
868+ (11318 and 18391) and 1E6+ (10176 and 13349) Jurkat cell lines. 
 
It has now been demonstrated that the introduced TCRs were both expressed via 
staining with specific vβ antibodies and possess the correct conformation of the 
TCR α and β chains as evidenced by MHCI multimer staining. These results, in 
conjunction with successful co-expression of the CD3 signalling machinery 
allows for the assessment of these TCRs to function i.e. to signal in response to 
the TCRs specific cognate peptide. 
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Figure 3-12 Transduced TCR- Jurkat cells up-regulate the CD3 complex upon TCR 
introduction. Jurkat cell lines were incubated with anti CD3 antibody to assess expression of the 
CD3 complex on transduced (A) J76 and (B) J76CD8α cells. The mean fluorescence intensity 
(MFI) of CD3 expression on (C) J76 and (D) J76CD8α cells was calculated. Data is 
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3.3.6. High Affinity MHC Class I Restricted TCR can be Activated by 
Cognate Peptide Irrespective of CD8α Expression 
To investigate whether the TCR transduced Jurkat T cell lines could be activated 
by their cognate peptide, the up-regulation of the lymphoid activation marker, 
CD69, was assessed. The CD69 marker is known to be an early marker of T cell 
activation and its expression has been demonstrated by flow cytometry 4 hours 
post TCR engagement (Simms and Ellis, 1996). To determine the optimal time-
point to assess CD69 up-regulation on the Jurkat cell lines, 868+J76CD8α cells 
were activated by the SL9 peptide and CD69 up-regulation measured over time. 
The assay set up detailed in Figure 3-3 was used and replicate wells harvested 
4,8, 16 and 20 hours post stimulation. The optimal time-point for CD69 
expression was deemed to be 16 hours as at 20 hours expression had reduced 
(Figure 3-13). This time-point was then used for all subsequent activation assays. 
To test the 868 TCR was functional within the Jurkat cell lines, both the 868+ J76 
and 868+J76CD8α cell lines were stimulated with PBMC pulsed with, PBS, 
CytoStim or SL9. CytoStim is an antibody-based product, which promotes TCR 
activation by binding to TCRs and cross-linking them to MHC molecules. Thus, 
CytoStim can be used as a positive control to verify that the introduced TCRs are 
capable of signalling. From initial FACS staining, CD69 up-regulation can be 
seen in response to both CytoStim and the SL9 cognate peptide (Figure 3-14 
(A)). The ability of the SL9 peptide to elicit CD69 up-regulation in the presence 
and absence of CD8α highlights that the 868 TCR can be classed as a CD8 
independent TCR, a result that has been previously shown in primary cells and 
ties in with the pattern of pMHC multimer staining (Plesa et al., 2012). 
Interestingly the activation of the 868 TCR was consistently higher in the CD8α- 
Jurkat cells compared to the CD8α+ Jurkat cells (P <0.0001) (Figure 3-14 (B)).   
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Figure 3-13 Time course for CD69 up-regulation following peptide specific activation of 
Jurkat cell lines. 868+J76CD8α Jurkat cell lines were activated with Violet labelled PBMCs 
pulsed with cognate peptide or PBS as a negative control. (A) Representative FACS plots of 
CD69 expression of stimulated 868J76CD8α cells at indicated time points.  Data is representative 
of three independent experiments and CD69 expression was normalised to the PBS stimulated 
control by subtraction of stimulation by PBS at each time point for (B) 868J76CD8α activation 
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Figure 3-14 Activation of 868 Transduced Jurkat Cells. 868 transduced J76 and J76CD8α 
were incubated with violet labelled PBMCs pulsed with PBS, CytoStim and index peptide SL9. 
CD69 expression on Jurkat cells was measured by Flow Cytometry 16 hours post activation. (A) 
Representative FACS plots show activation of 868+ J76 and 868+ J76CD8α cells activated with 
PBS, CytoStim and SL9. (B) Data is representative of three independent experiments, and the 
mean of one experiment shown. (C) Mock transduced J76 and J76CD8α cells were stimulated as 
described and data represents two independent experiments. An unpaired Student’s t test was 
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3.3.7. Reduced Responsiveness of Autoreactive MHCI Restricted TCRs 
The autoreactive 1E6 and 1D7 expressing Jurkat cells were similarly assessed 
for their ability to up-regulate CD69 in response to stimulation with cognate 
peptide. Both the 1E6+ J76 and 1E6+ J76CD8α were used in this assay and 
stimulated with PBS, CytoStim and the ALW peptide (Figure 3-15 (A)). Only the 
1E6+J76CD8α cells, and not the 1E6+J76 cells, were able to respond to the ALW 
peptide, highlighting the dependence of this TCR on CD8α expression. This 
result was consistent over multiple experiments and in all cases the 1E6 TCR 
only responded to ALW peptide via CD69 up-regulation in the presence of the 
CD8α co-receptor (Figure 3-15 (B)). This response was TCR specific as neither 
Mock J76 or Mock J76CD8α cells responded to PBMCs presenting the ALW 
peptide (Figure 3-15 (C)). In contrast to this, the 1D7+ Jurkat cells were incapable 
of up-regulating CD69 in response to the VMN peptide, even in the presence of 
the CD8α co-receptor (Figure 3-16 (A-B). Both 1D7+ Jurkat cells could up-
regulate CD69 in response to CytoStim however, showing that this TCR was 
functional. To compare the dose responsiveness of the three TCRs to their 
cognate peptide an 8-log fold dose titration was performed (Figure 3-17). A 
starting concentration of 100µM was chosen as a dose 10-fold higher than the 
concentrations previously used, to rule out any lack of response due to minimal 
peptide concentration. The response of both 868+J76 and 868+J76CD8α cells to 
the SL9 peptide were similar in magnitude, again highlighting that CD8α is not 
required for 868 TCR binding to MHCI and SL9 (Figure 3-17 (A)).  
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Figure 3-15 Activation of 1E6 Transduced Jurkat Cells. 1E6 transduced J76 and J76CD8α 
were incubated with violet labelled PBMCs pulsed with PBS, CytoStim as a positive control and 
index peptide ALW. CD69 expression on Jurkat cells was measured by Flow Cytometry 16 hours 
post activation. (A) Representative FACS plots show activation of 1E6+ J76 and 1E6+ J76CD8α 
cells activated with PBS, CytoStim and ALW. (B) Data is representative of three independent 
experiments, and the mean of one experiment shown. (C) Mock transduced J76 and J76CD8α 
cells were stimulated as described and data represents two independent experiments. An 
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Figure 3-16 Activation of 1D7 Transduced Jurkat Cells. 1D7 transduced J76 and J76CD8α 
were incubated with violet labelled PBMCs pulsed with PBS, CytoStim as a positive control and 
index peptide VMN CD69 expression on Jurkat cells was measured by Flow Cytometry 16 hours 
post activation. (A) Representative FACS plots show activation of 1D7+ J76 and 1D7+ J76CD8α 
cells activated with PBS, CytoStim and VMN. (B) Data is representative of three independent 
experiments, and the mean of one experiment shown. (C) Mock transduced J76 and J76CD8α 
cells were also stimulated as described and data represents two independent experiments.  
 
The response of the 1E6+J76CD8α cells in response to ALW peptide failed to 
reach maximum responsiveness even at the high dose of peptide used, 
suggesting a low affinity interaction between TCR and peptide (Figure 3-17 (B)). 
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Meanwhile, the high dose of peptide used failed to yield any response from the 
1D7+ Jurkat cells (Figure 3-17 (C)).  
 
 
Figure 3-17 Dose Response Curves of TCR Transduced Jurkat cells to Cognate Peptide. 
TCR transduced J76 and J76CD8α cells were stimulated with 8 log fold dilutions of cognate 
peptide. (A) 868 transduced J76 and J76CD8α cells were stimulated with SL9 peptide, (B) 1E6 
transduced cells with ALW and (C) 1D7 transduced cells with VMN peptide. Data is from two 
independent experiments. 
 
3.3.8. Heteroclitic Peptide can be used to Activate the 1E6 TCR 
Since its isolation, the 1E6 CD8+ T cell clone has been used in a variety of 
studies aiming to characterise autoreactive CD8+ T cells. One such study 
demonstrated that the 1E6 CD8+ T cell clone was capable of recognising more 
than a million different peptides (Wooldridge et al., 2012). Moreover, by 
employing a decamer combinatorial peptide library Wooldridge et al identified a 
range of decamer peptides that were more potent at activating the 1E6 CD8+ T 
cell clone. Two of these peptides, termed super agonist peptides, were chosen 
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to its far superior potency at activating the 1E6 CD8+ T cell clone compared to 
the ALW peptide, and the YQY peptide was selected as a medium activator of 
this TCR. These three peptides were then used to stimulate 1E6+ J76 and 1E6+ 
J76CD8α cells (Figure 3-18 (A)). Most interestingly, the RQF peptide could 
stimulate both the 1E6+J76 and 1E6+J76CD8α cells to up-regulate CD69, 
whereas the YQY and ALW peptide were only capable of activating the 
1E6+J76CD8α cells (Figure 3-18 (B)). To further investigate the potency of each 
peptide for activating the 1E6 TCR, 1E6+J76CD8α cells were stimulated with log 
dose titrations of the three peptides. These results show that the RQF peptide 
could activate the 1E6+J76CD8α cells at much lower peptide concentrations 
(10nM/ml) than either the ALW or YQY peptide (1-10µM/ml) (Figure 3-18 (C)). 
Furthermore, the maximum response achieved by the 1E6+J76CD8α cells when 
stimulated by either ALW or YQY peptide, ~20%, could be reached with four logs 
lower concentration of RQF peptide. Additionally, the maximum response 
reached by the 1E6+J76CD8α cells when stimulated with the RQF peptide was 
much higher (Mean 65 ± 5.7% SD) compared to stimulation with the maximum 
concentration of ALW (Mean 20.9 ± 5.3% SD). These results therefore suggest 
that the interaction between the 1E6 TCR and the RQF peptide is of such a high 
affinity that it does not require the CD8α co-receptor. Surprisingly, the YQY 
peptide, that was proffered as a medium activator of the 1E6 TCR, was no better 
at activating this TCR than the cognate ALW peptide, and in fact the maximal 
response to this peptide was lower than to the ALW peptide (Figure 3-18 (C)).  
 
Table 3-3 A list of the super agonist peptides used in their study and their relative 
functional sensitivity calculated as pEC50(agonist) - pEC50(index peptide) (Wooldridge et 
al., 2012) 
 Peptide Sequence Relative Functional Sensitivity 
ALW ALWGPDAAA 0 
YQY YQYGPDFINA 1.5 
RQF RQFGPDFPTI 3 
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Figure 3-18 Activation of 1E6 Transduced Jurkat Cells with Super Agonist Peptides. The 
1E6 clone from which the 1E6 TCR was isolated has previously been shown to have a greater 
functional sensitivity to super agonist peptides than to the WT peptide (Wooldridge et al., 2012). 
(A) 1E6 transduced Jurkat cells were activated as previously with the WT ALW peptide and super 
agonist YQY and RQF peptides. (B) Data is representative of three independent experiments. (C) 
To measure the functionally sensitivity of the 1E6 TCR transduced J76CD8α these cells were 
stimulated with eight log fold dilutions of ALW RQF and YQY. Data is representative of three 
independent experiments. An unpaired Student’s t test was used to calculate data significance. P 
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3.3.9.  The Activation of Autoreactive TCRs can not be Rescued by LV Co-
expression of CD8α 
The observation that 1E6+J76CD8α cells could respond to the ALW peptide led 
us to create a LV vector whereby CD8α could be co-expressed with the 1E6 TCR 
in any cell type of choice. This LV vector, designated 1E6.CD8α consisted of the 
1E6 TCRα and TCRβ chains linked to a CD8α fragment (Figure 3-19 (A)). To 
generate this vector, the pELNS.1E6.RatCD2 vector was first digested with NsiI 
and SalI restriction enzymes to remove the RatCD2 gene from this plasmid 
(Figure 3-19 (B)). A CD8α gene with 5’ NsiI and 3’ SalI restriction sites was a 
kind gift from Linda Wooldridge (University of Bristol). The prepared vector and 
CD8α gene fragment were ligated and the ligation products were transformed 
into competent cells, from which the plasmid DNA was prepared. The prepared 
DNA was digested with NsiI and SalI restriction enzymes to resolve the CD8α 
fragment (Figure 3-19 (C)). The pELNS.1E6.RatCD2 vector was also digested as 
a control. The Rat CD2 gene (705bp) and CD8α gene (712bp) were too close in 
size to determine by agarose gel if the CD8α gene had successfully replaced the 
Rat CD2 gene (Figure 3-19 (C)). 293Ts were transfected with the prepared DNA 
and transfected cells were stained with Rat CD2 and CD8α to confirm expression 
of CD8α over Rat CD2 (Figure 3-19 (D)). A positive plasmid preparation was 
then selected as the pELNS.1E6.CD8α vector. To test if the LV co-expression of 
CD8α could rescue the response of the 1E6 TCR, J76 cells were transduced with 
the 1E6.CD8α LV. These cells were then stimulated with either PBS or ALW to 
assess for CD69 up-regulation. 1E6+J76 and 1E6+J76CD8α cells served as a 
negative and positive control respectively. After the cells had been activated for 
16 hours, they were stained with antibodies against CD8α and CD69 (Figure 3-
20 (A)). This allowed for analysis of CD69 up-regulation in 1E6+CD8α+ cells only. 
In three individual experiments, no CD69 up-regulation was seen in cells co-
expressing 1E6 and CD8α, from the LV vector, in response to ALW peptide 
(Figure 3-20 (B)). However, as before, CD69 up-regulation was seen in the 
1E6+J76CD8α cells. Upon closer analysis of CD8 expression between these two 
Chapter 3 Evaluating the transfer of MHCI restricted TCRs in model T cell lines 
114 
cell lines, a difference in CD8 expression became clear. Overlays of histograms 
of CD8 MFI expression on 1E6+J76CD8α cells and 1E6.CD8α+J76 cells revealed 
that the CD8 expression from the 1E6.CD8α LV vector was markedly reduced 
compared to the J76CD8α cell line (Figure 3-20 (C)).  
Figure 3-19 Generation of 1E6.CD8α LV Vector. (A) A CD8α gene fragment was cloned into 
the 1E6 pELNS LV vector and linked to the 1E6 TCRβ chain by a T2A cleavage site. The 
resulting LV vector was designated 1E6.CD8α (B) To generate the vector the 
pELNS.1E6.RatCD2 vector was digested with NsiI and SalI to remove the 705bp Rat CD2 
fragment as indicated by the white arrow (C) the digested pELNS.1E6 vector and CD8α fragment 
with 5’ NsiI and 3’SalI restriction sites were ligated, transformed into competent cells and the 
plasmid DNA prepared. Gel shows: Lane 1 - pELNS.1E6.RatCD2 vector uncut, Lane 2 -  
pELNS.1E6.RatCD2 digested with NsiI and SalI and Lane 3-7 show ligation products digested 
with NsiI and SalI. White arrow shows the 700bp marker. (D) A representative FACS plot of 293T 
cells transfected with prepared DNA from the pELNS.1E6 and CD8α ligation, stained with CD8α 
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Figure 3-20 Activation of 1E6.CD8α transduced J76 cells. 1E6.CD8α transduced J76 cells 
were activated alongside 1E6+J76 and 1E6+J76CD8α cells with violet labelled PBMCs pulsed 
with either PBS as a negative control of the 1E6 TCR cognate peptide ALW. (A) Representative 
FACS plots show activated Jurkat cells stained with antibodies against CD69 and CD8α. (B) 
CD69 up-regulation was analysed within the CD8α+ population of both 1E6+J76CD8α and 
1E6+CD8α+J76 cells. Data is representative of three independent experiments.  P Value = **** < 
0.0001 (C) CD8α expression was assessed on 1E6.CD8αJ76 cells (Black histogram) and 
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3.4. Discussion 
The experiments in this chapter were designed to test the three MHCI TCRs that 
will be used throughout this study. The use of TCRαβ- Jurkat cells as model cell 
lines was useful to verify TCR constructs as any expression differences caused 
by competition with the endogenous TCR are removed. Using these cells, each 
TCR construct was examined for the ability to be fully expressed and to re-direct 
the Ag specificity of the model cell lines. These experiments revealed that the 
TCRα and TCRβ chains of each TCR could successfully pair and fold to form a 
complete cell surface TCR, and additionally they could successfully pair with the 
CD3 signalling complex. Interestingly, despite a lack of competition for TCR 
expression on the cell surface of the Jurkat cells there was a stark difference in 
TCR expression between the three TCRs tested. Expectedly, this low expression 
of TCRαβ correlated with a low expression of the CD3 complex. 
 
For a TCR to be successfully expressed on the surface of a T cell two crucial 
events must take place. Firstly the TCRα and TCRβ chains (which constitute the 
TCR) must successfully pair with one another and secondly this TCR must form 
non covalent bonds with all the subunits that create the CD3 complex. Only after 
these two processes take place can the optimal cell surface expression of the 
TCR-CD3 complex be observed (Ohashi et al., 1985; Saito et al., 1987). The 
model J76 cell lines used in the project are deficient in both TCRα and TCRβ 
genes, thus the introduced TCRs were under no competition for coupling to CD3. 
Therefore, the observation that the two autoreactive TCRs, 1E6 and particularly 
1D7, were expressed at much lower levels than the pathogen specific 868 TCR 
could be due to an inefficient pairing of the TCRα and β genes of each TCR. It 
has been previously shown that expression of introduced TCRs in primary T cells 
is controlled intrinsically by the qualities of the introduced TCR (Heemskerk et al., 
2007). Thus the hypothesis that the reduced expression of the two autoreactive 
TCRs is due to a reduced capacity of the TCRα and TCRβ chains of each TCR 
to pair is not unrealistic. A potential experiment to test this hypothesis could be to 
perform intracellular staining for the specific vβ of each TCR transduced Jurkat 
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cell line to determine whether the autoreactive TCRs’ ability to traffic to the cell 
surface is compromised.  However, it is known that unassembled TCR-CD3 
complexes are targeted for degradation within the endoplasmic reticulum only a 
few hours post synthesis (Bonifacino et al., 1989), thus potentially skewing any 
results using intracellular staining. 
 
After determining that the TCRs could be expressed on the cell surface of the 
Jurkat cell lines, it was examined whether the correct TCR conformation was  
displayed on the cells surface. To do this, pMHCI multimers were used to confirm 
the TCRs could bind to cognate pMHCI and PBMCs pulsed with peptide were 
used to demonstrate the signalling ability of TCR transduced cells in response to 
cognate peptide. These further experiments revealed a clear difference in the 
ability of the autoreactive TCRs to respond to cognate pMHC in comparison to 
the pathogen specific 868 TCR. The 868 TCR behaved equally in J76 and 
J76CD8α cells, which would be expected based on results seen by others in 
primary human T cell populations (Plesa et al., 2012). An SL9-MHCI multimer 
could positively stain both 868+J76 and 868+J76CD8α cell lines, demonstrating 
that this TCR was in the correct conformation on the surface of the Jurkat cells. 
Furthermore, both 868+ Jurkat cell lines could robustly and reproducibly up-
regulate CD69 in response to PBMCs pulsed with SL9 peptide. These results 
demonstrated that the 868 TCR could re-direct the Ag specificity of Jurkat cell 
lines irrespective of CD8α co-receptor expression. The interaction between the 
868 TCR and SL9-MHCI could therefore be classed as CD8 independent. 
Interestingly, the presence of CD8α in conjunction with the SL9 TCR increased 
non-specific activation- a result consistently observed when 868+ J76CD8α cells 
were incubated with PBMCs pulsed with PBS and when these cells were stained 
with an irrelevant pMHC multimer. The co-expression of CD8 and high affinity 
TCRs has previously been shown to decrease the Ag specificity of a TCR by 
increasing the length of interaction between TCR and pMHCI (Zhao et al., 2007). 
This phenomenon could also explain why the functional avidity of the 868 TCR, 
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as measured by SL9 dose titration, was comparable between 868+ J76 and 868+ 
J76CD8α cells.  
Cells transduced with the 1E6 TCR were found to be completely reliant on the 
presence of CD8α for the recognition of the WT ALW peptide. The 1E6+ 
J76CD8α showed a reproducible, yet modest response via CD69 up-regulation 
when presented with ALW peptide. Even when PBMCs were pulsed with the 
highest dose of peptide (100µM), the 1E6+J76CD8α did not reach maximal 
response to the WT peptide. These results mirror the data seen when these cells 
are stained with the ALW pMHCi multimer, with only a proportion of these cells 
capable of responding. This dependence of 1E6 on CD8α for functional response 
to ALW is unsurprising given its naturally low affinity for WT peptide (Bulek et al., 
2012). It is worthwhile to mention that the function of CD8αα homodimer as a co-
receptor is controversial (Cheroutre and Lambolez, 2008) and there is evidence 
of CD8αα acting as a suppressor of TCR activation in gut intra-epithelial T cells 
(Hayday et al., 2001). Studies using murine CD8β- and CD8βwt mice have shown 
that upon retroviral TCR transduction of CD8 dependent TCRs, these TCRs can 
only function in CD8βwt T cells. However, the ability of CD8αα to interact with 
HLA-A2*01 molecules and stabilise the TCR:pMHCI interaction has been well 
demonstrated and it is this function that may be integral for allowing a functional 
response to ALW from the 1E6+J7CD8α cells (Gao et al., 1997). The ability of the 
1E6 TCR to recognise peptides could also be rescued using previously identified 
peptides that were capable of activating the 1E6 CD8+ T cell clone to a much 
greater degree (Wooldridge et al., 2012). Most interestingly, the RQF peptide that 
was found to activate the 1E6 CD8+ T cell clone by >100 fold compared to WT 
peptide, was able to specifically activate both the 1E6+J76CD8α and 1E6+J76 
Jurkat cell lines. Thus, the interaction between the 1E6 TCR and RQF-MHCI is of 
such a high affinity it bypasses the requirement for CD8 co-receptor. The second 
peptide chosen, YQY, was chosen due to its intermediate functional sensitivity 
for the 1E6 TCR of >10 fold compared to ALW. Surprisingly the results seen with 
the YQY peptide were comparable to those seen with the ALW peptide, in both 
the CD8α dependency and its functional avidity for 1E6 TCR. In fact, at the same 
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concentrations the ALW peptide could elicit a slightly greater response from the 
1E6+J76CD8α cells than the YQY peptide.  
 
The second autoreactive TCR, the GAD65114-122 VMN specific 1D7 TCR, proved 
more of an anomaly than the 1E6 TCR. A modest percentage of these cells could 
be specifically identified with the VMN pMHCI multimer compared to staining with 
the irrelevant ALW MHCI multimer, however this positive staining was not as 
distinct as other positive TCR pMHC multimer stains. Despite this, cognate 
peptide pulsed PBMCs were unable to elicit a response from 1D7+J76 cells or 
1D7+ J76CD8α cells, despite very high concentration used in the peptide dose 
titration studies. However, it is clear that this is a functional TCR capable of 
signalling as it exhibited a robust response when stimulated with CytoStim as a 
positive control. It is plausible that the observed poor expression of the 1D7 TCR 
and CD3 complex could be the cause of this result. T cell activation via the TCR 
is the result of multiple TCR triggering events that amplifies the TCR signalling 
cascade (Valitutti et al., 1995) and potentially the lack of 1D7 TCR expression 
could results in minimal TCR triggering that does not exceed the threshold 
required for TCR activation. Furthermore, the minimal positive staining with the 
VMN tetramer reveals an extremely low affinity interaction between the 1D7 TCR 
and VMN tetramer, which appears to be even lower that the 1E6 TCR affinity for 
ALW tetramer.  
 
In this study the autoreactive MHCI multimers used were MHCI tetramers. MHCI 
tetramers are composed of four biotinylated pMHCI monomers that are 
assembled into a complex by streptavidin labelled fluorochromes. Since the 
discovery of the MHCI tetramer, other MHCI multimers have come onto the 
market such as pentamers, octamers and more recently dextramers (Batard et 
al., 2006). Dextramers consist of a dextran polymer backbone that carries a 
number of fluorochrome labelled pMHC molecules. The increased abundance of 
pMHC molecule ensures the dextramer has a higher avidity for binding to Ag 
specific TCRs. Recently, MHCI dextramers have proven to be superior to MHCI 
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tetramers at binding to Ag specific T cells that have a low affinity TCR pMHCI 
interaction (Dolton et al., 2014). In fact, this study used a 1E6 TCR+ clone to 
identify this and showed that the ALW MHCI dextramer could bind 17x more 
efficiently to the 1E6 TCR than the ALW MHCI tetramer. However, in a single 
assay no difference was seen in the staining of 1E6+ Jurkat cells with ALW MHCI 
tetramers or ALW MHCI dextramers (data not shown). During this current study, 
no VMN MHCI dextramers were available to test their staining of the 1D7+ Jurkat 
cell lines although this would be a useful test should they become available. A 
second tool that is used to improve MHCI multimer binding is the use of protein 
kinase inhibitor Dastanib, which can prevent TCR down-regulation, thereby 
improving pMHCI multimer binding (Lissina et al., 2009). All MHCI multimer 
staining in this section however was carried out after pre-incubation of the cells 
with PKI. Moreover, a side-by-side comparison of 1D7+ Jurkat cells that were pre 
incubated +/- PKI and then stained with either VMN MHCI tetramer or a pan 
TCRαβ antibody revealed no difference in the MFI of either reagent (data not 
shown). This suggests that PKI does not affect the expression of the introduced 
TCRs in Jurkat cell lines. Another interesting observation that has come from 
previous studies using MHCI multimers identified that the affinity threshold 
required for pMHCI tetramer binding was higher than that required for TCR 
activation (Laugel et al., 2007). This is in contrast to the results seen in this 
current study. Indeed, a higher percentage of 1E6+J76CD8α cells could stain 
with ALW MHCI tetramer (40%) over those that could be activated by the ALW 
peptide to up-regulate CD69 (20%). Additionally, 1D7+J76CD8α cells could bind 
VMN MHCI tetramer but could not up-regulate CD69 in response to this peptide. 
Although, this could be due to the use of the CD8α co-receptor, these results 
potentially demonstrate a difference between model Jurkat cell lines and 
autoreactive CD8+ T cells in that autoreactive CD8 T cells may have intrinsic 
properties that make them more susceptible to peptide activation.  
  
The observation that the 1E6+J76CD8α cells could respond to the ALW peptide 
pulsed PBMCs led us to try to recapitulate this result using LV co-expression of 
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CD8α. To this end the CD8α gene was inserted in the place of Rat CD2 in the 
pELNS.1E6 LV vector. Although using this vector the 1E6 TCR and CD8α could 
be co-expressed in J76 Jurkat cells, the expression of CD8α was not sufficient to 
allow signalling in response to the ALW peptide. Upon analysis of the CD8α 
expression, this gene was found to be markedly reduced in the LV transduced 
cells compared to the J76CD8α cell line. Therefore, the level of CD8α expression 
in the transduced cells may not be adequate to facilitate the stability of pMHCI 
and 1E6 TCR. On closer inspection of FACS plots whereby the 1E6+ J76CD8α 
cells had been activated by ALW, only the highest CD8α expressing cells 
responded to the peptide, a level of expression the transduced gene failed to 
reach. The reduced expression of CD8α after LV co-expression may be because 
it was the third gene to be expressed in the multi-cistronic pELNS.1E6.CD8α 
vector. Others have shown that when using tetra-cistronic vectors all four genes 
can be equally co-expressed on a transduced cell (Fisicaro et al., 2011). 
However, another study identified that the expression of downstream genes can 
be affected if the upstream genes are not efficiently expressed (Hurh et al., 
2013). In fact, retrospective review of Rat CD2 expression in the TCR transduced 
cells reveals a much lower expression of this marker compared to mock 
transduced cells. This may suggest that the either the TCRα or TCRβ genes are 
not efficient at being expressed which subsequently affects the expression of the 
marker gene. 
 
This section set out to thoroughly test the three MHC Class I TCR constructs at 
their ability to be expressed in model Jurkat cell lines and subsequently re-direct 
the Ag specificity of these cells. Through these data, it has been shown that all 
TCRs are functional, however the results show a consistent pattern in which islet 
Ag specific TCRs behave differently to a pathogen specific TCR. Despite these 
observed differences, the results in Jurkat cell lines provide a basis for the 
commencement of LV MHC class I TCR transduction of human CD4+ TREG cells. 
Chapter 4 LV TCR transduction and re-direction of the antigen specificity of 
Human primary T cell populations 
122 
4. LV TCR Transduction and Re-direction of the 
Antigen Specificity of Human Primary T Cell 
Populations. 
4.1. Introduction 
The second section of this study will investigate the transduction of primary human 
T cell populations with the previously described MHCI TCRs. Both the expression 
of these TCRs will be examined and their ability to redirect the Ag specific 
responses of human T cells, including conferring suppressive capabilities to human 
CD4+ TREG cells. The positive control 868 TCR was identified as a CD8 co-receptor 
independent TCR and thus is an invaluable tool for the progression of this thesis. 
However, it was seen in Jurkat cells, that the two autoreactive TCRs had different 
properties compared to the 868 TCR: their expression in TCR- Jurkat cells was 
lower and the 1E6 TCRs response relied on the CD8α co-receptor. Furthermore, 
the GAD specific 1D7 autoreactive TCR failed to signal in response to cognate 
peptide even in the presence of CD8α, despite some indication of correct 
expression as evidenced by pMHCI multimers.   
 
Although these data may suggest that MHCI restricted autoreactive TCRs may be 
unsuitable for the re-direction of CD4+ T cells, a recent study by Plesa et al 
identified that CD4+ TREG cells may have altered TCR signalling requirements 
compared to CD4+ TEFF cells. For part of this study, the authors used LV gene 
transfer to transfer two MHCI restricted TCRs into human CD4+ TREG cells (Plesa et 
al., 2012). One of these TCRs, as previously mentioned was the 868 TCR and the 
second was a TCR specific for the tumour Ag NY-ESO-1157-164. The NY-ESO-1 
specific TCR has previously been shown to have a relatively low affinity for its 
cognate peptide (32µM compared to 868 TCR affinity for SL9 of 85nM) (Zhao et 
al., 2007). To investigate whether this low affinity TCR-pMHCI interaction could 
successfully re-direct the Ag specificity of CD4+ TEFF cells, the authors transfected 
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CD4+ TEFF cells with a LV vector encoding the NY-ESO-1 specific TCR. 
Interestingly, despite high levels of TCR expression (assessed by specific TCRvβ 
up-regulation) the NY-ESO-1-TCR transfected CD4+ TEFF cells were undetectable 
by staining with an NY-ESO-1 pMHCI multimer. Furthermore, these cells were 
unable to mount an effector response, as measured by the secretion of IFN-γ and 
IL-2 when incubated with K562-A2 presenting the NY-ESO-1 peptide. However, 
under the same conditions, NY-ESO-1 TCR transfected CD8+ T cells mounted an 
effective effector response, suggesting the interaction of this TCR with its cognate 
peptide was dependent on the CD8 co-receptor. Most surprisingly, upon 
transfection of the NY-ESO-1 specific TCR into isolated CD4+ TREG cells, this TCR 
was capable of re-directing the Ag specific suppressive capabilities of these cells. 
This evidence led the authors to hypothesise that CD4+ TREG cells may have 
different TCR-pMHCI affinity requirements to a CD4+ TEFF cell.   
 
This hypothesis was further supported by evidence suggesting that compared to 
CD4+ TEFF cells, CD4+ TREG cells have a lower threshold for TCR activation due to 
the occurrence of TCR signalling in the absence of the CD4 co-receptor. For 
example, mice that were transfused with a CD4 blocking antibody developed a 
specific accumulation of CD4+ TREG cells (Oliveira et al., 2011). It was further 
suggested that TCR signalling can occur in mature CD4+ TREG cells in the absence 
of CD4 recruitment of Lck, an important molecule in the TCR signalling cascade 
(Artyomov et al., 2010). These data therefore suggest that low levels of TCR 
triggering and signalling are sufficient to fully activate the suppressive function of 
TREG cells. In theory, if an MHCII restricted TCR can signal in the absence of CD4 
recruited Lck in a TREG cell, it is possible that an MHCI restricted TCR may also 
signal in a co-receptor independent manner in the setting of a TREG cell. Therefore, 
an MHCI restricted TCR that may require CD8 recruitment of Lck to aid signalling 
in a CD8+ T cell, may not have the same requirements in a TREG cell (Figure 4-1). 
 
These results have therefore formed the working hypothesis for this study which is 
that an autoreactive MHCI restricted TCR can transfer Ag specificity to a CD4+ 
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TREG cell, despite its reliance on CD8α in model Jurkat cell lines – a hypothesis 
which will be thoroughly tested in this section of this thesis. This will be tested not 
only by assessing the functional response of TCR transduced CD4+ TREG cells but 
also by testing the ability of these TCRs to signal in CD4+ TEFF and CD8+ T cells 
 
 
Figure 4-1 Model of The Function of MHCI restricted TCRs in Human T Cell Populations. (A) 
In a CD8+ T cell an MHCI restricted TCR will recognise its specific pMHCI on the surface of an 
APC. The CD8αβ co-receptor stabilises this interaction and recruits the Lck tyrosine Kinase to the 
CD3 complex, which phosphorylates CD3 signalling domains, resulting in productive TCR 
signalling. (B) In a CD4+ TEFF cell, the CD4 co-receptor does not associate with MHCI to stabilise 
the interaction between the introduced MHCI TCR and pMHC interaction. Therefore, Lck is not 
recruited to the CD3 complex and productive TCR signalling does not occur. (C) In a CD4+ TREG 
cell, TCR signalling does not rely on CD4 recruitment of Lck. Therefore upon recognition of specific 
pMHCI by the MHCI restricted TCR, productive TCR signalling can occur. However, a mechanism 
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4.2. Materials and Methods 
Expansion of Transduced Primary Human T cell Populations. 
Primary cells were isolated by FACS and activated following established protocols 
as described in section 2-1 (Brusko et al., 2010; Canavan et al., 2012; Skowera et 
al., 2008). Transduced TEFF and TREG cells were maintained until the end of their 
first expansion period, typically 8-10 days for TREG and 10-12 days for TEFF before a 
second round of cell expansion as described. After this second round of expansion, 
transduced TREG and TEFF were FACS sorted based on Rat CD2 expression. 
Depending on cell number, transduced cells were either re-expanded a third time 
or cryopreserved for future use. Where indicated, TREG cells were additionally 
cultured in 100ng/ml Rapamycin (RAPA) (Rapammune, Pfizer Ltd, UK).  
Transduced CD8+ T cells were cultured until D8, sorted based on Rat CD2 
expression and then re-expanded using irradiated feeders at a ratio of 10:1 
feeders:CD8+ T cells with the addition of phytoheamagluttinin (PHA) at a final 
concentration of 5µg/ml. At the end of this round of expansion, transduced CD8+ T 
cells were cryopreserved. Full timelines of the expansion protocol of the different 
primary T cell populations were as shown (Figure 4-2). 
 
Activation assay for CD69 on Primary Human T Cell Populations 
On Day 6 post initial activation of T cells, all cells were harvested and the magnetic 
aCD3/CD28 beads were removed using a 1.5 ml Eppendorf size magnet (Dynal, 
Life Technologies, UK). Samples were incubated on the magnet for 2 minutes and 
the beads washed a minimum of two times for 2 minutes to ensure maximal cell 
recovery. The cells were then washed at 400g for 5 minutes, re-suspended in IL-2 
free XV5 and rested overnight to minimise background expression of CD69 in un-
stimulated cultures. On Day 7 autologous PBMCs were thawed from liquid N2, 
washed, labelled with Cell Trace Violet and re-suspended to 10x106/ml. PBMCs 
were then pulsed with either 10µg of the peptide to be tested (SL9, ALW, RQF or 
VMN), 10µl PBS or 10µl CytoStim for 2 hours at 37°C in a shaking water bath. 
Cells were then washed in 4 ml XV5 at 400g for 5 minutes and re-suspended to 
2x106 cells/ml. Transduced cells were harvested and re-suspended to a 
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concentration of 4x105/ml and the cells and PBMCs were added in a 1:1 mix to 96 
u-bottom plates for a final PBMC:T cell ratio of 5:1. The cells were incubated at 
37°C for 16 hours before being harvested and stained with fluorescently labelled 
antibodies against TCR specific vβ, Rat CD2 and CD69.  
 
 
Figure 4-2 Expansion Protocol of Primary Human T Cell Populations. The timeline for initial 
activation, transduction and expansion of FACS isolated primary T cells populations is shown by 
day number for (A) CD4+ TREG cells, (B) CD4+ TEFF cells and (C) CD8+ T cells. Black arrows indicate 
on which days cells were initially activated or activated for re-expansion. Red arrows indicate days 
where cells were split and given fresh IL-2 containing media. The red arrows decreasing in size 
indicate a halving in the amount of fresh IL-2 given to the cells. On D7 * denotes when cells were 
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Suppression of a Recall Response by Ag Specific TREG Cells 
Autologous PBMCs were thawed from liquid N2 and labelled with Cell Trace Violet 
Stain. After wash steps, the cells were re-suspended to 2x106/ml and added in 50µl 
to a 96 u-bottom plate for a final cell/well number of 1x105. The Agrippal vaccine 
(Novartis, UK) is an inactivated influenza vaccine that contains haemagglutinin 
(HA) from three strains and will be referred to as HA throughout this thesis. It was 
used at a dilution of 1:500, a final concentration equivalent to 180ng/ml of HA, to 
stimulate the PBMCs. The CEF viral peptide mix (Mabtech, Sweden) was used at 
final concentrations equivalent to 10µM, 2.5µM and 1µM. Candida Albicans, strain 
number XPLM73, is a purified protein derivative (Greer Laboratories, North 
Carolina) and was used at final concentrations equivalent to 10µg/ml, 5µg/ml and 
2µg/ml. The recall Ags HA, CEF and Candida were all used to test the memory T 
cell responses of each donor. HA was chosen for use in all suppression assays 
after eliciting the most robust proliferative responses from all donor PBMCs tested. 
Each peptide (SL9, ALW, RQF and VMN) used to stimulate the TREG cells were 
added at 1µg/ml. Cryopreserved FACS sorted transduced TREG cells were thawed, 
washed and re-suspended to 4x105/ml to be added in 50µl to the wells. This 
allowed for a PBMC:TREG ratio of 1:5. The assay was incubated at 37°C for 6 days 
before harvesting and staining with fluorescently labelled antibodies against CD3, 
CD4 and Rat CD2. The percentage suppression by the addition of peptide in the 
absence or presence of TREG cell populations was calculated by ((% proliferation + 
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4.3. Results 
4.3.1. Isolation of Primary Human T cell Populations by FACS and T cell 
Activation 
Purified populations of T cells were obtained using a FACS based approach 
(Figure 4-3). As cells were to be activated using αCD3/CD28 beads, detection of T 
cells using their definitive marker CD3 was avoided to ensure this signalling 
pathway would not be blocked by residual antibodies. To minimise contamination 
of isolated T cell populations, a dump channel was used. All cells were stained with 
CD14, CD16 and CD56 to minimise contamination of CD4+ T cells with CD14 and 
CD16 expressing monocytes and CD8+ T cells with CD16+CD56+ NK cells (Filion et 
al., 1990; Perfetto et al., 2004). Dump-CD4-CD8+ cells were then isolated as the 
CD8+ T cell population and Dump-CD4+CD8- cells were further separated into TREG 
and TEFF cell populations using expression of CD25 and CD127. It has been well 
established that Isolation of CD4+CD25+CD127lo cells yields a highly pure 
population of CD4+ TREG cells (Liu et al., 2006; Sakaguchi et al., 1995). Conversely, 
the CD4+CD25loCD127hi population of cells identifies CD4+ TEFF cells (Cao et al., 
2003). Therefore, in this study the CD8+ T cell population refers to Dump-CD4-
CD8+ cells, the CD4+ TEFF population as Dump-CD4+CD8-CD25loCD127hi cells and 
finally the CD4+ TREG population refers to cells that were Dump-CD4+CD8-
CD25+CD127lo when isolated. LV vectors were first selected for gene therapy 
based on their ability to transduce non-dividing cells (Naldini et al., 1996). 
However, it has been shown that for effective transduction of T cell populations, 
including full integration and reverse transcription of introduced genes, the T cells 
are required to be in the G1b phase of cell cycle (Korin and Zack, 1998). Thus, the 
three primary T cell populations described were activated with αCD3/CD28 beads 
and cultured in various levels of IL-2 to permit cell expansion as detailed (Figure 4-
2). CD4+ TREG cells were cultured in high exogenous levels of IL-2 and a bead to 
cell ratio of 1:1 in line with protocols used to expand large number of these cells 
(Earle et al., 2005; Putnam et al., 2009). The expansion potential of CD4+ TREG 
cells transduced with either the Mock, 868, 1E6 or 1D7 LV were measured over 
time in a single donor (Figure 4-4). This data was consistent with transduced CD4+ 
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TREG cells from other donors that were transduced and expanded following the 
same protocols (data not shown).  
 
 
Figure 4-3 FACS Isolation Strategy of Primary Human T Cell Populations. PBMCs from an 
HLA-A2+ donor were isolated and stained with fluorescently labelled antibodies. Live cells were 
selected on their FSC-A/SSC-A profile and doublets excluded based on FSC-A/FSC-H. A dump 
channel was used to exclude any CD14+, CD16+ and CD56+ cells. CD8+ cells were then isolated 
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Figure 4-4 Expansion of LV Transduced CD4+ TREG cells over time. The graph shows whole 
population cell counts of transduced TREG cells through three rounds of expansion Cells were sorted 
based on Rat CD2 expression on D16 and expanded for a further 10 days.  Data shown is from a 
TREG expansion from a single blood donor and is representative of other TREG expansions from 
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4.3.2. Human T cells can be transduced with LV and exhibit differential 
expression pattern of introduced TCRs. 
Primary human T cell populations were transduced with LV vectors 48 hours post 
their initial activation, in line with established protocols (Brusko et al., 2010). During 
the course of these studies, n=12 transduction were performed using cells from 
four HLA-A2+ donors. The transduction efficiency of all cell population were 
assessed on the basis of Rat CD2 expression. Analysis of this data using an 
analysis of variance statistical test identified a statistically significant difference 
between the transduction efficiency of the three T cell populations (p<0.01). 
Further analysis identified that transduction was significantly higher for CD4+ TREG 
(mean 37.5 ± 17.1% SD) than either CD4+ TEFF (mean 22.6 ± 11.9% SD) or CD8+ T 
cells (mean 17.3 ± 7.9% SD) (Figure 4-5).  
 
 
Figure 4-5 CD4+ TREG cells are more readily transduced that CD4+ TEFF and CD8+ T cells. The 
transduction efficiency of CD4+ TREG, CD4+ TEFF and CD8+ T cells was assessed by expression of 
the transduction marker Rat CD2. Plot shows the percentage transduction of cells from four blood 
donors that were transduced with either the 868 LV, 1E6 LV or 1D7 LV. Paired Student’s t tests 
were used to calculate data significance p value * = <0.05 and p value *** = <0.001  
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When comparing transduction of the three cell populations from a single individual 
with the 868 TCR a clear dual expression of the 868 clonotypic TCR vβ5 chain and 
Rat CD2 marker was observed in all three cell populations (Figure 4-6). This was in 
stark contrast to when cells were transduced with the autoreactive 1E6 and 1D7 
TCRs (Figure 4-7). Specifically, not all cells that were transduced with the 1E6 LV, 
as evidenced by Rat CD2 expression, were positive for expression of the 1E6 
clonotypic vβ chain, vβ8 (Figure 4-7(A)). This pattern was observed in all three cell 
populations was similar to transduction with the 1D7 TCR and its specific 
clonotypic vβ chain, vβ2 (Figure 4-7 (B)).  
 
 
Figure 4-6 Transduction with the 868 Pathogen Specific TCR. CD4+ TREG, CD4+ TEFF and CD8+ 
T Cells were transduced with LV encoding the 868 TCR and successful transduction was assessed 
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Figure 4-7 Expression of Transduced Autoreactive TCRs in Primary Human T Cell 
Populations. CD4+ TREG, CD4+ TEFF and CD8+ T cells were transduced with LV encoding 
autoreactive TCRs. Representative FACS plots show (A) cell populations transduced with the 1E6 
TCR and stained with αTCRvβ8 and αRat CD2 antibodies, (B) and cell populations transduced with 
the 1D7 TCR and stained with αTCRvβ2 and αRat CD2 antibodies. 
 
A further difference between the expression of the pathogen specific TCR and 
autoreactive TCRs was identified when the MFI of the endogenous vβ chain vs. the 
introduced vβ chains on CD4+ TREG cells was assessed (Figure 4-8). The 
expression of the endogenous vβ5 of the 868 was comparable to expression of 
introduced vβ5 (mean 760 and 958 respectively) (Figure 4-8 (A)). Although not 
significant, there was a definite trend of a higher expression of endogenous vβ8 
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trend for higher expression of the endogenous vβ chain was seen for vβ2 
expression vs. the introduced 1D7 Vβ2 (mean 2444 vs. 1170) (Figure 4-8 (C)).  
 
 
Figure 4-8 The Expression of Autoreactive TCRs Tends to be Lower Than The Expression of 
Endogenous TCR. Transduced populations of TREG cells were stained for the expression of the 
clonotypic vβ of the introduced TCR. The cells were then divided into non-transduced Rat CD2- and 
transduced Rat CD2+ cells and the MFI of the clonotypic vβ was assessed as being endogenous 
TCR and Introduced TCR respectively for (A) 868 vβ5 (B) 1E6 vβ8 and (C) 1D7 vβ2 expression. 
Each pair represents a population of cells from an individual donor.  
 
4.3.3. Transduced T Cells Retain Their Phenotype at D8 Post Expansion 
After the first round of expansion, the phenotype of transduced cells was assessed 
by flow cytometry to determine the purity of expanded populations. To this end, 
transduced primary T cell populations were stained with fluorescently labelled 
antibodies against CD3, CD4 and CD8. Using this panel of antibodies, it can be 
seen from the representative FACS plots that on D8 the CD4+ TREG cells were       
> 97% pure, the CD4+ TEFF cells > 99% pure and CD8+ T cells >95% pure (Figure 
4-9 (A)). It is well established, that constitutive high-level expression of the 
transcription factor FoxP3 denotes a stable human CD4+ TREG cell (Roncador et al., 
2005). However, it has also been shown that this marker can be transiently 
expressed within CD4+ TEFF cells (Gavin et al., 2006). Therefore, intracellular 
staining for FoxP3 expression was performed on the expanded transduced cells, 
along with co-staining for CD25. Importantly, all cells were starved of IL-2 for 48 
A B C 
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hours prior to FoxP3 staining to minimise expression of FoxP3 due to transient up-
regulation via the IL-2 pathway (Zorn et al., 2006). From the representative FACS 
plots shown, it is clear that stable high expression of FoxP3 was only found in the 
expanded CD4+ TREG cells (Figure 4-9 (B)). Although there was moderate co-
expression of FoxP3 and CD25 in both CD4+ TEFF and CD8+ T cells, this was 
consistently at a lower percentage and MFI compared to CD4+ TREG cells (Figure 4-
9 (B)). These data demonstrate that transduction and expansion of the individual T 
cell populations had no gross effect on the phenotype of these cells, as judged by 
CD3, CD4, CD8 and FoxP3 expression.   
  
 
Figure 4-9 Phenotype of Transduced and Expanded Cells. The phenotypes of transduced CD4+ 
TREG, CD4+ TEFF and CD8+ T cells were assessed on D8 post initial activation. (A) Representative 
FACS plots show surface phenotype stains of CD4+ TREG and TEFF cells stained with αCD3 and 
αCD4 fluorescent antibodies and CD8+ T cells stained with αCD3 and αCD8 antibodies. (B) 
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4.3.4. High Affinity 868 TCR can effectively Signal in All T Cell Populations 
Tested 
To determine whether the de novo expressed TCRs could signal in all three cells 
populations, CD69 up-regulation, as a marker of T cell activation, was assessed in 
response to specific peptide. This assay had a similar set up to the Jurkat 
activation assay used in Chapter 3-3 and for each donor tested, autologous Violet 
labelled PBMCs were used as the APCs.  In the Jurkat activation assay, sorted 
populations of TCR transduced cell lines were used to look at the response of only 
the TCR expressing cells. However, with the transduced primary T cells, the fact 
that there were four populations of cells, delineated by their TCRvβ and Rat CD2 
expression within the whole cell population, provided useful internal controls for 
each experiment. Taking the 868 TCR transduced cells as an example; the 
presence of Rat CD2- cells could be used as an internal negative control to ensure 
any CD69 up-regulation in response to SL9 peptide was specifically in the 868   
(Rat CD2+) transduced population (Figure 4-10 (A)). Moreover, by separating 
endogenous TCRvβ5 expressing cells in the non-transduced population, provided 
a control for the effect of Vβ5 expression on CD69 up-regulation in response to 
SL9 peptide. All transduced cell populations were then stimulated with autologous 
Violet labelled PBMCs that had been pulsed with PBS, as a negative control, 
CytoStim as a positive control, or the specific peptide for the transduced population 
(Figure 4-10 (B)).  
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Figure 4-10 Gating Strategy for CD69 Expression on Peptide Stimulated Transduced Cells. 
Transduced T Cell lines were incubated with autologous Violet labelled PBMCs pulsed with PBS, 
CytoStim or specific peptide on D8 post initial activation (A) Representative FACS plots show gating 
strategy used for 868 Transduced T cells. Live cells were gated based on their FSC-A/SSC-A 
profile and then Transduced T Cells positively gated on to remove Violet labelled PBMCs and 
7AAD+ dead cells. Cells were also stained with specific vβ antibody of the introduced TCR and Rat 
CD2 to split cells into non-transduced TCRvβ5-Rat CD2- cells (Black) and endogenous vβ 
expressing TCRvβ5+Rat CD2- (blue) cells and Transduced TCRvβ5Rat CD2+ (red) and TCRvβ5-Rat 
CD2+ (green) cells.  The CD69 expression on each population was then assessed for cells 
stimulated with (B) PBS (C) CytoStim and (C) SL9. 
 
To first test whether the 868 TCR could effectively signal in CD4+ TREG cells the 
868 TCR transduced TREG cells were stimulated with PBMCs pulsed with PBS, 
CytoStim or SL9 peptide. Using the gating strategy shown (Figure 4-11 (A)) the 
level of CD69 up-regulation in the four populations of TREG cells was ascertained. 
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3, cells transduced with the 868 TCR significantly up-regulated CD69 in response 
to the SL9 peptide pulsed PBMCs and not in response to PBS pulsed control 
PBMCs (Figure 4-11 (B). Moreover, this CD69 up-regulation was specific to the 
Rat CD2 transduced population. Interestingly up-regulation of CD69 was also 
observed in vβ5-RatCD2+ cells. As expected, the same pattern of activation was 
seen in both 868 transduced CD4+ TEFF and CD8+ T cells (Figure 4-11 (C-D)). 
 
Figure 4-11 Activation of 868 Transduced T Cell lines. (A) Representative FACS plot of CD4+ 
TREG cells showing the gating strategy used to identify non-transduced TCRvβ5-Rat CD2- cells 
(Black) and endogenous vβ expressing TCRvβ5+Rat CD2- (blue) cells as well as transduced 
TCRvβ5+Rat CD2+ (red) and TCRvβ5-Rat CD2+ (green) cells. Graphs show percentage CD69 on 
four population of activated 868 transduced (B) CD4+ TREG  (C) CD4+ TEFF and (D) CD8+ T cells. 
Data shown is for one donor and three replicates in a single assay and is representative of a further 
three blood donors. An unpaired Student’s t test was used to calculate data significance. P Value = 
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4.3.5. Signalling capabilities of autoreactive MHCI TCRs in Human T Cell 
Populations. 
The ability of the autoreactive TCR transduced T cells to signal in response to 
peptide were assayed in the same way as the 868 transduced T cells. The 1E6 
transduced T cells were stimulated with PBS, CytoStim, ALW cognate peptide or 
the super agonist peptide RQF pulsed PBMCs. For analysis of CD69 up-regulation, 
the transduced cells were delineated into 4 populations based on TCRvβ8 and Rat 
CD2 expression (Figure 4-12 (A)). Similar to results seen with the Jurkat cells, 
CD4+ TREG cells transduced with the 1E6 TCR failed to respond to the ALW peptide 
(Figure 4-12 (B)). The transduced cells however did respond to the super agonist 
RQF peptide showing that this TCR can signal in TREG cells. This response was 
observed only in the Rat CD2 expressing population and only in response to the 
RQF peptide. Interestingly, the TCRvβ8-RatCD2+ cells were capable of responding 
to the RQF peptide, although this response was of a lower magnitude than the 
TCRvβ8+RatCD2+ cells (Figure 4-12 (B)). Not surprisingly, the CD4+ TEFF cells 
transduced with the 1E6 TCR were also unable to up-regulate CD69 in response to 
the ALW peptide (Figure 4-12 (C)). However, it was of interest to note that 1E6 
transduced CD8+ T cells also failed to respond to the cognate ALW peptide, 
despite the presence of the CD8αβ co-receptor (Figure 4-12 (C)). Additionally, in 
all three cell populations tested, cells transduced with the 1D7 TCR were incapable 
of signalling in response to the cognate VMN peptide (Figure 4-13).   
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Figure 4-12 Activation of 1E6 Transduced T Cell lines. (A) Representative FACS plots of CD4+ 
TREG cells showing the gating strategy used to identify non-transduced TCRvβ8-Rat CD2- cells 
(Black) and endogenous vβ expressing TCRvβ8+Rat CD2- (blue) cells as well as transduced 
TCRvβ8+Rat CD2+ (red) and TCRvβ8-Rat CD2+ (green) cells. Graphs show percentage CD69 
expression on the four population of activated 1E6 transduced (B) CD4+ TREG  (C) CD4+ TEFF and 
(D) CD8+ T cells. Data shown is for one donor and three replicates in a single assay and is 
representative of a further three blood donors. An unpaired Student’s t test was used to calculate 
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Figure 4-13 Activation of 1D7 Transduced T Cell lines. (A) Representative FACS plot of CD4+ 
TREG cells showing the gating strategy use to identify non-transduced TCRvβ8-Rat CD2- cells 
(Black) and endogenous vβ expressing TCRvβ2+Rat CD2- (blue) cells as well as transduced 
TCRvβ2+Rat CD2+ (red) and TCRvβ2-Rat CD2+ (green) cells. Graphs show percentage CD69 
expression on the four population of activated 1D7 transduced (B) CD4+ TREG  (C) CD4+ TEFF and 
(D) CD8+ T cells. Data shown is for one donor and three replicates in a single assay and is 
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4.3.6. Optimisation of an Ag Specific Suppression Assay to Measure MHCI 
TCR Function in Human TREG Cells. 
Currently the ability of the MHCI restricted TCRs to signal in CD4+ TREG cells have 
only been assessed via the up-regulation of CD69. However, there is no evidence 
to suggest that the up-regulation of CD69 in response to peptide correlates with 
suppressive function. Therefore, an Ag specific suppression assay was designed 
to measure whether the introduced TCR could confer Ag suppressive capabilities 
to a CD4+ TREG cell. In order to have a standard responding population that all 
transduced TREG cells would be able to suppress, a recall Ag was chosen that 
could be used to stimulate PBMCs. Additionally, as discussed T1D pathogenesis is 
characterised by the effector functions of memory CD4+ and CD8+ T cells and 
therefore the ability of Ag specific TREG cells to suppress a memory T cell response 
is vital (Roep and Peakman, 2011). The Ag required, therefore would have to be 
capable of stimulating robust responses in CD4+ and CD8+ T cells in multiple 
donors. The recall Ags of choice were; Agrippal - an inactivated surface Ag 
influenza vaccine that will be referred to as HA, Candida Albicans a purified protein 
derivative, and CEF, a viral peptide mix. To minimise the potential for activation of 
CD4+ TREG cells due to alloreactivity, an autologous system was used. PBMCs 
were Violet labelled and stimulated with three doses of each Ag and the 
proliferation of CD4+ (CD3+CD4+) and CD8+ (CD3+CD4-) T cells (Figure 4-14) was 
analysed. In the two donors examined, the HA Ag gave the most robust and 
reproducible proliferative response from both CD4+ and CD8+ T cells and was 
chosen as the Ag for all suppression assays to follow.  The assay schematic is 
detailed in Figure 4-15 (A) and using this set up both “non-Ag specific” 
suppression, when CD4+ TREG cells were present in the culture but not activated 
through their introduced TCR, and Ag specific suppression could be measured. 
Only sorted Rat CD2+ cells were used in the suppression assays, to exclude these 
cells, based on the expression of this marker, from the analysis of proliferating 
CD4+ T cells (Figure 4-15 (B)).  
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Figure 4-14 Optimisation of Stimulation Dose for Suppression Assay. Violet labelled PBMCs 
from two donors, HAE36 and HAE11 were stimulated with three doses of HA Ag, Dose 1 – 1/50, 
Dose 2 – 1/500, Dose 3 – 1/5000, 3 doses of Candida, Dose 1 - 10µg/ml, Dose 2 - 5µg/ml, and 
Dose 3 –2µg/ml and 3 doses of CEF Peptide pool, Dose 1 – 10µM, Dose 2 – 2.5µM Dose 3 – 1µM. 
Proliferation was then measured 6 days later by assessing Violet dye dilution of (A) HAE36 
CD3+CD4+ and (B) HAE36 CD3+CD4- T cells as well as (C) HAE11 CD3+CD4+ and (D) HAE11 
CD3+CD4- T cells.  
 
A B 
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Figure 4-15 Schematic Representation and Gating Strategy for Ag Specific Suppression 
Assay. (A) Schematic shows the set up for the Ag specific suppression assay. Violet labelled 
autologous PBMCs were either un-stimulated, stimulated with HA recall Ag or stimulated with HA 
and specific peptide (PEP) for 6 days. A reduction in proliferation when TCR transduced TREG cells 
were present in culture, but not stimulated with their specific peptide, was referred to as “non-Ag 
specific” suppression. A reduction in proliferation when TCR transduced TREG cells were present in 
the culture and stimulated by their specific peptide was referred to as Ag specific suppression. (B) 
Representative FACS plots show the gating strategy used for the analysis of this assay. 
Lymphocytes were identified based on their FSC-A/SSC-A profile. Dead cells and transduced TREG 
cells were excluded based on their expression of 7AAD and Rat CD2. Responder T cells were 
identified as CD3+`Violet Dye+ and the proliferation in responding CD4+ and CD8+ subsets then 
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4.3.7. 868+ TCR Transduced TREG Cells exhibit Ag Specific suppression.  
To be able to assess the functional capabilities’ of the TCR transduced TREG cells 
the phenotype of these cells was determined to ensure the stability of the CD4+ 
TREG cell markers. The cells used in these assays had been sorted based on their 
expression of Rat CD2 on D16 and expanded with αCD3/CD28 beads a third time 
before being cryopreserved at the end of the third cycle of expansion. The cells 
were thawed and the phenotype of transduced 868+ TREG and 1E6+ TREG cells was 
ascertained. Co-staining with the clonotypic vβ and Rat CD2 antibodies confirmed 
these cells were >95% Rat CD2+ (Figure 4-16 (A-B)). Additionally these cells were 
stained for intracellular expression of FoxP3, and although some of these cells had 
lost FoxP3 expression they remained >80% FoxP3+ (Figure 4-16 (C)). Data shown 
is from expanded TREG cells from donor HAE36 however similar results were seen 
after expansion of transduced TREG cells from donor HAE11. 
 
 
Figure 4-16 Phenotype of Expanded Transduced TREG for use in Ag Specific Suppression 
Assay. Transduced TREG cells from donor HAE36 that had been expanded for 16 days, sorted 
based on their Rat CD2 expression and expanded for a further 8 days were used in the suppression 
assay. Representative FACS plots show the phenotype of (A) 868+ TREG and (B) 1E6+ TREG. (C) A 
representative histogram shows the FoxP3 expression of the cells when they were used in the 





























Chapter 4 LV TCR transduction and re-direction of the antigen specificity of 
primary human T cell populations 
146 
The following results are shown using transduced and expanded TREG cells and 
autologous PBMCs from Donor HAE36. In the absence of TREG cells, a robust 
proliferative response by HAE36 CD4+ T cells to the HA Ag was observed. This 
proliferative response was not affected by the presence of SL9 peptide (Figure 4-
17 (A&D)). Mock TREG cells, that were transduced but only express Rat CD2, were 
used as a control for the presence of TREG cells. Upon addition of either Mock TREG 
cells, or 868+ TREG cells, at a ratio of 5 PBMCs to 1 TREG cell, a marked reduction in 
the proliferation of HA responding CD4+ T cells was observed. This reduction in 
proliferation was comparable between the addition of Mock or 868+ TREG cells 
(Figure 4-17 (A-C)) and represents “non-Ag specific” suppression. When 868+ TREG 
cells were stimulated by the SL9 peptide, HA specific CD4+ T cell proliferation was 
further reduced (Figure 4-17 (C&F)). However, no such reduction was seen when 
Mock TREG cells were stimulated with SL9 (Figure 4-17 (B&E)). These results 
demonstrate that 868+ TREG cells are capable of mediating antigen specific 
suppression when stimulated with SL9 peptide. A similar pattern of proliferation 
was observed for HAE36 CD8+ T cell responses, with addition of both Mock and 
868+ TREG cells leading to a significant reduction in HA specific proliferation in the 
absence of SL9 peptide (Figure 4-18 (A-C)). A further reduction in proliferation was 
observed upon stimulation of 868+ TREG cells (Figure 4-18 (C&F)), but not Mock 
TREG cells (Figure 4-18 (B&E)), with SL9 peptide. The FACS plots in Figures 4-17 
and 4-18 represent pooled triplicate wells for each culture condition. Combined 
analysis of three independent triplicates for each culture condition are shown in 
Figure 4-19 (A&B) and demonstrate a reproducible and significant reduction in 
CD4+ and CD8+ T cell proliferation when 868+ TREG cells were stimulated with SL9 
peptide. Ag specific suppression was quantified by calculating the percent 
reduction in proliferation upon the addition of SL9 peptide in the presence or 
absence of a particular TREG cell population (Figure 4-19 (C&D)). These results 
were confirmed in a second completely independent experiment using transduced 
TREG cells and autologous PBMC from HAE11 (Figure 4-19 (E&F)). These data 
demonstrate that for optimal suppression of CD4+ and CD8+ T cells, stimulation of 
868+ TREG cells with specific Ag is required.  
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Figure 4-17 FACS plots Showing A Reduction of CD4+ T cell Proliferation by Activated 868+ 
TREG Cells. Violet labelled PBMCs from HAE36 were incubated with HA +/- SL9 peptide. 
Representative FACS plots show Violet dye dilution of CD3+CD4+ T cells in the absence of TREG 
cells upon stimulation with (A) HA alone or (D) HA + SL9. Similar FACS plots are shown for Violet 
dye dilution of CD3+CD4+ T cells in the presence of (B) Mock TREG cells + HA (E) Mock TREG cells + 




















Violet Proliferation Dye 





Chapter 4 LV TCR transduction and re-direction of the antigen specificity of 
primary human T cell populations 
148 
 
Figure 4-18 FACS plots Showing A Reduction of CD8+ T cell Proliferation by Activated 868+ 
TREG Cells. Violet labelled PBMCs from HAE36 were incubated with HA +/- SL9 peptide. 
Representative FACS plots show Violet dye dilution of CD3+CD8+ T cells in the absence of TREG 
cells upon stimulation with (A) HA alone or (D) HA + SL9. Similar FACS plots are shown for Violet 
dye dilution of CD3+CD8+ T cells in the presence of (B) Mock TREG cells + HA (E) Mock TREG cells + 
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Figure 4-19 868+ TREG can Suppress The Proliferation of CD4+ and CD8+ T cells when 
Stimulated by SL9 Peptide. Bar graphs show the mean proliferation when HAE36 PBMCs are 
stimulated by HA +/- SL9 in the absence of TREG or presence of either Mock TREG or 868+ TREG for 
both responding (A) CD3+CD4+ and (B) CD3+CD4- T cells. Bar graphs show the mean percentage 
suppression of proliferation of HAE36 PBMCs stimulated with HA Ag in the presence of SL9 peptide 
with either no TREG, Mock Transduced TREG or 868+ TREG for both (C) CD3+CD4+ and (D) CD3+CD8+ 
T cells. The mean percentage suppression of proliferation was calculated in an independent 
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4.3.8. Autoreactive MHCI TCR Transduced TREG cells only Exhibit Ag Specific 
Suppression When Stimulated By a High Affinity Ligand 
Similar suppression assays were performed using autoreactive 1E6+ TREG cells 
from HAE36, to examine their ability to suppress in response to cognate ALW 
peptide or super agonist RQF peptide. In the absence of TREG cells, a robust 
proliferative response by HAE36 CD4+ T cells to the HA Ag was observed. This 
proliferative response was not significantly affected by the presence of ALW or 
RQF peptide  (Figure 4-20 (A&D&G)). The addition of Mock or 1E6+ TREG cells 
caused a marked reduction in the proliferative response of HA specific CD4+ T 
cells, again demonstrating the presence of “non-Ag specific” suppression with both 
TREG cell populations (Figure 4-20 (A-C)). No further reduction in CD4+ T cell 
proliferation was observed when Mock TREG cells (Figure 4-20 (B&E)) or 1E6+ TREG 
cells (Figure 4-20 (C&F)) were stimulated with ALW peptide. In contrast, when 
1E6+ TREG cells were stimulated with the super agonist RQF peptide, the 
proliferation of HA specific CD4+ T cells was further reduced (Figure 4-20 (C&I)). 
However, no such reduction was seen when Mock TREG cells were stimulated with 
RQF peptide (Figure 4-20 (B&H)). A similar pattern of proliferation was observed 
for HAE36 CD8+ T cell responses, with addition of both Mock and 1E6+ TREG cells 
leading to a significant reduction in HA specific proliferation in the absence of ALW 
or RQF peptide (Figure 4-21 (A-C)). Similarly, no further reduction in CD8+ T cell 
proliferation was observed upon stimulation of Mock TREG cells (Figure 4-21 (B&E)) 
or 1E6+ TREG cells (Figure 4-21 (C&F)) with WT ALW peptide. However, a further 
reduction in CD8+T cell proliferation was observed when 1E6+ TREG cells (Figure 4-
21 (C&I)), but not Mock TREG cells (Figure 4-21 (B&G)), were stimulated with RQF 
peptide. These results demonstrate that in this donor, HAE36, 1E6+ TREG cells 
were capable of mediating antigen specific suppression when stimulated with 
super agonist RQF peptide, but not WT ALW peptide.  
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Figure 4-20 FACS plots Showing Reduction of CD4+ T cell Proliferation by Super Agonist 
Stimulated 1E6+ TREG Cells. Violet labelled HAE36 PBMCs were incubated with HA +/- ALW 
peptide or +/- RQF peptide. Representative FACS plots show violet dye dilution of CD3+CD4+ T 
cells in the presence of HA and (A) No TREG (B) Mock Transduced TREG and (C) 1E6+ TREG cells. 
Similar FACS plots are shown for Violet dye dilution of CD3+CD4+ T cells in the presence of HA + 
ALW with (D) No TREG (E) Mock Transduced TREG and (F) 1E6+ TREG cells and in the presence of 


































Chapter 4 LV TCR transduction and re-direction of the antigen specificity of 
primary human T cell populations 
152 
 
Figure 4-21 FACS plots Showing Reduction of CD8+ T cell Proliferation by Activated 1E6+ 
TREG Cells. Violet labelled HAE36 PBMCs were incubated with HA +/- ALW peptide or +/- RQF 
peptide. Representative FACS plots show violet dye dilution of CD3+CD8+ T cells in the presence of 
HA and (A) No TREG (B) Mock TREG and (C) 1E6+ TREG cells.  In the presence of HA + ALW with (D) 
No TREG (E) Mock TREG and (F) 1E6+ TREG cells and in the presence of HA + RQF with (G) No TREG 
(H) Mock  TREG and (I) 1E6+ TREG cells. 
Combined analysis of three independent triplicates for each culture condition are 
shown in Figure 4-22 (A&B) and demonstrate a reproducible and significant 
reduction in HAE36 CD4+ and CD8+ proliferation when 1E6+ TREG cells were 
stimulated with RQF, but not ALW, peptide. Ag specific suppression was quantified 
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RQF peptide in the presence or absence of a particular TREG cell population (Figure 
4-22 (C&D)). These experiments were repeated in a second completely 
independent experiment using transduced TREG cells and autologous PBMC from 
HAE11. However, in this donor, RQF stimulated 1E6+ TREG cells could mediate Ag 
specific suppression of HA responding CD8+ but not CD4+ T cells (Figure 4-22 
(E&F)), suggesting inter donor variation. 
Figure 4-22 1E6+ TREG can Suppress The Proliferation of CD4+ and CD8+ T cells but only 
When Stimulated by A Super Agonist. Bar graphs show the mean proliferation when HAE36 
PBMCs are stimulated by HA +/- ALW or +/- RQF in the presence of No TREG, Mock TREG or 1E6+ 
TREG for responding (A) CD3+CD4+ and (B) CD3+CD8+ T cells. Bar graphs show the percent 
suppression of proliferation of cells from HAE36 when ALW or RQF are added to the culture in the 
presence or absence of TREG cells (C) CD3+CD4+ and (D) CD3+CD8+ T cells. The mean percent 
suppression of proliferation in the presence of ALW or RQF was calculated for cells from HAE11 for  
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Similar suppression assays were performed using expanded 1D7+ TREG cells from 
HAE11. In the absence of TREG cells, a robust proliferative response by HAE11 
CD4+ T cells to the HA Ag was observed. This proliferative response was not 
affected by the presence of VMN peptide (Figure 4-23 (A&D)). Similarly, “non-Ag 
specific” suppression was observed upon addition of Mock TREG and 1D7 TREG 
cells. However, no Ag specific suppression of CD4+ T cells was exhibited by 1D7+ 
TREG cells upon addition of the VMN peptide to cultures (Figure 4-23 (C&F)). A 
similar pattern was observed for the proliferation of HA specific CD8+ T cells. 
Although 1D7+ TREG cells suppressed the proliferation of CD8+ T cells via “non Ag 
specific” suppression, a further reduction in proliferation was not observed upon 
addition of VMN peptide (Figure 4-24 (C&F)). 
 
Figure 4-23 FACS plots Showing No Effect on CD4+ T cell Proliferation by 1D7+ TREG Cells. 
Violet labelled PBMCs were incubated with HA +/- VMN peptide. Representative FACS plots 
show violet dye dilution of HAE11 CD3+CD4+ T cells in the presence of HA with (A) No TREG (B) 
Mock Transduced TREG and (C) 1D7+ TREG cells. FACS plots show violet dye dilution of CD3+CD4+ T 
cells in the presence of HA and VMN peptide with (D) No TREG (E) Mock Transduced TREG and (F) 
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Figure 4-24 FACS plots Showing No Effect on CD8+ T cell Proliferation by 1D7+ TREG Cells. 
Violet labelled PBMCs were incubated with HA +/- VMN peptide in the absence of presence of 
indicated TREG cell populations. Representative FACS plots show violet dye dilution of HAE11 
CD3+CD8+ T cells in the presence of HA with (A) No TREG (B) Mock Transduced TREG and (C) 1D7+ 
TREG cells. FACS plots show violet dye dilution of CD3+CD8+ T cells in the presence of HA and VMN 
peptide with (D) No TREG (E) Mock Transduced TREG and (F) 1D7+ TREG cells.  
 
Combined analysis of three independent triplicates for each culture condition are 
shown in Figure 4-25 (A&B) and demonstrate no reduction in the proliferation of 
HAE11 CD4+ or CD8+ T cells when 1D7+ TREG cells when stimulated with the VMN 
peptide. These data demonstrate that the 1D7+ TREG cells are not capable of 
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Figure 4-25 1D7+ TREG cells Can Not Suppress Proliferation of T Cells In the Presence of VMN 
Peptide. Bar graphs show the mean proliferation when HAE11 PBMCs are stimulated by HA +/- 
VMN in the presence of No TREG, Mock Transduced TREG or 1D7+ TREG for both responding (A) 
CD3+CD4+ and (B) CD3+CD8+ T cells 
 
4.3.9. Expansion of Transduced TREG Cells Using Rapamycin. 
During the course of these studies it was noted that expansion of TREG cells under 
the conditions described above resulted in varying levels of TREG cell purity. In 
agreement with other members of the laboratory performing TREG cell expansions, 
it was determined that loss of FoxP3 expression and outgrowth of TEFF cells that 
occurred within TREG cultures was a particular problem when Tregs were subjected 
to >2 cycles of expansion and was highly variable between donors. Other studies 
have identified a similar loss of FoxP3 expression during long term in vitro 
polyclonal stimulation of CD4+CD25+CD127lo TREG cells (Hoffmann et al., 2009; 
Hoffmann et al., 2006). It has been suggested, that long term in vitro culture can 
result in both epigenetic changes at the FoxP3 locus and loss of FoxP3 
expression. This loss of FoxP3 expression can also correlate with loss of TREG cell 
suppressive function (Hoffmann et al., 2009).  As suppression of CD4+ T cells by 
RQF stimulated 1E6+ TREG cells was observed in only 1 of 2 donors, the Ag specific 
capabilities of these cells required further examination. Methods were therefore 
sought to improve the phenotype of expanded TREG cell populations. Rapamycin 
A B 
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(RAPA) is an immunosuppressive agent that inhibits the mechanistic Target Of 
Rapamycin (mTOR) pathway and therefore blocks cell responsiveness to the IL-2 
pathway. It has been shown that this block in IL-2 responsiveness is selective for 
effector CD4+ and CD8+ T cells and consequently, CD4+ TREG cells can selectively 
expand in RAPA treated cultures of T cells (Battaglia et al., 2006). Additionally, 
RAPA has been shown to selectively outgrow the naïve and stable 
CD4+CD25+CD45RA+ TREG compartment, which has been identified as having 
superior suppressive capabilities compared to CD4+CD25+CD45RA- TREG cells 
(Hoffmann et al., 2006; Miyara et al., 2009; Scotta et al., 2013). Therefore, using 
TREG cells from a third healthy control donor, T01, RAPA was added to the culture 
of transduced TREG cells to determine whether it could improve the phenotype and 
suppressive function of the transduced TREG cells. Isolation of TREG cells by FACS 
from this particular donor led to a low recovery of TREG cells of only 4x105. 
Therefore, isolated TREG cells were split into two cultures on Day 2 and only 
transduced with the 1E6 or 868 TCR, and not with the Mock vector. RAPA has 
been shown to reduce the kinetics of TREG cell growth in mice, and indeed the 
protocol for the expansion of TREG cells had to be adapted from 8 day cycles of 
expansion to 12 days (Figure 4-26).   
 
 
Figure 4-26 Protocol for Expansion of CD4+ TREG with RAPA. CD4+ TREG were cultured in the 
presence of 600IU/ml IL-2 and 100ng/ml RAPA. Black arrows indicate when the cells were 
stimulated with αCD3/CD28 beads and red arrows indicate when cells were given fresh media with 
IL-2 and RAPA.  
 
Despite this reduction in kinetics of TREG cell growth, transduction of TREG cells 
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percentage of cells transduced with the 1E6 LV was 25% and 42% with the 868 LV 
(Mean % transduction without RAPA 25.98 +/- 11.6% SD and 32.6 +/- 10% SD for 
1E6 and 868 respectively) (data not shown). The phenotype of cells expanded in 
RAPA after each of the three rounds of expansion, D12, D24 and D36 (Figure 4-
27) was tested. At all time-points examined, >90% of expanded TREG cells were 
CD3+CD4+ (Figure 4-27 (A)). The FoxP3 expression of expanded TREG cells was 
also measured and a minimal loss of FoxP3 expression observed between D12 
and D24 of culture. However, an increased loss of FoxP3 expression was 
observed between D24 and D36 of culture, with FoxP3 expression reducing from 
87.9% to 67.7% (Figure 4-27 (B)).  
  
Figure 4-27 Phenotype of Transduced CD4+ TREG Expanded Using RAPA. The phenotype of 
T01 transduced CD4+ TREG cells was assessed at the end of each round of expansion on D12, D24 
and D36. Cells were surface stained with (A) αCD3 and αCD4 antibodies and (B) stained 
intracelullar for FoxP3 expression.  Grey line indicates FoxP3 expression on transduced CD4+ TEFF 
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At the end of the third round of expansion, the expanded Rat CD2+ sorted TREG 
cells were cryopreserved and then thawed for use in an Ag specific suppression 
assay. For this assay, as Mock transduced TREG cells were unavailable, 868+ TREG 
cell served as a control TREG population for suppression assays with 1E6+ TREG 
cells. Similar to the assays shown previously, CD4+ and CD8+ T cells exhibited a 
robust proliferative response to HA Ag, which was not significantly altered by the 
addition of ALW or RQF peptide (Figure 4-28 (A-B)). The HA proliferative response 
of both CD4+ and CD8+ T cells was reduced to a similar extent in the presence of 
1E6+ TREG cells and 868+ TREG cells again demonstrating non Ag specific 
suppression. The addition of RQF peptide, but not ALW peptide, caused a further 
significant reduction in proliferation of CD4+ and CD8+ T cells by 1E6+ TREG cells. 
The addition of these two peptides did not alter the suppression exhibited by 868+ 
TREG cells (Figure 4-28 (A-B)). These data again demonstrated Ag specific 
suppression by 1E6+ TREG cells when stimulated with RQF peptide. The 
percentage suppression induced by stimulation of each cell type by different 
peptides was calculated. The percentage suppression of proliferating CD4+ T cells 
upon addition of 1E6+ TREG cells and RQF peptide was 82.7%. No suppression was 
observed upon addition of 1E6+ TREG cells and ALW peptide (Figure 4-28 (C)). 
Similarly, the percentage suppression of proliferating CD8+ T cells was 87.1% upon 
addition of 1E6+ TREG cells and RQF peptide (Figure 4-28 (D)). 
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Figure 4-28 Ag Specific Suppression by 1E6+ TREG Cells Expanded in RAPA. Bar graphs show 
the mean proliferation when T01 PBMCs were stimulated by HA +/- ALW or +/- RQF in the 
presence of No TREG, 868+ TREG or 1E6+ TREG for both responding (A) CD4+ and (B) CD8+ T cells. 
Bar graphs show the percent suppression of proliferation of T01 cells when either ALW or RQF is 
present in the culture with no TREG, 868+ TREG or 1E6+ TREG for both (C) CD4+ and (D) CD8+ T cells.   
 
Taken together these studies confirm that when stimulated with RQF, 1E6+ TREG 
cells can exhibit Ag specific suppression of CD8+ T cells, and although not seen in 
every donor, CD4+ T cell responses. However in all cases, a large degree of “non 
Ag specific” suppression was also observed with all TREG cell populations at a ratio 
of 5 PBMCs: 1 TREG cell. We therefore sought to investigate the effect of different 
ratios of 1E6+TREG cells on the reduction in proliferation of HA responding CD4+ 
and CD8+ T cells. In this assay the “non Ag specific” suppression of proliferating 
CD4+ and CD8+ T cells could be determined. This was the suppression of 
proliferation observed when 1E6+ TREG cells were added to the culture without the 
addition of RQF peptide. This could therefore be compared to the Ag specific 
suppression exhibited by 1E6+ TREG cells stimulated by the super agonist RQF 
peptide. The ratios of PBMCs to TREG cells investigated were 5:1, 10:1, 20:1 and 
40:1. All percentage suppression calculations were carried out compared to the 
A B 
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absence of TREG cells.  At all ratios tested the 1E6+ TREG cells exhibited greater 
suppression of CD4+ T cell proliferation in the presence of RQF peptide (Range 
98.1 - 50.1%) compared to the absence of RQF peptide (Range 69.7 – 6.6%) 
(Figure 4-29 (A)). For comparison of this suppression, the ratio of PBMCs to TREG 
cells required to achieve 50% suppression of proliferating CD4+ and CD8+ T cells 
was estimated. To achieve 50% suppression of CD4+ T cell proliferation in the 
absence of RQF peptide, a ratio of PBMC:TREG cells of ~ 8:1 was required. To 
achieve the same percentage suppression in the presence of RQF peptide a much 
lower PBMC:TREG cell ratio of 40:1 was required (Figure 4-29 (A)). Similarly, at all 
ratios tested the 1E6+ TREG cells exhibited greater suppression of proliferating 
CD8+ T cells in the presence of RQF peptide (Range 94.8 – 36.7%) than in the 
absence of RQF peptide (Range 58.16 – 6.97%) (Figure 4-29 (B)). For 50% 
suppression of HA responding CD8+ T cells an estimated ratio of 6:1 PBMC:TREG 
cells would be required in the absence of RQF peptide. However in the presence of 
RQF peptide a lower PBMC:TREG cell ratio of 20:1 would be required. Thus, the 
potency of suppression of both CD4+ and CD8+ T cells exhibited by 1E6+ TREG cells 
is roughly 3-5 fold higher when the TREG cells are stimulated via the introduced 
TCR. 
 
Figure 4-29 Ag Specific TREG cells expanded in RAPA can suppress proliferation at low 
TREG:PBMC ratios. Violet labelled T01 PBMCs were stimulated with HA Ag either in the presence 
or absence of RQF peptide. Suppression under both conditions when 1E6+ TREG were added to the 
culture was calculated by ((%proliferation No TREG / % Proliferation 1E6+ TREG) / %proliferation No 
TREG)*100 for proliferation of responding (A) CD4+ and (B) CD8+ T Cells. The dotted line represents 
the ratio of 1E6+ TREG cells required for 50% suppression when they are un-stimulated in culture or 
stimulated with RQF peptide.  
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4.4. Discussion 
These experiments were designed to test the hypothesis that although autoreactive 
MHCI Restricted TCRs cannot re-direct the Ag specificity of a CD4+ TEFF cell, they 
can re-direct the Ag specificity of a CD4+ TREG cell (Plesa et al., 2012). Similar to 
the study carried out in Jurkat cells, a step-wise approach was taken to investigate 
the expression of the three MHCI restricted TCRs, their ability to signal in primary T 
cell populations and most importantly their ability to confer Ag specific suppressive 
capabilities to a CD4+ TREG cell.  
 
Firstly, it was important to test that all primary T cell populations examined could be 
successfully transduced with LV under the current protocols of activation. This 
study demonstrates, as others have shown that, CD4+ TEFF, CD8+ T cells and CD4+ 
TREG cells can be transduced with LV (Brusko et al., 2010; Dardalhon et al., 2001). 
It was surprising to note, that under the protocols followed, CD4+ TREG were 
significantly more susceptible to transduction with TCR containing LV compared to 
CD4+ TEFF and CD8+ T cells. Other have shown superior transduction of both CD4+ 
TEFF and CD8+ T cells (Dardalhon et al., 2001), however as the main focus of this 
project was CD4+ TREG, further optimisation to increase transduction of these cell 
types was not explored. It was also important to determine that the transduced 
TREG cells could be expanded to gain significant numbers of these cells for 
experiments. After each round of expansion, a 10-20-fold increase in TREG cell 
numbers was observed. Over three round of expansion, this resulted in ~1000 fold 
expansion, which is consistent with what other studies have observed using 
polyclonal expansion of non-transduced TREG cells (Putnam et al., 2009). 
Unfortunately, as CD4+ TREG cells from each donor were typically split four ways to 
be transduced with Mock, 868, 1E6 and 1D7 LV the number of CD4+ TREG cells 
was limited and therefore a side by side comparison of the expansion rates of non 
transduced and transduced cells was not possible. In general, transduced and 
expanded CD4+ TREG cells remained relatively stable during the expansion process, 
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with >75% maintenance of CD3+CD4+FoxP3+ cells at the end of the 24 day 
expansion period.  
 
The observation that autoreactive MHCI TCRs have a different pattern of 
expression to the 868 pathogen specific TCR in transduced primary T cell 
populations was similar to previous observations in Jurkat cell lines in chapter 3. 
The 868 pathogen specific TCR was readily expressed on the cell surface of 
transduced primary T cell populations as measured by consistent dual expression 
of the clonotypic vβ5 chain and Rat CD2. In contrast to this, when primary T cell 
populations were transduced with either the autoreactive 1E6 or 1D7 TCRs, only a 
proportion of the transduced Rat CD2+ cells co-expressed the clonotypic vβ chain 
of the respective TCRs. There are at least two explanations for this phenomenon, 
one is that the autoreactive TCRs are unable to compete with the endogenous 
TCR for CD3 assembly and the second is that the α and β chains of the 
autoreactive TCRs do not preferentially pair with one another. Turning first to the 
ability of TCRs to compete for assembly with CD3 chains, others have shown that 
TCRs can be classed as “strong” or “weak” TCRs based on their ability to complex 
with CD3 molecules (Stauss et al., 2007). It was demonstrated by Heemskerk and 
colleagues that expression levels of a retroviral introduced TCR depended on 
which endogenous TCR was expressed by the transduced cell (Heemskerk et al., 
2007). This variation in introduced TCR expression was due to the preferential 
binding affinity of the endogenous TCR for the CD3 complex over the introduced 
TCR. Due to the limited number of CD3 complexes within a cell, TCRαβ pairings 
that have a higher binding affinity for CD3 will be preferentially expressed on the 
cell’s surface in situations where two TCRs are present in a cell. The group of 
Hans Stauss, who has proffered the terms “weak” and “strong” TCRs, 
demonstrated that CD3 complexes are rate-limiting. In one study they showed that 
by increasing the availability of CD3 complexes using retroviral transduction of a 
CD3 expressing vector, they could increase the expression of a ‘weak” introduced 
TCR by up to 26 fold (Ahmadi et al., 2011). Therefore, by increasing the amount of 
available CD3 complexes the differences in expression of “weak” vs. “strong” TCRs 
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are less apparent. The ability of the 1E6 and 1D7 TCRs to be expressed may also 
be due to the inefficient pairing of the TCRα and TCRβ chains of these TCRs. In 
chapter 3, this study showed that in Jurkat cells, which possessed no endogenous 
TCR, the autoreactive TCRs were poorly expressed compared to the pathogen 
specific 868 TCRs. This study also showed that in primary T cells populations, 
there was a trend for a reduced level of introduced autoreactive TCR clonotypic vβ 
expression compared to the endogenous vβ expression as measured by MFI. 
Although these trends were not significant, no such trend was observed for the 868 
TCR vβ5, which was comparable to endogenous vβ5 expression. Therefore it can 
be suggested that the reduced ability of the 1E6 and 1D7 TCRs to be expressed 
on the surface of a T cell may be due both to inefficient pairing and a reduced 
affinity for CD3. In fact, Heemskerk and colleagues have suggested that the ability 
to complex with CD3 may be reliant on the interchain affinity of a TCR’s α and β 
chain (Heemskerk et al., 2007). Thus, it is possible to class the pathogen specific 
868 TCR as a “strong” TCR that has high interchain affinity and therefore a strong 
affinity for CD3 complexes allowing it to outcompete the majority of endogenous 
TCRs for cell surface expression. However, both the autoreactive 1E6 and 1D7 
appear to be “weak” TCRs, whose low TCRα and TCRβ interchain affinity 
culminate in a reduced ability to assemble in a TCR-CD3 complex. Whether this is 
true of all pathogen specific and autoreactive TCRs would require a larger panel of 
TCRs with both reactivity’s and was beyond the scope of this study. 
 
The signalling capabilities of each TCR in the three primary T populations 
transduced was very similar to the results observed in model T cell lines. As 
expected, CD4+ TREG, TEFF and CD8+ T cells transduced with the 868 TCR were 
capable of up-regulating CD69 in response to the SL9 peptide. However, in 
keeping with previous data, CD4+ TEFF or TREG cells transduced with the 1E6 TCR 
could not respond to its preproinsulin ALW peptide by up-regulating CD69. Most 
surprisingly, CD8+ T cells transduced with the 1E6 TCR also failed to up-regulate 
CD69 in response to the ALW peptide. This was particularly surprising when this 
observation is linked to the fact that expression of CD8α alone was able to rescue 
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the signalling of the 1E6 TCR in a Jurkat cell. It is possible however that due to the 
weak expression of the 1E6 TCR on the surface of the transduced T cells that the 
overall avidity of the 1E6 TCR ALW-MHCI interaction is insufficient for effective 
signalling despite the presence of the CD8 co-receptor. The productive hit rate 
model of TCR activation indicates that serial triggering of TCRs is required for full 
TCR signalling i.e. multiple TCRs must bind to pMHC before effective signalling 
can occur (Valitutti et al., 1995). Additionally it has been found that there is an 
optimal dwell time (length of interaction between pMHC and TCR) for effective 
TCR signalling, and a dwell time shorter or longer than this time can impair TCR 
signalling (Kalergis et al., 2001). The structural characteristics of the 1E6 TCR and 
its affinity for the index peptide ALW was recently described in a study published in 
2012 (Bulek et al., 2012). Significantly, in this study they showed that the kinetics 
of the interaction between the 1E6 TCR and the ALW peptide were too rapid too 
measure by SPR kinetic titration analysis, which would therefore lead to an overall 
short, and likely insufficient dwell time for TCR activation. In combination with the 
low expression of the 1E6 TCR on the surface of the transduced T cells, these 
factors could lead to an overall non productive TCR signal in response to the ALW 
peptide.  
 
Another noteworthy observation with regards to the 1E6 TCR was the ability of 
cells transduced with this TCR to up-regulate CD69 in response to the super-
agonist RQF peptide. This showed that this TCR could signal in any of the T cells 
transduced, when the TCR affinity for pMHC reached the threshold required for 
activation. Furthermore, the up-regulation of CD69 was not exclusive to the Rat 
CD2+ cells that co-expressed TCRvβ8 – but could also be seen in cells that were 
Rat CD2+ and TCRvβ8- (importantly not in cells that were TCRvβ8+Rat CD2-). It is 
possible that cells that appear TCRvβ8- are actually TCRvβ8low and that the high 
affinity interaction of the RQF peptide and TCR can overcome the poor TCR 
expression by increasing the amount of TCRs that are triggered with an optimal 
dwell time. A second possibility is that cells taken to be 1E6 TCR- based on their 
lack of expression vβ8 expression could in fact be expressing the vα chain of the 
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1E6 TCR, which potentially has paired with the transduced cells endogenous vβ. 
Studies in mice from the group of George Eisenbarth showed that when a TCRα 
chain of an insulin autoreactive T cell clone was paired with various TCRβ chains, 
these TCR pairings could still promote the production of insulin reactive antibodies 
(Kobayashi et al., 2008). However, the mice baring only the TCRα chain of the 
insulin reactive TCR did not develop the insulitis seen in mice that were fully 
transgenic for the original TCRα and TCRβ chain of the insulin reactive TCR. 
Suggesting that although the TCRα chain could confer insulin specificity alone it 
was optimal when paired with the original vβ chain of this autoreactive TCR. It is 
therefore plausible that the vα of the 1E6 TCR could be conferring Ag specificity 
when paired with endogenous vβ of transduced cells, which allows response to the 
RQF peptide. Currently, as there is no vα chain antibody available for the 1E6 
TCRvα12-3.1 chain this hypothesis would be difficult to test. Potentially, a LV 
vector that solely encoded the vα12-3.1 chain could be used to evaluate this, by 
testing the response of vα12-3.1 transduced cells to the RQF peptide. Similarly to 
the 1E6 TCR, the cells transduced with the 1D7 TCR were also unable to up-
regulate CD69 in response to its index peptide VMN. Unfortunately, due to a lack 
of a super-agonist peptide for this TCR it was impossible to determine if the 1D7 
TCR behaves the same as the 1E6 TCR or if its specificity for the VMN peptide 
was compromised during the clonotyping of this TCR. 
 
The study by Plesa et al looked at the ability of the low affinity NY-ESO-1 specific 
TCR to signal in a TREG cell by looking at its ability to confer Ag specific 
suppressive capabilities. It is unclear how strong (or weak) a TCR signal is 
required by a TREG to become suppressive vs. up-regulating CD69. In fact, studies 
in CD8+ T cells have identified a hierarchy in effector function dependent on the 
level of TCR stimulation a cell receives (van den Berg et al., 2013). It was therefore 
pertinent to measure whether or not the MHCI TCRs could confer Ag specific 
capabilities, despite the failure of TREG cells transduced with these TCRs to up-
regulate CD69 in response to peptide. Therefore, an Ag specific suppression assay 
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was developed to measure whether the autoreactive MHCI TCRs could confer Ag 
specific capabilities to a CD4+ TREG cell. In this assay, autologous PBMCs were 
stimulated with a recall Ag, HA, in order to have naturally responding proliferating T 
cells to suppress. To these cultures, combinations of sorted transduced TREG cells 
and their specific peptides were added. Therefore, the ability of transduced TREG to 
suppress the proliferation of responding HA T cells when they were stimulated by 
their specific peptide compared to the absence of peptide specific stimulation could 
be assayed.  Consistent with all other results, the 868+ TREG cells, were capable of 
suppressing the proliferation of HA specific CD4+ and CD8+ T cells in an Ag 
specific manner. In contrast, mock LV transduced TREG cells that solely expressed 
Rat CD2, did not. In this assay we observed high levels of “non-Ag Specific” 
suppression i.e. suppression when 868+ TREG  were not exposed to SL9 peptide, or 
when mock LV transduced TREG cells were added to the culture. In this study, this 
observation has been termed “non-Ag specific” suppression as it occurs without 
antigenic stimulation of the CD4+ TREG cells via their introduced TCRs. However, 
there are a number of possible explanations for the high level or suppression 
exhibited by the non-peptide stimulated CD4+ TREG cells. It has been well 
characterised that CD4+ TREG cells require stimulation via the TCR before 
becoming suppressive (Thornton and Shevach, 2000) and indeed the TREG cells 
used in these assay had been pre-activated with αCD3/CD28 beads during the 
course of their expansion. Therefore, it is possible that the TREG cells were still 
activated when used in the suppression assays.  However, to minimise this 
possibility, the expanded TREG cells were rested without beads and IL-2 for 48 
hours, cryopreserved and then thawed for use in the suppression assays. Another 
possibility is that the expanded CD4+ TREG cells were specific for pMHCII 
complexes on the surface of APC’s within the culture, and after becoming activated 
through the endogenous TCR elicited suppressive function. A seminal study by 
Taams et al showed that CD4+CD25+ TREG cells were able to exhibit suppressive 
function against a range of Ags, including self-Ag human heat Shock Protein 60 
(hHSP60) and tetanus toxoid (Taams et al., 2002). This study also used a panel of 
TCRvβ antibodies to demonstrate that the TCRvβ usage of isolated CD4+CD25+ T 
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cells was no different to the usage of CD4+CD25- TEFF cells. Therefore, it is 
possible that a small number of Ag specific TREG cells within the culture were 
specific for either self-pMHCII on the surface of APCs, or for the HA Ag. TREG cells 
with these specificities in the culture could therefore have become activated to 
suppress the HA specific proliferative responses of the CD4+ and CD8+ T cells. 
Although, determining the exact nature of this “non-Ag specific” suppression would 
be beyond the scope of this study, it is clear from clinical data from the adoptive 
transfer of polyclonal TREG cells that these cells are capable of suppressing T cell 
responses (Riley et al., 2009). However, it is also apparent from the data shown 
here that larger populations of CD4+ TREG cells activated in an Ag specific manner 
were more efficacious at eliciting suppressive function. 
 
In contrast to the study by Plesa et al, this study showed that low affinity MHCI 
restricted TCRs were unable to re-direct the Ag specificity of CD4+ TREG cells. In an 
Ag specific suppression assay, 1E6+ TREG cells were unable to exhibit suppressive 
function when stimulated by the WT ALW peptide. However, when these cells were 
stimulated with the super-agonist RQF peptide, they were capable of suppressing 
the proliferation of CD4+ and CD8+ T cells in response to HA Ag. This 
demonstrated that the 1E6 TCR could only confer Ag specific capabilities to a 
CD4+ TREG cells when the interaction between the introduced TCR and pMHCI was 
of a high affinity. This was in contrast to the study by Plesa et al, and suggests that 
although CD4+ TREG cells may possess a lower threshold for activation, the 
interaction between autoreactive MHCI restricted TCRs and pMHCI does not 
exceed this threshold. It is therefore possible to propose a new model for the 
requirements of an MHCI TCR to function in a CD4+ TREG cell that includes 
extremely low affinity autoreactive TCRs, which to date have not been used in this 
setting (Figure 4-30).  From this study, it would be interesting to explore whether 
the up-regulation of CD69 can mark an MHCI TCR with the potential to re-direct 
the Ag specificity of a CD4+ TREG cell. This would allow for much quicker and easier 
testing of a panel of autoreactive MHCI restricted TCRs for their suitability in this 
approach. It would therefore be extremely worthwhile to determine whether CD4+ 
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TREG cells transduced with the NY-ESO-1 TCR could up-regulate CD69 in 
response to the NY-ESO1 peptide. 
 
 
Figure 4-30 Model for MHCI restricted TCR Requirements in CD4+ TREG cells. MHCI TCRs can 
be split into three groups of pathogen specific, tumour specific and autoreactive TCRs. Both 
pathogen specific and tumour specific TCRs tend to be highly expressed (++++) when transduced 
into a CD4+ TREG cells and they tend to be of a high (++++) to medium-low (++) affinity for cognate 
Ag. This enables them to effectively re-direct the Ag specificity of a CD4+ TREG. Autoreactive TCRs 
tend to be weakly expressed (++) and have a low affinity for index peptide (+), which results in an 
overall low avidity interaction that may be dependent on the presence of CD8 co-receptor. 
During a number of TREG cell expansions, this study observed a reduction in the 
expression of FoxP3 as well an outgrowth of contaminating effector T cells.  This 
led to a number of transduced TREG cell expansions collapsing or being too low 
purity for use in Ag specific suppression assays. Additionally, there was inter-donor 
variation in the ability of RQF stimulated 1E6+ TREG cells to suppress the 
proliferation of CD4+ T cells. To improve both the phenotype and suppressive 
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The maintenance of FoxP3 expression was determined in the RAPA expanded 
transduced cells after each round of expansion. Surprisingly, by the end of the third 
round of expansion the FoxP3 levels had dropped to below 70%. However, due to 
a limitation in the number of CD4+ TREG cells isolated in this study, it was not 
possible to perform a side-by-side comparison of non-RAPA expanded and RAPA 
expanded TREG cells. Therefore, it could not be determined what the FoxP3 
expression of these donors’ TREG cells would have been had they not been 
expanded in RAPA. Despite this observed reduction in FoxP3 expression, the 1E6+ 
TREG cells were potent suppressors in an Ag specific suppression assay.   
 
1E6+ TREG cells stimulated with the super agonist RQF peptide were capable of 
suppressing >80% of the proliferation of HA specific CD4+ and CD8+ T cells. This 
was much higher than in previous experiments using non-RAPA expanded TREG 
cells. Due to this high percentage suppression an experiment to examine the 
potency of the RAPA expanded 1E6+ TREG cells was performed. The ratio of 
PBMCs to TREG cells that had previously been used was 5:1 and therefore in this 
experiment the ratio of PBMC to TREG cells was titrated down to 40:1. It was clearly 
shown that at this low ratio of PBMC to TREG cells the 1E6+ TREG cells were still 
capable of suppressing, in an Ag specific manner, >50% of HA specific CD4+ and 
>35% of HA specific CD8+ T cell proliferation. In this experiment, the percentage 
suppression of “non-Ag specific” suppression was calculated and compared to the 
percentage suppression of Ag specific suppression. This revealed, that for the 
RAPA expanded 1E6+ TREG cells to suppress 50% of the proliferation of HA 
specific CD4+ and CD8+ T cells, then estimated ratios of 8:1 and 6:1 PBMCs:TREG 
cells respectively were required. However, for the same percentage suppression, 
1E6+ TREG cells that were stimulated with RQF peptide were required at lower TREG 
cells ratios of 40:1 and 20:1. These data clearly demonstrated the benefit of Ag 
specific over polyclonal TREG cells.    
 
In conclusion to this section of this study, we have demonstrated that the two 
autoreactive MHCI TCRs were weakly expressed when transduced into primary 
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human T cell populations. This weak expression and overall low affinity for cognate 
peptide culminated in an overall inability to signal when introduced into primary 
human T cell populations. Therefore, it can be concluded that for low affinity MHCI 
TCRs to re-direct the Ag specificity of a CD4+ TREG cells they will require further 
optimisation such as an improvement of expression, affinity for cognate peptide or 
co-expression of the CD8αβ co-receptor.   
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5. Approaches to Enhance 1E6 TCR Function in Human 
TREG Cells 
5.1. Introduction 
TCR signalling is initiated by TCR recognition and binding to pMHC on the surface 
of APCs. For an MHCI restricted TCR, the binding to pMHCI is stabilised by the 
CD8 co-receptor. The stability provided by the co-receptor is integral to low affinity 
TCR-pMHC interactions, but dispensable for high affinity interactions (Holler and 
Kranz, 2003). Additionally, the productive hit rate model of T cell activation infers 
that the threshold for T cell activation is the product of multiple TCR-pMHC 
interactions (Valitutti et al., 1995). Therefore, the ability of an MHCI TCR to transfer 
Ag specificity to a CD4+ T cell is influenced by the high avidity interaction between 
TCR and pMHC and it appears that there is a threshold below which productive 
signalling will not occur, even in TREG cells. Theoretically, there are four methods 
that can be used to improve the functional avidity between transferred TCRs and 
pMHC (Figure 5-1):  
1. Engineering of the hypervariable CDR3 regions of the TCR to increase 
TCR-pMHC binding affinity 
2. Engineering altered peptide ligands that bind TCR with a greater affinity. 
3. Increasing the expression level of the TCR to promote enhanced TCR serial 
triggering. 
4. Increasing the stabilisation of TCR-pMHCI interactions by introducing the 
CD8 co-receptor into CD4+ T cells.  
 
The alteration of CDR3 regions requires PCR directed mutagenesis of this region 
in both the TCRα and TCRβ chains and the ability to screen mutated TCRs for 
enhanced pMHCI binding. As the methods involved in CDR3 engineering are 
highly time-consuming, this method was beyond the scope of this study. 
Furthermore, others have shown the dangers of re-directing T cell Ag specificity 
using altered TCRs, as increasing a TCRs’ affinity for a single peptide can increase 
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the risks of T cell off target toxicity (Cameron et al., 2013; Linette et al., 2013). The 
second method of using altered peptide ligands has already been explored in 
Chapters 3 and 4 with the use of the high affinity RQF peptide, which activates the 
1E6 TCR in a CD8 independent manner. Furthermore, whilst this approach is 
useful for proof of concept studies, it lacks translational potential. Therefore, this 
Chapter will concentrate of the two final mechanisms of enhancing autoreactive 
MHCI restricted TCR function in TREG cells. 
 
 
Figure 5-1 Mechanisms to enhance autoreactive MHC Class I TCR function in human TREG 
cells. Four potential mechanisms can be used to improve the function of MHCI TCRs in human 
CD4+ TREG cells. 1) engineering of the TCR CDR3 region, 2) The use of altered peptide ligands with 
enhanced affinity for TCR 3) increased expression of introduced TCRs on the surface of TREG cells 
and 4) the introduction of the CD8 co-receptor on the surface of TREG cells.  
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In theory, the 1E6 TCR should be able to function in a CD8 independent manner 
as evidenced by the data already shown using the super agonist RQF peptide to 
activate this TCR. It was observed that the 1E6 TCR was expressed at a low level 
on the surface of all primary human T cell populations, which may explain why the 
transfer of the 1E6 TCR could not re-direct the Ag specificity of CD8+ T cells 
towards the ALW peptide. The reduced TCR expression, combined with a low 
affinity for pMHC, may lead to the overall TCR-pMHC interaction being of too low 
an avidity to activate the T cell. Therefore, increasing the expression of the 1E6 
TCR on the surface of primary human T cells may rescue the ability of this TCR to 
respond to the ALW peptide, by increasing the available number of TCRs that can 
be triggered by pMHCI. The main hypothesis for poor expression of introduced 
TCRs is a low interchain affinity of the TCRα and TCRβ – this can lead to reduced 
pairing of TCR chains and a reduced ability to compete for CD3 molecules. In the 
past, multiple methods have been identified to improve interchain affinity and 
subsequently the expression of exogenous TCRs. Two of these have already been 
incorporated into the vector expression system of the 1E6 TCR – 1) codon 
optimisation of TCR genes to improve translation and production of TCR protein 
(Scholten et al., 2006) and 2) the use of 2A linker sites between TCRα and TCRβ 
chains to improve pairing of introduced chains (Leisegang et al., 2008). Other 
potential modifications that have shown to improve expression of the exogenous 
TCRs, include the incorporation of a second disulphide bond between the constant 
domains of the TCRα and TCRβ chains to improve pairing (Cohen et al., 2007) and 
the removal of TCR glycosylation sites, which has been shown to improve the 
functional avidity of re-directed T cells (Kuball et al., 2009). However, these have 
not been tested for the 1E6 TCR in this thesis. The inclusion of the second 
disulphide bond was incorporated into the 1D7 TCR, however as observed in 
Chapters 3 and 4, the expression of this TCR was still compromised.   
 
A somewhat surprising route identified to improve the expression of weak TCRs 
was the replacement of human TCRα and TCRβ chain C regions with the murine 
equivalent (Cohen et al., 2006). These human-murine (“murinised”) hybrids led to 
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an over-expression of the TCRs in comparison to fully human TCRs, due to a 
preferential pairing of murine C domains and an overall improved TCR-CD3 
stability (Cohen et al., 2006). However, the adoptive transfer of T cells expressing 
murine TCRs led to some patients developing a humoral immune response against 
the xenogeneic gene sequences (Davis et al., 2010). In order to reduce the 
potential immunogenicity to “murinised” TCRs, the amino acids in the murine TCRα 
and TCRβ chains that are important for increased TCR expression have been 
identified (Sommermeyer and Uckert, 2010). Indeed, only 9 human to murine 
amino acid substitutions were found to be crucial in facilitating increased TCR 
expression, thus these minimal changes may reduce immunogenicity of these 
TCRs. In a similar vein, substitutions in the transmembrane domain of the human 
TCRα can improve the expression of introduced TCR chains. A full TCR-CD3 
complex is first assembled in the endoplastic reticulum and then transported to the 
cell surface. The TCRα chain has been identified as the most instable chain of this 
complex and can decrease the efficiency of TCRαβ pairing and it’s coupling to CD3 
molecules (Bonifacino et al., 1990; Kearse et al., 1994; Shin et al., 1993). 
Therefore, investigations were made as to whether TCRα chain stability could be 
improved by increasing the hydrophobicity of the TCRα transmembrane domain 
(Haga-Friedman et al., 2012). In this study it was found that three substitutions of 
mutable amino acids for hydrophobic leucine or valine amino acids could almost 
double the percentage of transduced cells that stained with specific pMHC 
multimer (Haga-Friedman et al., 2012). 
 
The final method of improving the function of MHCI restricted TCRs in CD4+ T 
cells, is the introduction of the CD8 co-receptor in these cells. The data from model 
cell lines in Chapter 3 suggested that Jurkat T cells transduced with the 1E6 TCR 
could signal in response to ALW peptide in the presence of high level CD8 
expression.  Therefore, the ability of the CD8 co-receptor to rescue the 1E6 TCR in 
human CD4+ TREG cells will be assessed. It was also determined in Chapter 4 that 
the 1E6 TCR was unable to re-direct the Ag specificity of CD8+ T cells, although it 
is unclear whether this was due to poor 1E6 TCR expression, which culminated in 
Chapter 5 Approaches to Enhance 1E6 TCR Function in Human TREG cells 
176 
a low functional avidity. Consequently, the ability of a high affinity CD8 co-receptor 
to stabilise 1E6 TCR-pMHC interactions in TREG cells will also be explored. The 
high affinity CD8 co-receptor has a single amino acid substitution in the CD8α 
chain that has been shown to enhance CD8 binding to HLA-A2 by up to 4-fold 
(Cole et al., 2007b). It is hypothesised that the use of a high affinity CD8 co-
receptor may overcome reduced 1E6 TCR expression by increasing the dwell time 
between TCR and pMHC. To explore this mechanism, LV vectors will be used to 
co-express either the WT CD8αβ or the high affinity CD8αβ-S53N co-receptor with 
the 1E6 TCR on the surface of CD4+ TREG cells.  
 
The final section of this thesis will therefore incorporate the described techniques 
to enhance the signalling ability of the 1E6 TCR in response to the ALW peptide in 
CD4+ TREG cells.  
 
5.2. Materials and Methods 
Plasmids 
The 1E6 variant TCR vectors, 1E6 LVL and 1E6 MMu were identical to the original 
pELNS.1E6.RatCD2 vector, apart from the amino acid substitutions described. 
Both these vectors were generated by and kindly provided to us by John 
Bridgeman (Cardiff University, UK). The CD8 expression vectors, 
pELNS.CD8β.IRES.CD8α and pELNS.CD8β.CD8αS53N were also generated by 
John Bridgeman (Cardiff University, UK) and were a kind gift from Linda 
Wooldridge (University of Bristol, UK). 
 
Dual-Transduction of CD4+ TREG Cells 
CD4+ TREG cells were transduced with two LV vectors concurrently to obtain cells 
co-expressing genes encoded from each vector. As with single transduction, each 
LV was titrated, as previously described, to achieve a value of transducing units/ml 
(TU/ml). 2 x105 TREG cells were activated with αCD3/CD28 beads and IL-2 for 48 
hours as described previously (Chapter 4.2). Each LV was added to 2x105 cells in 
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the same Eppendorf at a TU/cell of 5TU/cell and cells were spin infected as 
previous. Therefore, the total LV titre added to the TREG cells was 10TU/ml.  
 
Ag Specific Suppression Assay 
Autologous cryopreserved PBMCs were thawed and labelled with Cell Trace 
Violet. The cells were re-suspended to 1x106/ml and 100µl cells were aliquoted per 
well of a 96 well u-bottom plate. HA Ag was used to stimulate the PBMCs at a final 
concentration equivalent to 180ng/ml HA. Transduced and expanded 1E6-CD8-
S53N+, 1E6+CD8-S53N+ and 1E6+CD8-S53N- TREG cells were thawed from liquid 
N2, washed and re-suspended to 2x105/ml. 10,000 TREG cells were added to each 
well in 50µl for a final PBMC:TREG cell ratio of 10:1. ALW and RQF peptide were 
added to each well at a final concentration of 1µg/ml. The assay was set up in 
triplicate wells, with one triplicate per condition. The cells were incubated for 6 days 
at 37°C 5% CO2. 100µl of supernatant from each well was retained for IFNγ ELISA 
and stored at -80°C. The triplicate wells were harvested into a single FACS tube 
and stained with fluorescently labelled antibodies for expression of CD3, CD4, Rat 
CD2 and CD8. 7AAD was included to exclude dead cells from analysis and 
proliferation of responding CD4+ and CD8+ T cells was measured by loss of Cell 
Trace Violet. 
 
IFNγ  Enzyme-Linked Immunosorbant Assay (ELISA) 
IFNγ ELISAs were performed using an ELISA MAX IFNγ set (Biolegend, UK). 
Briefly, 96 well Maxisorp plates (Nunc, UK) were coated with 50µl pre-titrated IFNγ 
capture antibody and incubated at 4°C overnight. The following day the antibody 
was removed and excess protein binding sites blocked for 1 hour at room 
temperature in 200µl blocking buffer (PBS 1% bovine serum albumin (BSA, Sigma 
Aldrich, UK)). The plates were then washed 4 times in wash buffer, PBS 1% 
Tween (Tween, Cytotech, Denmark) using a 12 channel Nunc Immunoplate 
washer (Nunc, UK). 50µl of culture supernatant from the Ag specific suppression 
assay was diluted 1:10 in assay buffer (PBS 1% BSA) and added to the plate. To 
quantify the amount of IFNγ release, recombinant protein standards were added to 
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duplicate wells at a range of doubling dilutions from 2000pg/ml to 31.3pg/ml. The 
supernatants and standard were incubated for a further 2 hours at room 
temperature, the plates were washed four times and 50µl of biotinylated detection 
antibody, diluted 1:200 in assay buffer was added to the wells for 1 hour at room 
temperature and then removed. 50µl of avidin HRP, diluted 1:1000 in assay buffer, 
was added to the wells for 30 minutes at room temperature in the dark and the 
plates washed a further five times. 50µl of substrate solution, equal volumes of 
stabilised Hydrogen Peroxide and stabilised tetramethylbenzidine (R&D, UK) were 
added to the wells and the assay left to develop for 20-30 minutes at room 
temperature in the dark. The reaction was stopped using 50µl of 1M hydrosulphuric 
acid and the absorbance of each well measured at 450nM using a microplate 
spectrophotometer (Biorad, Hertfordshire) A standard curve was generated using 
Microsoft excel from the optical density (OD) values of the dilution of recombinant 
IFN-γ protein. The unknown values were calculated using the equation of the 
straight line y=mx+c where y is the OD value, m the gradient of the line, c the y 
intercept and x the unknown quantity.  
 
5.3. Results 
5.3.1. Minimal Amino Acid Modifications of the 1E6 TCR can Increase its 
Expression in Primary Human T Cells. 
To investigate whether improving the expression of the 1E6 TCR could rescue its 
response to the ALW peptide, two variants, that have minor amino acid 
substitutions in either the C regions or transmembrane region of the TCR were 
obtained. The 1E6 LVL variant caries three amino acid substitutions in the 
transmembrane domain of the TCRα chain that increases its’ hydrophobicity 
(Figure 5-2 (A)). The increase in hydophobicity has been shown to improve the 
expression of a number of exogenously expressed MHCI restricted TCRs by 
increasing the stability of the TCRα chains (Haga-Friedman et al., 2012). The 1E6 
MMu variant has four and five human to murine amino acid substitutions in the C 
regions of the 1E6 TCRα and TCRβ chains respectively (Figure 5-2 (B)). Although 
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it has been shown that these substitutions do not increase the exogenous 
expression of TCRs to the same extent as “murinised” TCRs, the minimal 
substitutions are hypothesised to decrease any immunogenicity of these TCRs 
(Sommermeyer and Uckert, 2010).  
 
Figure 5-2 Schematic Representation of Substitutions in the Variant 1E6 TCRs. Sequence 
alignments are shown indicating the position of variants in the (A) transmembrane domain of the 
1E6 TCRα chain for the 1E6 LVL variant and (B) C region of the 1E6 MMu variant. The amino acid 
substitutions are highlighted in red.  
 
To first test the expression of 1E6 LVL and 1E6 MMu variants in comparison to the 
1E6 (from herein designated 1E6 WT) TCR, TCRαβ+ Jurkat cells were transduced 
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there would be competition for cell surface expression between the introduced and 
endogenous TCRs. However, in contrast to the transduction of primary T cell 
populations, all transduced TCRαβ+ Jurkat cells expressed TCRvβ8, with only a 
proportion of these cells expression Rat CD2 (Figure 5-3 (A)). This was a very 
similar pattern of expression observed when TCRαβ- Jurkat cells were transduced, 
as seen in Chapter 3. Therefore, differences in expression between 1E6 variant 
TCRs could only be measured by assessing the MFI of TCRvβ8 expression. 
However, no significant enhancement of TCRvβ8 expression was observed in 
comparison of the 1E6 variant and WT TCRs.  
 
 
Figure 5-3 Expression of 1E6 Variant TCRs in a TCRαβ+ Jurkat Cell Line. LV encoding the 1E6 
WT, LVL and MMu variant TCRs were transduced into TCRαβ+ NFB2-1 Jurkat cell lines. (A) 
Transduced Jurkat cell lines were stained with TCRvβ8 and Rat CD2 fluorescently labelled 
antibodies and analysed by FACS. (B) The MFI of TCRvβ8 expression was assessed in TCRvβ8- 
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It is possible that the lack of difference between the expression of the 1E6 variants 
in Jurkat cells was due to the endogenous Jurkat cell TCR providing little to no 
competition for the introduced 1E6 TCRs. Therefore, to determine whether 
transduction with the 1E6 TCR variants could lead to an increased expression of 
the 1E6 TCR on transduced primary cells, CD4+ TEFF cells were transduced with 
either the 1E6 WT, 1E6 LVL or 1E6 MMu TCR. CD4+ TEFF cells were chosen over 
CD4+ TREG cells due to their abundance and the assumption that competition 
between TCRs would not significantly differ between TEFF and TREG cells. CD4+ 
TEFF cells were therefore isolated from three healthy control donors and transduced 
with 1E6 WT, 1E6 LVL or 1E6 MMu encoding LV. The transduced cells were then 
stained for TCRvβ8 and Rat CD2 expression 72 hours post transduction. These 
analyses showed that in two of three cases for LVL and in all cases for MMu, the 
substitutions in the 1E6 TCR resulted in a greater proportion of transduced cells 
that co-express the 1E6 TCRvβ8 and Rat CD2 (Figure 5-4 (A)). Additionally, the 
1E6 MMu variants led to a significant increase in the co-expression of TCRvβ8 and 
Rat CD2 in comparison to the 1E6 WT TCR (Figure 5-4 (C)). Furthermore, in the 
three donors, transduction with the 1E6 MMu construct also led to a higher level of 
TCRvβ8 expression on the Rat CD2+ transduced cells, compared to the 1E6 WT 
construct (Figure 5-4 (E)).  
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Figure 5-4 Expression of 1E6 Variant TCRs in CD4+ TEFF Cells. CD4+ TEFF cells were 
transduced with LV encoding the different 1E6 variant TCRs. (A) FACS plots show 1E6  variant 
TCR, transduced cells stained for expression of TCRvβ8 and Rat CD2. (B) The percentage of dual 
expressing TCRvβ8 and Rat CD2 transduced cells was compared between CD4+ TEFF cells 
transduced with 1E6 WT and 1E6 LVL TCR and (C) 1E6 WT and 1E6 MMu TCR. (D) The MFI of 
TCRvβ8 of total RatCD2+ cells was compared between CD4+ TEFF cells transduced with 1E6 WT 
and 1E6 LVL TCR and (E) 1E6 WT and 1E6 MMu TCR. Statistical significance was calculated 
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5.3.2. Increased Expression of the 1E6 TCR on the Surface of TREG Cells is 
Insufficient to Rescue the TREG Cells Response to WT Peptide 
Given the promising results with the 1E6 variant TCRs in TEFF cells, we sought to 
transduce TREG cells with each 1E6 TCR variant to test the signalling capability of 
each TCR in response to ALW peptide. This was tested in CD4+ TREG cells as the 
signalling requirements are thought to be different between these two cell subsets, 
as discussed previously (Plesa et al., 2012). CD4+ TREG cells from a single donor 
were isolated, activated, split into three groups and transduced with either the 1E6 
WT TCR or one of the two 1E6 variant TCRs (Figure 5-5 (A)). Similar to the profile 
seen post transduction of CD4+ TEFF cells, transduction with the 1E6 TCR variants 
yielded a higher percentage of Rat CD2+ cells co-expressing TCRvβ8 with 
percentages of 61% for 1E6 LVL and 70% for 1E6 MMu compared to 47% for 1E6 
WT TCR (Figure 5-5 (B)). The overall TCRvβ8 MFI of TREG cells transduced with 
1E6 MMu was also higher compared to TREG cells transduced with 1E6 LVL and 
1E6 WT (Figure 5-5 (C)). To determine whether this increased expression of the 
1E6 TCR led to a rescue in its response to ALW peptide, the ability of transduced 
cells to up-regulate CD69 in response to peptide was measured. Transduced cells 
were incubated with autologous PBMCs that had been pulsed with PBS, ALW or 
super-agonist peptide RQF for 16 hours, as with previous experiments. The 
expression of CD69 was then measured in Rat CD2+ populations. This analysis 
revealed that there was no difference in the response of CD4+ TREG cells to the 
ALW peptide when cells were transduced with the 1E6 higher expression variants 
(Figure 5-5 (C)). There was however a significant increase in the percentage of 
cells that up-regulated CD69 in response to the RQF peptide when TREG cells 
transduced with the LVL or MMu TCRs were stimulated (Figure 5-5 (D)).  
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Figure 5-5 Increased expression of TCRvβ8 in CD4+ TREG cells fails to rescue the 1E6 TCR 
response to the ALW peptide. CD4+ TREG cells from a single donor were transduced with LV 
encoding one of the three 1E6 Variant TCRs. (A) Expression of TCRvβ8 and Rat CD2 was 
assessed by flow cytometry in CD4+ TREG cell transduced with either the 1E6 WT, LVL or MMu 
variants. (B) The Percentage of TCRvβ8+Rat CD2+ cells for TREG cells transduced with each 1E6 
variant TCR and (C) the MFI of TCRvβ8 expression in total Rat CD2+ cells for each variant was 
assessed. (D) The transduced populations shown were stimulated with autologous PBMCs that had 
been pulsed with either PBS, WT peptide ALW or RQF peptide. Expression of CD69 was assessed 
in all Rat CD2+ cells under each stimulation condition. Data shown is from one healthy control 
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5.3.3. Transduction of Jurkat Cells with CD8αβ Co-receptor and a High 
Affinity Variant, can Rescue the 1E6 TCRs Response to WT Peptide. 
In the previous experiments, it was determined that the increased expression of the 
1E6 TCR on CD4+ TREG cells was not sufficient to re-direct the Ag specificity of 
these cells to the ALW peptide. It was hypothesised, that to fully re-direct the Ag 
specificity of CD4+ TREG cells towards the ALW epitope, the expression of the 
CD8αβ co-receptor would be required. As previously mentioned, for productive 
TCR signalling sufficient numbers of TCRs must be triggered and each triggering 
must be within the optimal dwell time for TCR-pMHC interactions (Kalergis et al., 
2001; Valitutti et al., 1995). Therefore the expression of CD8αβ may be able to 
increase the dwell time between TCR-pMHC interactions and subsequently lead to 
productive signalling. From experiments in model cell lines in Chapter 3, it was 
observed that CD8α expression on Jurkat cells could rescue the 1E6 TCRs’ 
response to ALW peptide. However, the ability of CD8α to rescue the response 
only occurred when CD8α was highly expressed on a transfected cell line 
(J76CD8α) and not when it was co-expressed with the 1E6 TCR via the same LV 
construct. This suggested that to achieve full expression of CD8α, this gene would 
need to be expressed on a separate construct to the 1E6 TCR. Therefore, a 
separate LV vector that encoded the full CD8αβ co-receptor was obtained, a kind 
gift from Professor Linda Wooldridge (Figure 5-6 (A)). Furthermore, results from 
Chapter 4 also demonstrated that transduction with the 1E6 TCR was unable to re-
direct the Ag specificity of primary CD8+ T cells towards the ALW peptide. Thus, a 
second construct encoding a high affinity CD8αβ co-receptor variant was obtained. 
This high affinity CD8αβ variant contains a serine to arginine substitution at amino 
acid 53 of the CD8α chain and has been designated CD8βαS53N (Figure 5-6 (B)) 
(Cole et al., 2007b). The ability of both the CD8βα WT co-receptor and 
CD8βαS53N co-receptor to rescue the 1E6 TCR could therefore be tested 
simultaneously. For simplicity in all following experiments, cells transduced with the 
CD8αβ WT construct will be referred to as CD8-WT+ and those transduced with the 
CD8βαS53N co-receptor as CD8-S53N+. 
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Figure 5-6 CD8αβ  Expression Plasmids. The CD8α and CD8β chains were cloned into the 
pELNS LV vector under the control of the EF1α promoter with an IRES site separating the two 
chains (A) A schematic of the CD8βα WT genes inserted into the vector (B) A schematic of the 
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The ability of both the CD8 co-receptors to rescue the 1E6 TCR was first examined 
using Jurkat cell lines. The TCRαβ- Jurkat cell line J76, which had previously been 
transduced with the 1E6 TCR, were transduced for a second time with either the 
CD8-WT LV or the CD8-S53N LV. J76CD8α cells that had been transduced with 
the 1E6 TCR served as a positive control for the following experiments. J76CD8α 
cells, that had previously been transfected to express CD8α were transduced with 
the 1E6 TCR for the following experiments and therefore were all CD8α+ but only 
20% 1E6 TCR+ at the time of staining, due to a low transduction efficiency. The 
transduced cell lines were stained using CD8α and TCRvβ8 fluorescent antibodies 
and a clear population of cells that co-expressed both receptors was observed 
(Figure 5-7 (A)). Similar to results seen in Chapter 3, expression of CD8-WT and 
CD8-S53N was lower in the LV transduced cells compared to CD8α expression on 
the transfected Jurkat cell line. The transduced cells were stained with an ALW-
HLA-A2 multimer to determine if the introduced CD8 co-receptors could stabilise 
the 1E6 TCR-pMHC interaction. The results of the multimer staining revealed that 
20% of cells expressing both the 1E6 TCR and the CD8-S53N could be stained 
with the ALW-MHCI multimer (Figure 5-7 (B)). In contrast, only 3% of cells co-
expressing the 1E6 TCR and the CD8-WT co-receptor stained with the same MHCI 
multimer. As observed in Chapter 3, 40% of 1E6+J76CD8α cells stained with the 
ALW-MHCI multimer and little staining was observed in CD3- cells (Figure 5-7 (B)). 
The staining of the 1E6 TCR+ cells lines with the ALW-MHCI multimer was specific, 
as no staining was observed with an irrelevant peptide control VMN multimer 
(Figure 5-7 (C)).  
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Figure 5-7 Expression of CD8αβ  Genes via LV Transduction in 1E6+ J76 cells. 1E6+ J76 cells 
were transduced with LV encoding either the CD8-WT or the CD8-S53N co-receptor. (A) To assess 
for successful transduction of 1E6+ J76 cells with the two CD8 expression vectors, the cells were 
stained with antibodies against TCRvβ8 and CD8α. 1E6 transduced J76CD8α cells were stained as 
a positive control (B) The CD8 expressing, 1E6+ Jurkat cell lines were stained with an αCD3 
antibody and an MHCI multimer in complex with ALW peptide (C) or a VMN pMHCI multimer, as an 
irrelevant multimer control. The 1E6+J76CD8α cell lines were stained as a positive control.  
Having established that co-expression of CD8-S53N increased ALW-MHCI 
multimer binding in at least a proportion of 1E6 expressing Jurkat cells, it was 
investigated if expression of this co-receptor could increase the 1E6 TCRs 
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transduced J76 (1E6+J76) cells served as a negative control and 1E6 transduced 
J76CD8α (1E6+J76CD8α) as a positive control. All transduced cell lines were 
FACS sorted so 100% of cells in culture had the desired phenotype. All three CD8 
expressing cell lines were capable of responding to PBMCs pulsed with the ALW 
peptide (Figure 5-8 (A)). Although a clear hierarchy in the level of response was 
observed, with stimulation of 1E6+J76CD8α yielding the greatest response, 
followed by 1E6+CD8-S53N+ J76 cells and then 1E6+CD8-WT+ J76 cells. As 
before, the 1E6+J76 cells were unable to respond to PBMCs pulsed with ALW 
peptide. All four population of cells responded to PBMCs pulsed with the RQF 
peptide, with 1E6+J76CD8α yielding the highest response (Figure 5-8 (B)). 
 
Figure 5-8 Co-expression of the 1E6 TCR and CD8αβ  co-receptors re-direct the specificity of 
Jurkat cells. The cell lines indicated were sorted to a high purity of transduced cells and incubated 
with PBMCs pulsed with log dilutions of (A) ALW or (B) RQF peptide and the up-regulation of CD69 
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5.3.4. CD4+ TREG cells can be Co-Transduced to Express Both CD8-S53N and 
the 1E6 TCR  
The results observed in model cell lines suggest that transduction of CD4+ TREG 
cells with CD8-S53N would have the best chance of aiding the 1E6 TCR in re-
directing the Ag specificity of these cells. For expression of both the 1E6 WT TCR 
and CD8-S53N co-receptor, CD4+ TREG cells were co-transduced with both LV 
vectors. Others have shown success with co-transduction of high titre, VSV-G 
pseudotyped LV’s when cells are infected with each LV at the same time 
(Frimpong and Spector, 2000). Therefore, TREG cells were isolated from a healthy 
control donor, T02 and after 48 hours of aCD3/CD28 stimulation, both the 1E6 LV 
and the CD8-S53N LV were added to the TREG cells and spin infected as previously 
described. The co-transduction of the cells was then characterised 72 hours post 
transduction. The co-transduced cells were stained with α-TCRvβ8 and α-Rat CD2 
antibodies to confirm transduction with the 1E6 WT TCR (Figure 5-7 (A)). The cells 
were also stained with α-CD8α and single populations of CD8α expressing cells 
and TCRvβ8 expressing cells were observed, with a small 1.65% of cells co-
expressing these two markers (Figure 5-7 (B)). The cells were similarly analysed 
for Rat CD2 and CD8α expression, which similarly identified a small percentage of 
co-transduced cells (Figure 5-7 (C)).  
 
Figure 5-9 Evaluation of Co-transduction of CD4+ TREG Cells. CD4+ TREG cells from healthy 
control donor T02, were co-transduced with LV encoding the 1E6 WT TCR and CD8-S53N co-
receptor. After 72 hours the phenotype of the transduced cells was assessed by staining with (A) α-
TCRvβ8 and α-Rat CD2 (B) α-TCRvβ8 and α-CD8α and (C) α-CD8α and α-Rat CD2 antibodies. 
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5.3.5. Co-expression of 1E6 TCR and CD8βαS53N can Re-direct the Antigen 
Specificity of Human CD4+ TREG cells. 
Although the percentage of dual 1E6+CD8-S53N+ was low, a peptide stimulation 
assay was performed and up-regulation of CD69 was examined in four cell 
populations, characterised by Rat CD2 and CD8-S53N expression (Figure 5-10 
(A)). The results from this experiment showed that up-regulation of CD69 in 
response to ALW peptide was only observed in cells co-expressing Rat CD2 and 
CD8-S53N (Figure 5-10 (B)). Stimulation with the super agonist RQF peptide 
resulted in CD69 up-regulation in all Rat CD2+ expressing cells but not in cells 
expressing CD8-S53N alone. Furthermore, expression of CD8-S53N led to a 
significant increase in the 1E6 TCRs’ response to RQF peptide (Figure 5-10 (B)).  
 
 
Figure 5-10 Co-expression of CD8-S53N rescues the 1E6+ TREG cells response to WT peptide. 
CD4+ TREG cells were transduced with LV encoding the WT 1E6 TCR and a second LV encoding 
CD8-S53N. (A) Transduced cells from donor T02 were stained with antibodies against CD8α and 
Rat CD2 to assess transduction with both viruses. (B) Transduced cells were incubated with 
autologous PBMCs pulsed with PBS, ALW or RQF. CD69 was analysed on cell populations shown 
in (A) and the expression of CD69 in each quadrant was assessed. Data shown is from a single 
individual and stats calculated from replicates within a single assay. P<0.05 = *  and P<0.0001 = 
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5.3.6. Combination of CD8-S53N and 1E6 TCR Variants Expression in TREG 
Cells 
The expression of either the 1E6 TCR variants or CD8-S53N co-receptor, led to a 
significant increase in the response of the 1E6 TCR to RQF peptide. Furthermore, 
the expression of CD8-S53N enabled signalling via the 1E6 TCR in response to 
the ALW peptide. It was therefore examined whether co-expression of a 1E6 TCR 
variant and the CD8-S53N co-receptor could enhance the response of 1E6+ TREG 
cells to ALW peptide. As before, TREG cells were isolated from a healthy control 
donor, T03, and 48hours post stimulation were co-transduced with CD8-S53N and 
either 1E6 WT, 1E6 LVL or 1E6 MMu TCR. After 7 days of expansion the cells 
were then incubated with autologous Violet labelled PBMCs as before. The CD69 
expression was then assessed on either the single 1E6+ cells or the dual 
1E6+CD8-S53N+ cells (Figure 5-11 (A)). CD69 up-regulation was observed on cells 
co-expressing either the 1E6 WT, LVL or MMu TCRs with CD8-S53N co-receptor 
(Figure 5-11 (B)). Interestingly, CD69 expression was significantly increased on 
cells expressing the 1E6 LVL or 1E6 MMu variant TCRs with CD8-S53N in 
response to ALW peptide compared to cells expressing the 1E6 WT TCR (mean 
±SD for 1E6 WT – 10.9% ±0.69, 1E6 LVL – 17.1% ±2.5 and 1E6 MMu – 18.1 
±2.9). CD4+ TREG cells only expressing the 1E6 TCR up-regulated CD69 in 
response to RQF but not in response to ALW peptide, irrespective of the 1E6 TCR 
variant expressed, as seen previously (Figure 5-11 (C)). 
Chapter 5 Approaches to Enhance 1E6 TCR Function in Human TREG cells 
193 
 
Figure 5-11 Co-transduction of CD8-S53N and 1E6 TCR Variants can Increase the 1E6 TCRs 
Response to Cognate Peptide. (A) FACS plots show gating of 1E6 and CD8-S53N transduced 
TREG cells from donor T03. The same gating strategy was used for each 1E6 TCR variant tested. 
(B) CD69 expression was assessed on dual 1E6+CD8-S53N+ TREG cells, as depicted by the arrow. 
(C) CD69 expression was assessed on single 1E6+ TREG cells. 
5.3.7. Expansion of Dual 1E6+CD8-S53N+ TREG cells 
From previous results, it appeared that transduction of CD4+ TREG cells with CD8-
S53N and the 1E6 MMu TCR would be the optimal combination to increase the 
functional avidity 1E6 TCR-ALW-MHCI interaction. The 1E6 MMu TCR was chosen 
for these experiments as it had the highest level of expression in CD4+ TREG cells.  
CD4+ TREG cells were isolated from a third healthy control donor, T04, and co-
transduced with 1E6 MMu and CD8-S53N. As seen previously, the co-transduction 
of 1E6MMu and CD8-S53N was very low, with only 1.16% cells co-expressing Rat 
CD2 and CD8-S53N. The transduced TREG cells were expanded in RAPA and after 
two rounds of expansion, the cells were sorted into three populations of cells: 1E6-
CD8-S53N+, 1E6+CD8-S53N+ and 1E6+CD8-S53N-, based on Rat CD2 and CD8 
expression (Figure 5-1- (A)). The sorted cells were expanded for one further round 
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S53N+ cells remained Rat CD2-, however lost expression of CD8-S53N, remaining 
only 67% CD8-S53N+ (Figure 5-12 (B)). Within this population of cells there was 
also a CD8hi population which is presumed to be contaminating CD8+ T cells, 
however this contamination was only ~3% of the total population. The sorted 
1E6+CD8-S53N+ cells were highly pure for Rat CD2 expression but a quarter of 
cells lost CD8-S53N expression (Figure 5-12 (C)). Cells that were sorted as 
1E6+CD8-S53N- remained >98% Rat CD2+, however, 30% of these cells co-
expressed low levels of CD8-S53N (Figure 5-12 (D)). Since expression of CD8-
S53N was lower in this population of cells than for the cells sorted based on CD8-
S53N expression, it can be presumed that the FACS gating strategy was not 
stringent enough to distinguish between CD8-S53Nlow and CD8-S53Nhi cells.  
 
Figure 5-12 Expansion of sorted 1E6+/-CD8-S53N+/- from transduced populations of CD4+ TREG 
cells. CD4+ TREG cells were transduced with 1E6 MMu and CD8-S53N LVs and expanded through 
two rounds of expansion (A) Transduced cells were sorted into three populations as indicated. The 
cells were then expanded a third time and stained with antibodies against CD8 and Rat CD2. FACS 
plots show the phenotype of expanded (B) 1E6-CD8-S53N+ (C) 1E6+CD8-S53N+ and (D) 1E6+CD8-
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The phenotype of the sorted cells was further assessed by flow cytometry staining 
of CD3, CD4, CD25 and FoxP3. Due to a limited availability of 1E6+CD8-S53N+ 
cells, these cells were not included in this analysis. However, as all TREG cells from 
this donor were expanded in the same manner, the phenotypes were predicted to 
be similar amongst the three populations. Both the 1E6-CD8-S53N+ population and 
the 1E6+CD8-S53N- population were found to be >95% CD3+CD4+ (Figure 5-13 (A-
B)). A 3% population of contaminating CD3+CD4- cells was observed in the 1E6-
CD8-S53N+ population, which were also found to be CD8hi, identifying these cells 
as contaminating CD8+ T cells seen previously (Figure 5-12 (B)). Furthermore, 
Intracellular staining for FoxP3 expression identified that both populations of cells 
were >89% CD25+FoxP3+ (Figure 5-13 (C-D)). With confirmation that the sorted 
populations of cells were >89% CD4+CD25+FoxP3+, the cells were cryopreserved 
to be used in an Ag specific suppression assay performed at a later date.  
 
Figure 5-13 Phenotype of Expanded 1E6-CD8-S53N+ and 1E6+CD8-S53N- TREG cells. At the end 
of the third round of expansion, the phenotype of the sorted 1E6-CD8-S53N+ and 1E6+CD8-S53N+ 
cells was assessed by flow cytometry. FACS plots show (A) 1E6-CD8-S53N+ and (B) 1E6+CD8-
S53N- cells stained with αCD3 and αCD4 antibodies. As well as staining for CD25 and FoxP3 
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5.3.8. Dual CD8-S53N and 1E6 TCR TREG cells can suppress recall responses 
in an Ag specific manner. 
Using a similar suppression assay to that described in chapter 4, the ability of 
1E6+CD8-S53N+ TREG cells to suppress a recall response when stimulated by the 
ALW peptide was investigated. Due to a limited availability of dual 1E6+CD8-S53N+ 
TREG cells, a ratio of PBMCs:TREG cells of 10:1 was used. At this lower ratio of TREG 
cells, 1E6+ TREG cells stimulated by RQF peptide were previously shown to be 
effective at suppressing 80% of HA specific CD4+ and CD8+ T cell proliferation 
(Figure 4-26). Additionally, the low numbers available of 1E6+CD8-S53N+ TREG 
cells permitted only one replicate (triplicate wells pooled for FACS staining) to be 
set up per condition. To control for CD8-S53N expression in TREG cells, 1E6-CD8-
S53N+ TREG cells were included in this suppression assay. The gating strategy for 
this assay was similar to that used in Chapter 4 in that proliferation of live CD3+ T 
cells was assessed based on FSC-A/SSC-A profile, the exclusion of 7AAD+ dead 
cells and the inclusion of CD3+ T cells (Figure 5-14 (A)). 1E6+CD8-S53N- and 
1E6+CD8-S53N+ TREG cells were excluded from analysis of proliferating T cells 
based on the expression of Rat CD2 (Figure 5-14 (B)).  The CD3+ T cell population 
was then separated into CD4+ and CD8+ T cells for analysis of HA specific 
proliferation via Violet dye dilution in the subpopulations (Figure 5-14 (C)). In the 
case of assays including 1E6-CD8-S53N+ TREG cells, the initial plan was to exclude 
these cells on the basis of co-expression of CD8 and CD4. However, as the LV 
expression of CD8-S53N led to lower expression of CD8 in comparison to natural 
CD8+ T cells, these TREG cells could not be efficiently excluded from the population 
of HA responding CD4+ T cells (Figure 5-14 (C)). Therefore, the effect of 1E6-CD8-
S53N+ TREG cells on the proliferation of HA specific T cells could not be assessed 
in this assay.  
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Figure 5-14 Gating Strategy Used for Suppression Assay With 1E6 and CD8-S53N 
Transduced TREG cells. (A) Lymphocytes were identified based on their FSC-A/SSC-A profile. 
Dead cells were excluded based on their expression of 7AAD and total T cells were identified by 
expression of CD3. (B) 1E6+ TREG cells were excluded from analysis based on expression of Rat 
CD2 (highlighted in red). (C) T cells were separated into CD4+ and CD8+ T cell populations to 
assess Violet dye dilution of each subpopulation. 1E6-CD8-S53N+ could not be excluded from 
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In the absence of TREG cells, a robust proliferative response by T04 CD4+ T cells to 
the HA Ag was observed. However, in this donor proliferation was reduced upon 
addition of ALW peptide, (35% reduction, Figure 5-15 (A&D)), and RQF peptide 
(28% reduction, Figure 5-15 (A&G)). As observed in all previous suppression 
assays, the addition of TREG cells in the absence of peptide led to a significant 
reduction in the proliferation of CD4+ T cells (Figure 5-15 (A-C)). In contrast to 
previous assays, proliferation was further reduced when 1E6+CD8-S53N- TREG 
cells were stimulated by ALW peptide (Figure 5-15 (B&E)), and this reduction was 
further enhanced when these cells were stimulated with RQF peptide (Figure 5-15 
(B&H)). Stimulation of 1E6+CD8-S53N+ TREG cells with ALW peptide also resulted 
in a reduction of CD4+ T cell proliferation compared to that seen when the TREG 
cells were unstimulated (Figure 5-15 (C&F), which was comparable to stimulation 
of these cells with RQF peptide (Figure 5-15 (C&I)). A similar pattern in the 
reduction of proliferation was observed for CD8+ T cells with addition of both TREG 
cell populations leading to a significant reduction in HA specific proliferation in the 
absence of peptide (Figure 5-16 (A-C)). A further reduction of proliferation was 
observed upon addition of either ALW or RQF peptide to stimulate 1E6+CD8-S53N- 
TREG cells. Furthermore, a marked reduction in CD8+ T cell proliferation was 
observed when 1E6+ CD8-S53N+ TREG cells were stimulated by either ALW or RQF 
peptide. In all cases, the reduction of proliferation caused by addition of either ALW 
or RQF to stimulate TREG cells was greater that the addition of peptide in the 
absence of TREG cells. It is noteworthy that 30% of the 1E6+CD8-S53N- TREG cells 
did in fact express CD8-S53N+. This may account for the reduction in proliferation 
of CD4+ and CD8+ T cells upon stimulation of 1E6+CD8-S53N- with ALW peptide, 
which is in contrast to results in Chapter 4. Furthermore, FACS plots represent a 
single replicate from pooled triplicate wells and therefore further replicates would 
be required to confirm the results shown.  
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Figure 5-15 FACS plots Showing Reduction of CD4+ T cell Proliferation by Activated 1E6+ 
CD8βαS53N+ TREG Cells. Violet labelled PBMCs were incubated with HA +/- ALW peptide or +/- 
RQF peptide. Representative FACS plots show violet dye dilution of CD3+CD4+ T cells in the 
presence of (A) No TREG (B) 1E6+CD8-S53N- and (C) 1E6+CD8-S53N. The red arrows indicate the 
Ag specific suppression on proliferation upon addition of ALW peptide in the absence or presence 


















Violet Proliferation Dye 
A B C 





















Chapter 5 Approaches to Enhance 1E6 TCR Function in Human TREG cells 
200 
 
Figure 5-16FACS plots Showing Reduction of CD8+ T cell Proliferation by Activated 1E6+ 
CD8βαS53N+ TREG Cells. Violet labelled PBMCs were incubated with HA +/- ALW peptide or +/- 
RQF peptide. Representative FACS plots show violet dye dilution of CD3+CD4+ T cells in the 
presence of (A) No TREG (B) 1E6+CD8-S53N- and (C) 1E6+CD8-S53N+. The red arrows indicate the 
Ag specific suppression on proliferation upon addition of ALW peptide in the absence or presence 
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Autoreactive T cells in T1D are characterised by secretion of pro-inflammatory 
cytokines, including IFNγ (Arif et al., 2011; Arif et al., 2004; Cnop et al., 2005). We 
therefore investigated whether transduced TREG cells, stimulated in an Ag specific 
manner, could suppress a memory T cells’ IFNγ response. As the levels of IFNγ 
were measured by ELISA and not by FACS, the production of IFNγ by HA 
responding T cells in the presence of 1E6-CD8-S53N+ TREG cells could also be 
measured in these analyses. The absolute levels of IFNγ (mean ± SD) under each 
condition tested were as shown (Figure 5-17 (A)). As with proliferation, the addition 
of TREG cells has a “non Ag specific” suppressive effect on the secretion of IFN-γ by 
HA stimulated T cells. We therefore compared IFNγ secretion in the presence of 
TREG cells stimulated by ALW or RQF relative to the level of IFNγ secretion in the 
presence of un-stimulated TREG cells. Stimulation of both 1E6+CD8-S53N- and 
1E6+CD8-S53N+ TREG cells with RQF peptide led to a significant reduction in the 
secretion of IFNγ. However, no such reduction was observed in the absence of 
TREG cells or in the presence of 1E6-CD8-S53N+ TREG cells. Interestingly, 
stimulation with ALW only led to a reduction of IFNγ in the presence of 1E6+CD8-
S53N+ TREG cells, and not any other TREG cell population. The mean percentage 
suppression upon addition of either ALW or RQF peptide was quantified in 
triplicate wells (Figure 5-17 (B)). These data show that only the stimulation of 
1E6+CD8-S53N+ TREG cells with ALW peptide led to a marked suppression of IFNγ 
secretion. In contrast, stimulation with RQF peptide led to a marked suppression of 
IFNγ secretion by both 1E6+CD8-S53N- TREG cell and 1E6+CD8-S53N- TREG cells. 
 
Taken together, the proliferation and IFNγ secretion data suggest that the co-
expression of CD8-S53N and the 1E6 TCR confers suppressive activity to TREG 
cells in response to the WT ALW peptide. However, due to the severe limitation in 
TREG cell numbers available, this data is preliminary and a more comprehensive 
analysis of the suppressive capabilities of 1E6+CD8-S53N+ TREG cells in response 
to ALW peptide is required for confirmation. 
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Figure 5-17 Analysis of IFNγ  secretion in Culture Supernatants of Ag Specific Suppression 
Assay. For each well of the Ag specific suppression assay, the secretion of IFNγ was assessed by 
ELISA. (A) Raw data is plotted for the amount of IFNγ secreted (in ng/ml) per well of the Ag specific 
suppression assay. An unpaired Student’s t test was used to calculate data significance. P * < 0.05. 
(B) The mean percentage suppression was calculated for the addition of either ALW or RQF 
peptide in the absence or presence of TREG cell populations. 
 
5.4. Discussion 
To date there have been no studies on the transfer of autoreactive MHCI restricted 
TCRs into human CD4+ TREG cells with a view of re-directing the Ag specificity of 
these cells. It was determined early on in this thesis that the autoreactive TCRs 
used in this study had a different pattern of behaviour to the pathogen specific 868 
TCR and other pathogen and tumour specific MHCI restricted TCRs used in 
studies by others (Brusko et al., 2010; Plesa et al., 2012). Results from Chapter 3 
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profiles and a reliance on the CD8 co-receptor, culminated in an unsuitability of 
these TCRs for the re-direction of the Ag specificity of CD4+ TREG cells. The 
experiments presented in this chapter sought to identify methods of rescuing the 
ability of autoreactive MHCI restricted TCRs to re-direct the Ag specificity of human 
CD4+ TREG cells.  
 
It was first determined whether the responsiveness of the 1E6+ TREG cells for WT 
ALW peptide could be enhanced by increasing the expression and stability of the 
1E6 TCR on the surface of transduced cells. To examine this, two 1E6 variant 
TCRs were obtained, the 1E6 LVL and the 1E6 MMu TCRs. Using the variant 
TCRs the expression of the 1E6 TCR on the surface of CD4+ TREG cells could be 
enhanced as measured by an increase in TCRvβ8+ RatCD2+ TREG cells. However, 
this increase of 1E6 TCR on the surface of CD4+ TREG cells was insufficient for the 
recognition of the WT ALW peptide by transduced TREG cells as measured by 
CD69 up-regulation in a peptide stimulation assay. The study that first described 
the LVL modification of TCRs showed that this modification could improve the 
expression, stability and consequently the function of a number of TCRs (Haga-
Friedman et al., 2012). Moreover, the study by Haga-Friedman et al, showed an 
improvement in the function of an MHCI restricted TCR in a CD4+ TEFF cell. 
However, unlike the 1E6 TCR, the unmodified MHCI restricted TCR used in their 
study was able to endow a CD4 TEFF cell with Ag specificity, although at a much 
reduced capacity. It is therefore possible that although an increased expression 
may lead to an increased avidity interaction between the 1E6 TCR and ALW 
peptide, this is not sufficient for signalling through this TCR. For this reason, 
additional methods to improve the stability of the interaction between the 1E6 TCR 
and ALW-MHCI were investigated.  
 
Consequently, two further LV vectors encoding either the human WT CD8αβ co-
receptor (CD8-WT) or a high affinity variant of this co-receptor (CD8-S53N) were 
obtained for this study. These vectors were first used to transduce 1E6+J76 cells to 
determine if the LV expression of the full CD8-WT co-receptor could rescue the 
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response of these cells to the ALW peptide. Indeed, expression of either CD8-WT 
or CD8-S53N in 1E6+J76 cell endowed these cells with the capacity to respond to 
the ALW peptide. Interestingly, in a dose titration, the magnitude of the response 
by 1E6+J76CD8α cells to ALW peptide was greater than the response by either 
1E6+CD8-WT+ J76 cells or 1E6+CD8-S53N+ J76 cells. In fact, the response 
achieved by the 1E6+J76CD8α cells was much higher than observed in previous 
experiments performed in Chapter 3. It was also observed, that the 1E6+CD8-
S53N+J76 cells exhibited as increased up-regulation of CD69 in response to ALW 
peptide compared to 1E6+CD8-WT+ J76 cells. Interestingly, in all four 1E6+ Jurkat 
cell lines tested, all cells respond to the RQF peptide but it is clear that 
1E6+J76CD8α cells respond much better 1E6 and CD8 transduced J76 cells.  
 
In chapter 4 it was shown that the 1E6 TCR could not endow Ag specificity to CD8+ 
T cells. Therefore, for the progression of this study it was determined that the 
examination of 1E6 TCR and CD8-S53N co-transduced TREG cells would be the 
most productive route of study. It was first shown that TREG cells could be 
transduced with two LV vectors at the same time as evidenced by co-expression of 
the 1E6 TCR and CD8-S53N. The ability of the 1E6+CD8-S53N+ TREG cells to 
respond to the ALW peptide in a peptide stimulation assay was examined. For the 
first time in primary T cells, a response to the ALW peptide was observed from 1E6 
TCR transduced TREG cells but only when these cells were co-expressing CD8-
S53N. Furthermore, the response of 1E6+CD8-S53N+ TREG cells was increased 
when either the 1E6 LVL or 1E6 MMu TCRs were expressed, compared to the 1E6 
WT TCR.  
 
With these encouraging results, the ability of the 1E6 TCR, co-expressed with 
CD8-S53N, to confer suppressive capabilities to CD4+ TREG cells was explored. As 
the 1E6 MMu TCR had been shown to have the most improved expression and 
subsequently better functional response compared to the 1E6 WT TCR only 
1E6MMu and CD8-S53N co-transduced cells were explored in this setting. From 
preliminary suppression assay data, it was suggested that these co-expressing 
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TREG cells were capable of suppressing the proliferation of HA specific CD4+ and 
CD8+ T cells when ALW peptide was present in the culture. In fact, the reduction in 
proliferation of the CD4+ and CD8+ T cells observed in the presence of 1E6+CD8-
S53N+ TREG cells was comparable to when the super agonist RQF peptide was 
present in the culture. As a control for these experiments, the ability of 1E6+CD8-
S53N- TREG cells to suppress HA proliferative responses when stimulated by the 
ALW peptide was also assessed. In contrast to what was observed previously, the 
stimulation of 1E6+CD8-S53N- TREG cells with ALW peptide reduced the 
proliferation of HA specific CD4+ and CD8+ T cells. However, the suppression of 
CD4+ T cells was lower when 1E6+CD8-S53N- TREG cells were stimulated with the 
ALW peptide compared to the RQF peptide. Characterisation of the 1E6+CD8-
S53N- TREG cells used in this assay revealed that 30% of these cells were 
expressing low levels of CD8-S53N, which may account for the ability of these 
TREG cells to respond to ALW peptide. Due to a limitation in the number of 
1E6+CD8-S53N+ TREG cells this assay could only be performed once, with only one 
replicate (three replicate wells pooled to form a single replicate) analysed for the 
reduction of CD4+ and CD8+ T cell proliferation per condition. Thus, the reduction 
in proliferation observed only points to a trend in the ability of 1E6+CD8-S53N+ to 
suppress T cell responses when stimulated by the ALW peptide. 
 
It was encouraging to note that the IFNγ secretion from cultures of PBMCs with HA 
Ag was significantly reduced in the presence of 1E6+CD8-S53N+ TREG cells and 
ALW peptide. This reduction in IFNγ secretion was not observed when ALW 
peptide was used to stimulate 1E6+ or CD8-S53N+ single positive TREG cells. As 
previously mentioned, there is strong evidence in human disease and in mouse 
models that secretion of IFNγ by autoreactive T cells plays a role in β cell death 
(Arif et al., 2004; Cnop et al., 2005). Therefore, the ability of Ag specific TREG cells 
to suppress IFNγ secretion could have therapeutic potential, particularly MHCI 
restricted TREG cells, which have been hypothesised to function at the site of 
inflammation. The secretion of IL-17 by autoreactive TH17 cells has also been 
shown to play a role in inducing β cell death (Arif et al., 2011). It would therefore be 
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interesting to determine whether Ag specific TREG cells can suppress the 
production of this cytokine by memory T cells 
 
These experiments will require further repetition, with a number of internal 
replicates, before the ability of 1E6+CD8-S53N+ TREG cell to suppress memory T 
cell proliferative responses can be fully examined. A more appropriate control for 
these experiments perhaps would be to split the initial TREG  cell population prior to 
LV transduction, into cells to be transduced with 1E6 LV only and cells to be co-
transduced with 1E6 and CD8-S53N LV. This would prevent any contamination of 
the single 1E6+ TREG cells with cells co-expressing low levels of CD8-S53N. 
Unfortunately, a low initial yield of TREG cells was obtained from donor T04, and 
with the aim to improve cell yields, all cells were co-transduced and sorted into the 
described populations at the end of two rounds of expansion.  
 
To improve upon these data, the suppression assays involving dual 1E6 TCR and 
CD8-S53N expressing TREG cells need to be repeated. Unfortunately, a low level of 
co-transduction of these two receptors, which was < 2% of TREG cells, led to a very 
low yield of these cells at the end of three rounds of expansion. In the data shown 
two co-transductions were performed using TREG cells from two different donors 
and in every instance the co-expression of 1E6 and CD8-S53N was below 2%. The 
co-transduction and expansion of TREG cells was repeated in a third donor, 
however after three rounds of expansion there were not enough 1E6+CD8-S53N+ 
TREG cells to perform a meaningful suppression assay. Unfortunately, time 
constraints prevented further optimisation of the co-transduction of TREG cells, 
however there are methods that could be pursued in future experiments. It may be 
optimal to transduce TREG cells with the 1E6 LV during the first round of expansion, 
select the transduced cells and then transduced the selected cells with CD8-S53N 
during the second round of expansion. Dual expressing 1E6+CD8-S53N+ TREG cells 
could then be selected at the end of the second or third round of expansion. 
Alternatively, as 1E6+CD8-S53N+ TREG cells can recognise ALW-pMHCI, as shown 
in peptide stimulation assays, it may be possible to expand these cells with ALW 
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peptide pulsed APCs. This would permit the selective outgrowth of cells that can 
respond to the ALW peptide, which would negate the requirement for cell sorting of 
transduced cells. Additionally, it has been shown that CD4+ TEFF cells can be 
transduced with a multi-cistronic vector encoding TCR genes and the CD8αβ co-
receptor genes, which results in co-expression of both TCR and CD8αβ (Xue et al., 
2013). Thus an LV vector that encodes both the 1E6 TCR and CD8-S53N from a 
single promoter could be engineered. However, it would need to be fully 
determined that all genes could be expressed to the same extent. In Jurkat cells, it 
was observed that the Rat CD2 and CD8α genes were compromised when co-
expressed on the same LV vector. However, in the transduction of primary T cells, 
the expression of the Rat CD2 gene is expressed to the same extent, and 
sometimes greater than the TCRvβ genes. Therefore, engineering a single vector 
may be worth pursuing.  
 
Due to low cell numbers, the effect of CD8-S53N expression in a TREG cell was not 
explored in this study. In theory, the expression of the CD8-S53N co-receptor in 
TREG cells should be safe as the co-receptor can not interact with MHCII and 
therefore will only aid the interaction between the introduced 1E6 TCR and pMHCI. 
The study by Xue et al transferred an MHCI restricted TCR into CD4+ and CD8+ T 
cells and identified that the re-directed CD8+ T cells had a 10-fold higher avidity 
than the CD4+ T cells (Xue et al., 2013). Interestingly, the co-expression of the 
TCR and CD8αβ co-receptor genes in CD4+ T cells enabled a functional avidity 
that rivalled the response exhibited by CD8+ T cells. Importantly, the expression of 
the CD8αβ co-receptor did not alter the cytokine profile of the re-directed CD4+ T 
cells, therefore suggesting that CD8 expression in a CD4+ T cell cannot alter CD4+ 
T cell function. However, the safety of CD8-S53N expression in a CD4+ TREG cell 
will need to be fully elucidated in future studies. For example, the full cytokine 
range that expanded dual 1E6+CD8-S53N+ TREG cells secrete upon recognition of 
the ALW peptide could be examined. However, it would not be possible to compare 
cytokine secretion profile of single 1E6+ TREG cells activated with ALW peptide to 
examine any differences in cytokine secretion.   
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In summary, the results presented here elude to the ability of a high affinity CD8-
S53N to rescue the capacity of low affinity autoreactive MHCI restricted TCRs in 
re-directing the Ag specificity of human CD4+ TREG cells. Although the suppression 
assay data is preliminary, the ability of 1E6+CD8-S53N+ TREG cells to up-regulate 
CD69 in response to ALW peptide is encouraging. This therefore, is the first study, 
which has successfully engineered CD4+ TREG cells to recognise an MHCI 
restricted autoimmune disease relevant Ag through LV gene transfer. 
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6. Final Discussion 
 
Adoptive TREG cell therapy, using polyclonal TREG cells, is currently being 
investigated as a therapy to halt T1D progression (Marek-Trzonkowska et al., 
2012; Putnam et al., 2009). Evidence from mouse models however, indicates that 
TREG cells with islet Ag specificity would be more efficacious at controlling T1D 
pathogenesis than polyclonal TREG cells (Tang et al., 2004; Tarbell et al., 2007). 
Although, human islet Ag specific TREG cells can be identified or generated from 
naïve T cells, the number and stability of expanded Ag specific TREG cell may not 
be suitable for human therapy (Brusko et al., 2008). To generate a large number of 
Ag specific TREG cells, this study utilised LV vectors to transfer TCR genes into 
human TREG cells. In this manner, large number of TREG cells can be generated to 
any desired Ag specificity.  Moreover, this study investigated the gene transfer of 
MHCI restricted TCRs to TREG cells. This was based on the hypothesis that MHCI 
engineered TREG cells would be more effective than MHCII restricted TREG cells at 
entering autoimmune tissues and eliciting Ag specific suppression. 
 
In agreement with previous studies, MHCI restricted TCRs can re-direct the Ag 
specificity of TREG cells to Ags that have a high affinity interaction with the 
introduced TCR (Brusko et al., 2010; Plesa et al., 2012). It had previously been 
suggested that naturally occurring low affinity MHCI restricted TCRs could re-direct 
the Ag specificity of TREG cells but not CD4+ TEFF cells (Plesa et al., 2012). 
However, this study identified that this is not the case for all low affinity MHCI 
restricted TCRs. The 1E6 TCR was unable to re-direct the Ag specificity of CD8+ T 
cells, TEFF cells or TREG cells in response to its cognate PPI peptide. High 
expression of CD8α in TCRαβ- Jurkat cell lines could rescue the low affinity 
interaction between the 1E6 TCR and ALW-MHCI. However, a reduced capacity to 
compete with endogenous TCRs in primary cells led to a reduced expression of the 
1E6 TCR that was insufficient to re-direct the Ag specificity of CD8+ or CD4+ T cells 
including TREG cells. Although increasing the expression of the 1E6 TCR in TREG 
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cells was unable to rescue the TCRs response to ALW peptide, the co-expression 
of a high affinity CD8αβ co-receptor, CD8-S53N was capable of rescuing the 
interaction between 1E6 TCR and ALW-MHCI This suggests, that very low affinity 
islet Ag specific MHCI restricted TCRs require further modifications or co-receptor 
engagement to confer potent suppressive capabilities to TREG cells. This study 
therefore extends the knowledge base of the clinical applicability of using 
autoreactive MHCI restricted TCRs to confer potent suppressive capabilities to 
human TREG cells 
 
6.1. Enhancing MHCI Restricted TCRs for Gene Therapy 
TCR signalling upon engagement of pMHC molecules is reliant on a number of 
different factors, such as the affinity of the interaction, the engagement of co-
receptors and clustering of TCRs at the immunological synapse. It has previously 
been shown in CD8+ T cells that the higher the affinity a TCR has for its pMHC the 
less reliant this interaction is on the CD8 co-receptor (Holler and Kranz, 2003). 
Therefore, methods to increase the affinity of the TCR-pMHC interaction or the 
introduction of the CD8 co-receptor in CD4+ T cells could theoretically enhance 
MHCI restricted TCR function. Furthermore, an increase in the expression of the 
introduced TCR on the cell surface would seek to promote T cell activation by 
improving TCR serial triggering and overall functional TCR-pMHC interaction 
avidity.  
 
It has been observed in this study and by others that certain so called “weak TCRs” 
are ill equipped to outcompete endogenous TCRs for cell surface expression 
(Heemskerk et al., 2007; Stauss et al., 2007). This leads to a reduced expression 
of the introduced TCR on the transduced T cell surface as observed with the 
autoreactive 1E6 and 1D7 TCRs. As previously mentioned, the productive hit rate 
model of T cell activation relies on serial triggering of multiple TCRs by pMHC 
complexes (Valitutti et al., 1995). This is aided by formation of the immunological 
synapse, which is a clustering of TCRs with adhesion, co-stimulatory and signalling 
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molecules (Grakoui et al., 1999). T cell activation occurs when the overall avidity of 
the TCR-pMHC interactions reaches the threshold for productive T cell signalling. 
Therefore, a greater number of low affinity TCR-pMHC interactions would need to 
take place than the number of high affinity interactions. Subsequently, the low 
expression of the 1E6 TCR, even in the context of CD8+ T cells, prevents the 
avidity threshold being reached in response to the ALW peptide. In contrast, the 
low expression of the TCR had no effect on the ability of the TCR to signal in 
response to the super agonist peptide, irrespective of the cell context. Due to time 
constraints, it was not examined whether the increased expression of the 1E6 TCR 
on CD8+ T cells could promote signalling in response to ALW peptide. The 
examination of this would fully test the hypothesis that the inability of the 1E6 TCR 
to signal in CD8+ T cells was due to low expression. 
 
An additional method to improve introduced TCR surface expression not explored 
in this study, is the removal of endogenous TCRs. In addition to removing 
competition for expression with the endogenous TCR this would improve the safety 
of TCR gene transfer by forgoing the potential of TCR mis-pairing and formation of 
neo-reactivities (van Loenen et al., 2010). Zinc finger nucleases, delivered by viral 
vectors, can be used to disrupt endogenous TCRα and TCRβ chains at the genetic 
level, imprinting cells and their progeny as TCRαβ-. Cells can then be reconstituted 
with any TCR of choice by LV gene transfer. TCR gene transfer into TCR-edited T 
cells yields improved expression of the introduced TCR as well as superior Ag 
recognition in comparison to TCR gene transfer in non-edited T cells (Provasi et 
al., 2012). However, the process of TCR gene editing in this study was arduous 
and contained four viral transduction steps, including two rounds or cell sorting and 
αCD3/CD28 stimulation, before re-directed T cells were produced. For TCR gene 
therapy of low numbers of CD4+ TREG cells, this method would reduce the recovery 
of transduced cells.   
 
An alternative route to stabilising low affinity TCR pMHC interactions by co-
expressing the CD8-WT or CD8-S53N co-receptor in CD4+ TREG cells would be to 
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isolate or engineer MHCI restricted TCRs with a high enough affinity for pMHC so 
that the CD8 co-receptor is dispensable. It has been suggested that the natural 
TCR affinity range of TCRs is between 1µM and 100µM (Thomas et al., 2011). To 
put this into context of the current study, the 1E6 TCR has a reported affinity below 
this range of 278µM and the 868 TCR above this range of 0.08µM. Unlike B cells, 
T cells do not undergo affinity maturation in vivo. To circumvent this, techniques 
have been developed to engineer T cells that have a higher affinity for Ag in vitro. 
TCRs with mutations in the CDR3 regions of TCRα and TCRβ chains can be 
screened for improved peptide binding using yeast phage display and has been 
used to identify TCRs with supra-physiological affinities for pMHC (Li et al., 2005). 
For example, Varela-Rohena and colleagues engineered the 868 TCR to possess 
a 360-fold increase in affinity, which conferred a superior control over the spread of 
HIV in vivo compared to WT 868 TCR (Varela-Rohena et al., 2008). However, 
others have identified that the affinity maturation of TCRs can lead to reduced Ag 
specificity or impact the ability to recognise low concentrations of pMHC (Thomas 
et al., 2011; Zhao et al., 2007). The study by Thomas et al identified that the 
increased TCR affinity, caused by an increased TCR-pMHC dwell time, resulted in 
reduced serial TCR triggering. Therefore, increasing the affinity of the TCR-pMHC 
interaction did not affect its functional avidity. Additionally, the safety of affinity 
matured TCRs was called into question in 2013, when the transfer of cells 
expressing an affinity matured TCR, exhibited toxicity due to cross reactivity that 
was not predicted during in vitro testing (Cameron et al., 2013; Linette et al., 2013). 
It may however be useful to test affinity-matured 1E6 TCRs in their ability to re-
direct the specificity of TREG cells, whilst taking into consideration the described 
results and safety concerns. 
 
6.2. Identification of autoreactive MHCI Restricted TCRs  
From the data in this study, it can be determined that the successful re-direction of 
CD4+ TREG cells using autoreactive MHCI restricted TCRs is reliant on the TCRs 
high affinity for self-Ag. However, the process of negative selection makes the 
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identifications of TCRs with these properties in circulation highly unlikely. As 
previously mentioned, during negative selection T cells that possess TCRs that 
react too strongly against self-pMHC complexes are deleted from the T cell 
repertoire. In this way, only T cells that have a high affinity for Ags not presented in 
the thymus will exit into the periphery. It is however possible to look out-with the 
normal TCR repertoire for CD8+ T cells with a high affinity for self Ag by turning to 
patients with defects in negative selection or alternatively, HLA transgenic mice.  
 
Autoimmune polyendocrinopathy syndrome type 1 (APS-1) is a rare disorder 
characterised by a spectrum of organ specific autoimmune diseases, including 
T1D. In the course of identifying the genetic determinants of this disease, a loss of 
function mutation was found in the gene now known as the autoimmune regulator 
(Aire) gene (Nagamine et al., 1997). Since the discovery of the Aire gene, its 
critical role in negative selection has been revealed. To first identify the function of 
this gene, a seminal study by Liston et al employed the 3A9 TCR transgenic 
mouse model whose T cells possess high avidity TCRs for an Ag of hen egg 
lysosome (HEL) (Liston et al., 2003). When the HEL gene is expressed under the 
control of the rat insulin promoter (RIP), the majority of high avidity HEL specific T 
cells are deleted in the thymus through negative selection. However, when these 
mice were crossed with Aire-/- mice, a complete failure in the thymic deletion of 
HEL specific T cells was observed. It is now known that Aire is expressed in the 
thymic medullary epithelial cells and is responsible for the promiscuous gene 
expression of thousands of tissue specific Ags that are presented to developing T 
cells in the thymus. Consequently, the failure of negative selection in these patients 
makes it plausible that they harbour high affinity T cells specific for T1D associated 
Ags such as insulin. It is possible, that T cells with a high affinity for self Ag may be 
deleted or rendered anergic in the periphery by mechanisms of peripheral 
tolerance. However, these patients may provide a window of opportunity for the 
isolation of autoreactive T cells with a higher than normal affinity for self-Ag.  
Potentially, MHCI multimer staining could be used to identify T1D associated Ag 
specific CD8+ T cells from these patients. Additionally, modified MHCI multimers 
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that do not interact with human CD8 could be used to identify high affinity CD8 
independent TCRs (Choi et al., 2003). Cloning of the TCR genes from these T cells 
could potentially yield MHCI restricted TCRs more potent at re-directing the Ag 
specificity of TREG cells than those used in the current study.  
 
HLA transgenic mice are engineered to express human MHC molecules and are a 
useful tool in the generation of high affinity, human Ag specific TCRs (Theobald et 
al., 1995). One such example is the HHD transgenic mouse, which expresses a 
human-mouse hybrid HLA-A2*01 MHCI molecule (Pascolo et al., 1997). The hybrid 
transgene consists of human β2M-HLA-A2*01 peptide binding domains, α1 and α2, 
coupled to the murine α3 domain from H-2Db MHCI molecules. Importantly, these 
mice lack murine MHCI molecules due to a disruption in the murine B2M and H-2Db 
genes ensuring the full CD8+ TCR repertoire is restricted to human HLA-A2*01. 
This model has previously been used by the group of Steve Rosenberg to identify 
high avidity TCRs specific for the human melanoma associated Ag gp100:64-162 
(Johnson et al., 2009). This epitope differs from the murine epitope at a single 
amino acid, and immunisation of HHD mice with the human gp100 enabled the 
identification of a high avidity TCR. T cells transduced with the resulting high 
avidity murine TCR were shown to be capable of mediating cancer regression in 
19% of melanoma patients. The main caveat of using murine derived TCRs in TCR 
gene therapy however is the development of a xenogeneic immune response 
against the adoptively transferred T cells. In a follow up study, a humoral response 
to murine TCRs was identified in 25% of patients treated with T cells expressing 
murine TCRs. It was promising to note however that the development of antibodies 
against the transferred T cells was not consistent with reduced T cell persistence 
or responsiveness to therapy (Davis et al., 2010). In 2010, transgenic HHD mice 
that possess a diverse human TCR repertoire were described (Li et al., 2010). 
Using yeast artificial chromosomes the full human TCRα and TCRβ loci were 
expressed in HHD mice deficient of murine TCRα and TCRβ genes. Importantly, 
the immunisation of these mice with a human melanoma derived Ag enabled the 
identification of high avidity Ag specific CD8+ T cells. Therefore, identification of PPI 
Chapter 6 Final Discussion 
215 
specific CD8+ T cells in these mice would permit the identification of fully human 
TCRs from HHD mice.  
 
Human insulin protein has only 82% and 79% shared sequence homology with 
murine insulin 1 and insulin 2 protein respectively. Furthermore, the human PPI15-24 
ALW epitope used in this study has a 70% disparity to the same murine epitope of 
insulin 2, the murine form of insulin that is predominately expressed in the thymus 
(Chentoufi and Polychronakos, 2002). Theoretically, the CD8+ T cells of HHD mice 
would not be negatively selected on the basis of a high affinity TCR for the HLA-
A2*01 restricted ALW epitope and would be permitted entry into circulation. Based 
on this rationale, HHD mice could be immunised with the human ALW epitope of 
PPI to identify high affinity HLA-A2*01 restricted TCRs. Of particular interest in this 
study, high affinity TCRs that are CD8 independent may be indentified for the re-
direction of human CD4+ TREG cells. The α3 domain of MHCI molecules, which in 
the HHD mouse is murine derived, provides the CD8 binding domain. Importantly, 
there is no cross binding between the murine α3 domains with human CD8αβ 
(Purbhoo et al., 2001). In theory, fully human HLA-A2 multimers could be used to 
identify Ag specific CD8+ T cells that are independent of human CD8. 
 
The described immunisations have been carried out in collaboration with Farzin 
Farzenah (Rayne institute, Kings college London). In total, one mouse was 
immunised with PBS and three with a high dose of ALW peptide following a 
previously described immunisation protocol that enables combined and synergistic 
triggering of DCs to promote potent CD8+ T cell responses (Wells et al., 2008). One 
of the three immunised mice yielded a potent CD8+ T cell response to the ALW 
peptide as evidenced by ALW HLA-A2 multimer staining (Figure 6-1). Splenocytes 
and lymphocytes from all mice have since been isolated and cryopreserved for 
future analysis. It is hypothesised that HLA-A2 ALW multimer+ cells could be 
isolated and expanded. It would then be possible to isolate TCR genes following 
the previously described 5’ RACE clonotyping protocol from ALW specific CD8+ T 
cells.  
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Figure 6-1 Immunisation of HHD Mice with PPI15-24 Epitope. HHD mice were immunised as 
shown and after 3 weeks tail blood was stained with an HLA-A2 ALW multimer followed by α 
murine CD8 and CD3 antibodies. Staining with CD3 was used to analyse multimer staining of total 
CD3+ T cells and FACS plots show staining of (A) a single mouse immunised with PBS and (B) 
mice immunised with a 400µg dose of ALW peptide.  
 
6.3. Future of MHCI Restricted TCR Gene Therapy in CD4+ TREG 
cells 
On target toxicity exhibited by TCR gene modified T cells is one of the biggest 
concerns of the adoptive transfer of T cell therapy of CD4+ or CD8+ T cells. Another 
concern in TCR gene therapy is mis-pairing of endogenous and introduced TCRα 
and TCRβ genes, which may form harmful neo-reactivity’s (Bendle et al., 2010; 
Rosenberg, 2010). Although, TCR mis-pairing has been observed in pre-clinical 
mouse models, mis-pairing of TCRα and TCRβ genes has so far not been 
observed in the human setting. Theoretically, on target toxicity does not pose as 
big a threat using gene modified TREG cells, as these cells should not exhibit the 
deleterious effects observed from TCR engineered TEFF cells. Therefore, the main 
safety concern of TCR gene therapy of CD4+ TREG cells is the unintended transfer 
of an autoreactive MHCI restricted TCR into TEFF or CD8+ T cells. The unwitting 
transfer of autoreactive TEFF cells into patients with T1D could exacerbate and 
worsen disease state, particularly for MHCI restricted TCRs as they could directly 
recognise and target MHCI expressing islets. Therefore, it is imperative that only 
the purest populations of TREG cells are used for this therapy. As discussed, there 

















































































































































































Chapter 6 Final Discussion 
217 
CD4+CD25+CD127loCD45RA- may reduce the risk of TEFF cell contamination 
(Hoffmann et al., 2006; Miyara et al., 2009; Putnam et al., 2009). Towards the end 
of this study, RAPA was used in TREG cell expansion with a view of promoting the 
sole expansion of TREG cells (Battaglia et al., 2006). Although, a direct comparison 
between RAPA expanded and non-RAPA expanded TREG cells would be required 
to confirm any benefits provided from the inclusion of RAPA.  
 
The stability and plasticity of CD4+ TREG cells in mice has also been called into 
question, particularly at sites of inflammation. Genetic fate mapping studies of 
FoxP3+ TREG cells identified an accumulation of “exFoxp3+” TREG cells in 
inflammatory sites (Zhou et al., 2009). However, it has since been suggested that 
these “exFoxp3+” TREG cells arise from non-committed, transiently activated cells 
and that true suppressive TREG cells do not undergo reprogramming under 
inflammatory conditions (Miyao et al., 2012). FoxP3 stability is maintained 
epigenetically by the DNA demethylation of the TSDR region within the FoxP3+ 
gene. It would therefore be prudent to determine the demethylation status of the 
TSDR region within LV transduced and expanded populations of TREG cells. Prior 
to adoptive TREG cell therapy with cells expressing MHCI restricted TCRs, it would 
be crucial to determine the stability of these cells.  
 
It has been suggested that one mechanism of Ag specific TREG cell suppression is 
the direct killing of TEFF cells and APCs in a granzyme or perforin dependent 
manner (Cao et al., 2007; Gondek et al., 2005; Grossman et al., 2004). Both 
adaptive and activated CD4+CD25+ human TREG cells have been shown to kill 
autologous target cells (Grossman et al., 2004). Naturally occurring islet Ag 
specific, IL-10 secreting TREG cells have also been found to selectively kill APCs 
expressing specific pMHCII (Tree et al., 2010). Therefore, the expression of MHCI 
restricted islet Ag specific TCRs in TREG cells could potentially endow these cells 
with the ability to recognise and kill islets. A more recent study has suggested that 
expanded CD4+CD25+ and not CD4+CD25+CD127low TREG cells display cytotoxicity 
activity post stimulation with recombinant bispecific antibodies (Koristka et al., 
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2014). However, this has not been assessed using Ag specific TREG cells. Due to 
low cell numbers of dual 1E6+CD8-S53N+ TREG cells, it was not possible to test in 
this study the ability of these cells to kill in response to pMHCI. In future 
experiments, cytotoxicity assays can be performed using Ag pulsed HLA-A2 
expressing K562 cells as surrogate islets and 1E6+CD8-S53N+ TREG cells as 
effector T cells. Transduced TREG cells that had been incubated with surrogate islet 
cells could also be stained for expression of CD107, a marker of degranulation. 
These experiments could shed light on the cytotoxicity capabilities and safety of 
these cells.  
 
In this study, Rat CD2 was used solely as a marker in the LV expression cassette 
to evaluate in vitro transduction efficiencies of cells. LV expression vectors can 
encode up to 10kb and therefore additional genes can be encoded to promote the 
safety of TCR gene therapy. To reinforce the regulatory function of transferred 
TREG cell, the FoxP3 gene could be expressed in the LV vector and co-transferred 
with the TCR genes. In mice, the transfer of a FoxP3 gene to islet Ag specific TEFF 
cells endowed the TEFF cells with suppressive capabilities, enabling them to 
reverse diabetes in mice with recent onset disease (Jaeckel et al., 2005). To 
alleviate safety concerns of the transfer of TCR gene re-directed TREG cells, suicide 
genes could be included in the LV expression vector in the place of the Rat CD2 
marker gene. The B cell marker CD20 has been investigated as a suitable suicide 
and marker gene as its expression can be detected by flow cytometry, and cells 
expressing this gene can be killed after exposure to the therapeutic αCD20 
monoclonal antibody, Rituximab (Introna et al., 2000). More recently, the use of a 
compact marker/suicide gene comprised of CD34 and CD20 epitopes (RQR8) has 
been described. The use of the RQR8 gene enabled selection of transduced cells 
via the GMP approved CliniMACS CD34 system (Miltenyi Biotec, Germany) as well 
as retaining the Rituximab binding site of CD20 (Philip et al., 2014). However, 
treatment with Rituximab to remove transduced T cells would also deplete B cells 
for up to 6 months or more post treatment. Another potential suicide gene is 
caspase 9, a late stage component of the apoptotic pathway. Expression of an 
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inducible caspase 9 can cause apoptosis of transduced cells upon exposure to a 
chemical inducer of dimerisation (CID) (Straathof et al., 2005). Patients undergoing 
haploidentical stem cell transplantation were co-transfused with donor T cells 
transduced to express the inducible caspase 9 suicide gene (Di Stasi et al., 2011). 
Upon the first signs of GVHD development, patients were treated with the CID, 
AP1903, and 90% of donor T cells were eliminated within 30 minutes of CID 
administration. Importantly, the treatment with CID AP1903 has no serious side 
effects. 
 
6.4. Suitability of TCR Gene Modified TREG Cells as a Treatment 
for T1D. 
The safety of the adoptive transfer of gene modified T cells has already been 
demonstrated in a number of clinical trials (Johnson et al., 2009; Robbins et al., 
2011). However, to date, the use of gene modified T cells has not been explored 
as a treatment for autoimmune diseases. The incidence of T1D is rising in the 
western world and a therapy that aims to prevent or treat the causes of T1D, as 
opposed to the effects is greatly required. The transfer of polyclonal autologous 
TREG cells have already shown to be safe and well tolerated in patients with newly 
onset T1D (Marek-Trzonkowska et al., 2014; Marek-Trzonkowska et al., 2012). 
The integration of a transgene into the host genome poses the risk of insersertional 
mutagenesis. However to date there have been no reports of this using cells 
modified by LV vectors. Furthermore, the improved safety in viral base gene 
therapy and availability of GMP grade facilities for isolation, transduction expansion 
of T cells will significantly aid the transition of TCR gene therapy of TREG cells in 
T1D.    
 
Pan immunosuppressive agents, such as cyclosporine have been shown to 
ameliorate the effects of T1D. However the number of side effects associated with 
this treatment is an unacceptable risk in T1D, particularly in the young (Silverstein 
et al., 1988). This has paved the way for the identification of more specific forms of 
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immunosuppression in T1D that pose little widespread effects. The use of islet Ag 
specific TREG cell therapy should fit this remit as in theory their suppressive effects 
will be exhibited within the islets and pancreatic draining lymph nodes. However, it 
is possible that the administration of islet Ag specific TREG cells could have pan 
immunosuppressive effects. As was observed in suppression assays in chapters 4 
and 5, the presence of TREG cells could reduce proliferation of HA responding CD4+ 
and CD8+ T cells, although this reduction significantly increased when TREG cells 
were activated by their specific peptide. Additionally, evidence from mouse models 
suggests that lower numbers of Ag specific TREG cells, compared to polyclonal TREG 
cells would be required for disease prevention and reversal (Tang et al., 2004). 
Therefore, the adoptive transfer of reduced numbers of TREG cells may prevent any 
pan immunosuppressive effects. Furthermore, the use of MHCI restricted TCR 
expressing TREG cells should aid the homing of TREG cells specifically to the islets, 
which would also reduce pan immunosuppressive effects. Therefore, the ability of 
adoptive transferred islet Ag specific TREG cells to home to the pancreatic draining 
lymph nodes and islets is essential to this therapy. It has been observed previously 
that expanded TREG cells retain expression of the lymph node homing markers 
CD62L and CCR7 (Hoffmann et al., 2004). It would be important for this study to 
determine expression of these markers post LV transduction and expansion. 
Expression of the chemokine receptor CXCR3 is important for homing of 
autoreactive T cells to the islet via the chemokine CXCL10 (van Halteren et al., 
2005). Human TREG cells expressing CXCR3 that migrate in response to CXCL10 
have been identified (Hoerning et al., 2011). Therefore, it would be interesting to 
assess the level of CXCR3 on the LV transduced and expanded TREG cells used in 
this study and whether these cells can migrate in response to CXCL10 using 
chemotaxis assays. This would give an idea of whether TREG cells generated in this 
study would be able to home to the islets as expected.  
 
A major consideration in using islet Ag specific TREG cells as a treatment for T1D is 
the timing at which they are administered. A Josilin Medalist study identified that 
residual β cell function and turnover can be found in patients with T1D, even when 
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disease duration was over 50 years (Keenan et al., 2010). Moreover, studies of 
pancreata from patients with T1D suggest that upon T1D diagnosis, 50% of β cell 
mass remains (Coppieters et al., 2012). Importantly, in a mouse model of 
autoimmune diabetes, only the transfer of islet Ag specific TREG cells, and not 
polyclonal TREG cells could reverse disease (Tang et al., 2004). These studies 
would suggest that immunotherapies aimed at preserving β cell mass could 
reverse the requirements of exogenous insulin in patients who have previously 
been diagnosed with T1D. Therefore, adoptive islet Ag specific TREG cell therapy 
need not be selectively targeted to patients recently diagnosed with T1D. Risk of 
T1D development in first-degree relatives can be predicted by assessing genetic 
predisposition, presence and number of islet autoantibodies and metabolic testing 
(Achenbach et al., 2005). If the use of islet-Ag specific TREG cells is deemed safe 
with little side effects then these could also be used as an interventional therapy. 
Alternatively, TREG cells for adoptive transfer could be generated from high-risk 
individuals, cryopreserved and used as a therapy upon initial diagnosis.  
 
A concern with using adoptive TREG cell therapy to treat patients with T1D is that 
the inherent genetic defects that predispose patients to disease would reduce the 
efficacy of this therapy. A number of the genetic polymorphisms associated with 
T1D predisposition, particularly in the IL-2 signalling axis, are implicated in 
defective TREG cell function (Dendrou et al., 2009; Garg et al., 2012; Long et al., 
2010). The low dose IL-2/RAPA trial, although showing no clinical improvement in 
subjects with T1D, did identify an improvement in the overall TREG cell 
responsiveness to IL-2 that persisted for at least a year post treatment (Long et al., 
2012).  Therefore, expansion of TREG cell in high dose IL-2, which is the protocol 
currently used, may overcome defects in IL-2 responsiveness. Moreover, reduced 
IL-2 responsiveness in patients with T1D is associated with a loss of FoxP3 
maintenance (Garg et al., 2012; Long et al., 2010). However, this defect could be 
overcome by including FoxP3 in the LV construct when generating Ag specific TREG 
cells by LV TCR gene transfer. Studies have also shown that the TEFF cells from 
patients with T1D are more resistant to TREG cell mediated suppression (Lawson et 
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al., 2008; Schneider et al., 2008). It has been suggested however that the 
resistance of TEFF cells to be suppressed may be overcome by increasing TREG cell 
numbers. The use of Ag specific TREG cells may also aid in overcoming TEFF cell 
resistance to suppression. To fully test this hypothesis however, the methods 
described in this study using TREG cells from healthy controls will need to be 
explored fully in TREG cells from patients with T1D. The generation of Ag specific 
TREG cells from patients will allow for full examination of the ability of these cells to 
suppress autologous TEFF cell Ag specific responses.  
 
The final step for this study would be to assess the efficacy of 1E6CD8-S53N TREG 
cells in a humanised mouse model of autoimmune diabetes. In a HLADR4 
expressing immunodeficient NOD-scid mouse, the transfer of human islet 
autoreactive CD4+ T cells could selectively infiltrate murine islets and selectively 
destroy β cell (Viehmann Milam et al., 2014). As the 1E6 TCR is HLA-A2 restricted, 
then previously described NOD-scid.HLA.A2.1 mice would serve as a useful 
humanised mouse model to test the efficacy of 1E6CD8-S53N+ TREG cells. 
Additionally, due to the disparity between murine and human preproinsulin genes, 
transgenic mice expressing the human insulin gene would be required (Selden et 
al., 1986). Using these transgenic mice, the ability of the 1E6 CD8+ T cell clone to 
transfer diabetes could first be assessed. Adoptive transfer studies of 1E6+CD8-
S53N+ TREG cells, or other MHCI restricted expressing TREG cells, could be 
performed to assess the ability of these cells to prevent or reverse autoimmune 
diabetes. Alternatively, humanised mouse models have been used to examine the 
efficacy of human alloantigen specific TREG cells in mediating tolerance to an 
allogeneic human skin graft (Sagoo et al., 2011). A similar approach could be 
taken to examine the efficacy of human TCR gene modified TREG cells in 
suppressing the rejection of transplants of human islet cells. In a NOD-scid mouse 
model, it would be possible to transplant human HLA-A2/DR4+ islets under the 
kidney capsule of these mice. To promote autoreactivity to the transplanted islets, 
HLA-A2 restricted CD8+ or HLA-DR4 restricted CD4+ T cells that are specific for 
islet Ags could be adoptively transferred. The efficacy of MHCI islet Ag specific 
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TREG cells at protecting the human islets from T cell mediated destruction could 
then be efficiently assessed in adoptive TREG studies. 
 
6.5. Concluding Remarks 
This study provided the first evidence that the specificity of CD4+ TREG cells can be 
re-directed towards a MHCI restricted autoimmune disease relevant Ag. The 1E6 
TCR is so far the best-described autoreactive MHCI restricted TCR available. Due 
to its low affinity for self-peptide this TCR required the co-expression of a high 
affinity CD8 co-receptor for the successful re-direction of CD4+ TREG specificity. 
However, the safety of CD8 co-receptor transfer into human CD4+ TREG cells 
requires further assessment. For the successful progression of this therapy it may 
be prudent to identify further MHCI restricted TCR that would be suitable for 
transfer into human TREG cells without additional enhancement. This can be 
approached by using either HLA transgenic mice or cells from patients with APS-1. 
This would enable further investigations into the feasibility of autoreactive MHCI 
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